Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-2000

Function and Properties of groE Chaperonins in Bacterial and
Mammalian Cells
Gregory M. Nelson

Follow this and additional works at: https://scholarsrepository.llu.edu/etd
Part of the Microbiology Commons, and the Molecular Genetics Commons

Recommended Citation
Nelson, Gregory M., "Function and Properties of groE Chaperonins in Bacterial and Mammalian Cells"
(2000). Loma Linda University Electronic Theses, Dissertations & Projects. 694.
https://scholarsrepository.llu.edu/etd/694

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. For more information, please contact scholarsrepository@llu.edu.

UNIVERSITY LIBRARY
LOMA LINDA, CAUFORNIA
LOMA LINDA UNIVERSITY
Graduate School

Function and Properties of GroE Chaperonins in Bacterial and Mammalian Cells
by
Gregory M. Nelson

A Dissertation submitted in partial satisfaction of
the requirements for the degree of
Doctor of Philosophy in Microbiology and Molecular Genetics

June, 2000

Each person whose signature appears below certifies that this dissertation in their opinion
is adequate, in scope and quality, as a dissertation for the degree of Doctor of Philosphy.

.Chairman
Alan P. Escher, Assistant Professor of Microbiology and Molecular Genetics

Ora M. Green, Associate Professor of Microbiology and Molecular Genetics

Q
/Vv
David A. Hessinger, Professor of Pharmacology and Physiology

____ fdi___/

_____ ___________________________

John Ji Rossi, Adjunct Professor of Microbiology and Molecular Genetics and
Biochemistry, Beckman Research Institute, City of Hope

L
Barry L. Taylor,Professor of Microbiology and Molecular Genetics and Biochemistry

ACKNOWLEDGMENTS

I would like to express my appreciation to the individuals who helped me complete this
study. I am grateful to Loma Linda University Department of Microbiology and
Molecular Genetics and the Center for Molecular Biology and Gene Therapy for
providing the facilities and for the financial support. I wish to thank the members of my
guidance committee, Lora M. Green, David Hessinger, John J. Rossi and Barry L. Taylor
for their advice and comments. I am especially grateful to Alan P. Escher, my advisor,
for many helpful discussions, guidance and support during this research. I am also
grateful to Jason Liu, Marina Zemskova and Maria Filippova for their assistance and
support. I could not have accomplished this work without the constant personal and
emotional support of Shannon V. Nelson and my family.

m

TABLE OF CONTENTS

ii
iii

Approval Page.......
Acknowledgements
Table of Contents...
List of Figures........
Abbreviations....... .
Abstract..................
I.

iv
vii
ix
x

Introduction............................................................................................. .
A. Protein folding in vitro and in vivo...................................................
B. Molecular chaperones........................................................................
1. Small Hsp's and a-crystallin......................................................
2. HSPlOO/Clp.................................................................................
3. HSP90..........................................................................................
4. Hsp70/Hsp40...............................................................................
5. Ring chaperones: group I and II chaperonins.......................... .
a) Chaperonins of archaebacteria and eukaryotic cytosol...
(1) Archaebacteria...........................................................
(2) TRiC...........................................................................
b) Chaperonins of bacteria, mitochondria and chloroplasts
(1) GroES........................................................................
(2) GroEL.........................................................................
(3) GroES/GroEL mediated protein folding.................
(4) Substrates of GroEL..................................................
(5) Large polypeptides bound by GroEL......................
(6) GroES and GroEL rescue of misfolding proteins ...
C. Protein misfolding and diseases.......................................................
1. Gene therapy approach to misfolding disease..........................
a) Function of p53....................................................................
b) The V143A p53 mutant......................................................
2. GroEL as a molecular probe......................................................
3. Research aims.............................................................................

II. Materials and Methods.......................................................... .
A. DNA cloning, restriction analysis and general reagents
B. Media................................................................................
C. Cell lines and strains used...............................................
1. Plasmid constructions................................................
a) Plasmid Vectors..................................................
b) groE plasmids.....................................................
c) Bacterial luciferase and GFP plasmids............
d) p53 plasmids.......................................................

iv

1
1
7
8
9
10
11
14
15
15
16
17
19
19
20
22
28
30
32
34
37
38
39
42
44
44
44
45

46
46
47
50
52

e) MCAD plasmid construction
D. Blunt ending
E. PCR.............
F. Ligation.........................................................................................................
G. Visualization of GFP fluorescence in Escherichia coli cells......................
H. Microscopy of mammalian cells..................................................................
I. Differential centrifugation and immunoblot analysis................................
J. LipofectAMINE PLUS transfection of mammalian cells..........................
K. Calcium phosphate transfection of cultured mammalian cells.................
L. Preparation of 35S-methionine radiolabeled mammalian cell lysates and
immunoprecipitation...........................................................................................
1. Radiolabeling..........................................................................................
2. Harvesting and immunoprecipitation...................................................
M. One dimensional SDS-PAGE.......................................................................
N. Immunoblot procedure................................................................................
O. Electroporation of NCI-H1299 cells............................................................
P. Mammalian cell lysates preparation for Firefly luciferase and Renilla
luciferase assay....................................................................................................
1. Analysis of Firefly luciferase activity....................................................
2. Analysis oi Renilla luciferase activity....................................................
Q. E. coli radiolabeling.....................................................................................
R. Immunocytochemistry of COS-7 cells.........................................................
S. Heat shock treatment of CHO Cells, analysis of Hsp70 induction and
radiolabeling........................................................................................................
T. Heat shock survival of CHO cells................................................................

III. Results....................................................................

52
53
54

54
55
55
56
57
57
58
58
58
61
62
63
64
64
64
65
66
67
68
70

A. Construction of groE mammalian expression vectors
70
1. groESL genes are expressed in mammalian cells..
73
2. GroEL forms a 14-mer...........................................
81
3. GroEL coimmunoprecipitates with proteins........
84
4. GroEL coimmunoprecipitates are not GroEL protein degraded in vitro
88
5. GroEL coimmunoprecipitates are not GroEL protein degraded \n vivo
91
94
6. Polypeptides bind to GroEL in vivo.......................................... .
B. Difference in spectrum of bound proteins between bacterial and
mammalian cells.....................................................................................
97
C. Increased polypeptide binding to GroEL in heat shocked cells...
103
D. Increased thermotolerance of mammalian cells expressing the groEL gene..
111
E. Overexpression of a luciferase-gfp fusion gene construct and folding of its
product in Escherichia coli and COS-7 Cells.................................
115
1 Construction of the luciferase-gfp fusion gene plasmids ...
117
2. Expression of the luciferase-gfp gene construct in E. coli
119

v

a) Rescue of the luciferase moiety of the luciferase-GFP fusion
protein by expression of the groESL genes...................................... 119
b) Visualization in situ of soluble and aggregated luciferase-GFP
fusion protein in E. coli...................................................................... 122
c) The GFP moiety of the luciferase-GFP fusion protein requires
GroESL for folding............................................................................ 125
d) The luciferase-GFP fusion protein interacts with GroEL in E. coli
131
F. Mammalian cell overexpression of the luciferase-gfp gene.................... 136
1. The luciferase-GFP fusion protein does not form aggregates in
mammalian cells....................................................................................... 139
2. GroEL does not interact with the luciferase-GFP fusion protein in
COS-7 cells................................................................................................ 142
G. GroESL and Gene Therapy...................................................................... 149
1. Synthesis of GroES and GroEL does not rescue a temperature-sensitive
150
p53 mutant VI43A at nonpermissive temperature in HI 299 cells
155
2. GroES and GroEL effect on p53 temperature sensitivity........
3. Probing Interaction between GroEL and p53...........................
159
IV. Discussion.........................................................
164
A. Properties of GroESL in mammalian cells
165
B. Spectrum of proteins bound by GroEL in bacteria and mammalian cellsl68
C. Different folding behavior of a GroEL substrate in bacteria and
mammalian cells....................................................................................... .
170
170
1. State of the luciferase-GFP fusion protein in E. coli................. .
2. State of the luciferase-GFP fusion protein in mammalian cells
173
D. Folding of a large multidomain protein substrate by GroESL.....
176
177
1. GroES binding to cis GroEL.......................................................
2. GroES binding to trans GroEL...................................................
181
E. Protein availability to GroEL and cell survival under heat shock conditions
in mammalian cells....................................................................................
184
184
1. Availability of proteins to GroEL under heat shock conditions
185
2. Cell survival under heat shock conditions..................................
187
F. GroESL and Gene Therapy...............................................................
V. Perspectives....... ..............................................................
A. GroESL protein rescue should be protein specific
B. GroESL as therapeutic agents................................
C. Conclusions..............................................................

190
190
191
194

VI. Reference List

195

VII. APPENDIX

219

vi

LIST OF FIGURES
Figure 1. Substrates that interact with GroEL in vivo and in vitro

,23

Figure 2. Bacterial groE operon and major plasmid constructions used in this work
71
Figure 3. Simian COS-7 cells express thzgroES and groEL genes of Is. coli

,74

Figure 4. GroES and GroEL immunoprecipitated from COS-7 cells,

76

Figure 5. GroES is synthesized in COS-7 cells

79

Figure 6. GroEL forms a large oligomeric complex in COS-7 cells

82

Figure 7. GroEL coimmunoprecipitates with a wide range of polypeptides in COS-7
cells
,85
Figure 8. GroEL coimmunoprecipitates are not degraded GroEL polypeptides from
the immunoprecipitation procedure
89
Figure 9. GroEL is not degraded in vivo

,92

Figure 10. GroEL binds polypeptides in vivo

95

Figure 11. The same polypeptide spectrum is coimmunoprecipitated with GroEL
independent of the transfection method................................................... ,98
Figure 12. GroEL coimmunoprecipitates a different polypeptide spectrum in E. coli
and COS-7 cells
101
Figure 13. Induction of Hsc70/Hsp70 protein after heat shock at 45°C

105

Figure 14. GroEL coimmunoprecipitates from CHO cells heat shocked at 45°C ..107
Figure 15. GroEL coimmunoprecipitates from COS-7 cells heat shocked at 45°C
109
Figure 16. Heat shock survival of CHO cells transiently transfected with various
chaperonin plasmids.................................................................................. 112
Figure 17. Abbreviated plasmid construction of the luciferase-gfy fusion gene
constructs.............................................................................................

vn

120

Figure 18. Luciferase bioluminescence from bacterial colonies grown at 37°C on
agar plates................................................................................................ . 123
Figure 19. GFP fluorescence activity at 37°C oiE. coli cells cotransformed with
plasmid pACGNl and (A) vector only, (B) pGEL7, and (C) pbl+groE
126
Figure 20. Solubility of the luciferase-GFP fusion protein in E.coli at 37°C.......... 128
Figure 21. GroEL coimmunoprecipitates the luciferase-GFP fusion protein in E.
coli at 37°C................................................................................................ 132
Figure 22. No cross-reactivity between anti-GroEL antibodies and the luciferaseGFP fusion protein
134
Figure 23. GFP fluorescence oiE. coli cells grown at 37°C under conditions used for
radiolabeling
137
Figure 24. GFP fluorescence activity of COS-7 cells expressing the luciferase-gfp
gene from the p3.1FG plasmid................................................................. 140
Figure 25. Solubility of the luciferase-GFP fusion protein synthesized in COS-7 cells
143
Figure 26. GroEL does not coimmunoprecipitate the luciferase-GFP fusion protein
in COS-7 cells
146
Figure 27. Plasmid construct for the p53 responsive reporter

151

Figure 28. Luciferase activity in response to different plasmid transfections........ 153
Figure 29. Transactivation of the p53CON-LUC reporter gene at 30°C and 37°C
156
Figure 30. p53 does not coimmunoprecipitate with GroEL

161

Figure 31. Model of luciferase-GFP fusion protein folding in a cis GroEL complex
179
Figure 32. Model of luciferase-GFP fusion protein folding on the cis GroEL ring
with GroES interaction on the trans GroEL ring................................... 182

vm

ABBREVIATIONS
Abbreviation
BSA
CMV ..
DMEM
DOC .
DPBS .
DTT
El-alpha

FBS
GFP
HEPES
HPLC.
Hsp
IRES
LB
MBP
pF
MCAD
NP-40 .
O.D.600

PAGE
PBS
PMSF
PVDF
SDS
SDS-PAGE ..
TEST ..........
tef promoter

Definition
bovine serum albumin
cytomegalovirus
Dulbecco’s modified Eagle’s medium
sodium deoxycholic acid
Dulbecco’s phosphate buffered saline
dithiothreitol
N-terminus of the alpha subunit of the decarboxylase (El)
component of the human mitochondrial branched-chain
alpha-ketoacid dehydrogenase complex
fetal bovine serum
green fluorescent protein
A-2-hydroxyethylpiperazine-A-2-ethanesulfonic acid
high pressure liquid chromatography
heat shock protein
encephalomycarditis virus internal ribosome entry site
Luria-Bertani broth
maltose binding protein
microfarad
medium chain acyl-CoA dehydrogenase
Nonidet P-40
optical density at 600 nm
polyacrylamide gel electrophoresis
phosphate buffered saline
phenylmethylsulfonyl fluoride
polyvinylidene difluoride
sodium dodecyl sulfate
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
Tris-buffered saline-Tween 20
promoter for the tetracycline resistance gene

ix

ABSTRACT
Function and Properties of GroE Chaperonins in Bacterial and Mammalian Cells
by
Gregory M. Nelson
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, March 2000
Dr. Alan Escher, Chairperson

Molecular chaperones play an integral role in the folding of most polypeptides in
vivo, and protect proteins against aggregation when a cell is under stress. The GroESL
proteins of Escherichia coli are the best characterized of the ringed chaperones, or
chaperonins. Chaperonins of the eukaryotic cytoplasm interact with a limited number of
polypeptides, whereas GroEL is promiscuous as it binds and mediates the folding of
many polypeptides. This feature makes GroEL an attractive protein for investigating
various aspects of protein folding in eukaryotic cells because its substrate interaction is
diverse. In this work we have expressed the groES and groEL genes in the eukaryotic
cytosol and investigated three aspects of GroEL activity.
First, we examined whether properties of GroES and GroEL in bacteria were
retained in mammalian cells, such as GroELi4 and GroES? formation, and whether
GroEL could bind and release proteins. Second, we investigated whether GroEL could
be used as a molecular probe for proteins that misfold in mammalian cells under stress.
Third, we tested the hypothesis that GroES and GroEL could rescue a disease-causing
dysfunctional protein in mammalian cells, whose molecular defect was suspected to be
due to misfolding. A temperature sensitive mutant of the tumor suppressor protein p53

x

was used as a model to test whether GroES and GroEL could rescue a misfolded protein
in mammalian cells. In addition, we developed a multidomain fusion protein with in situ
reporter activity to investigate the folding of large proteins in bacteria and mammalian
cells.
Results indicated that proteins folding in mammalian cells appeared to be
sequestered from the bulk cytoplasm compared to proteins folding in bacteria. Unlike
E. coli cells, mammalian cells appear to have the inate ability to fold large multidomain
proteins encoded by overexpressed genes. GroEL has the potential to be used as a
molecular probe, but GroES and GroEL do not appear to rescue a mutant p53 protein
implicated in colon cancer progression. Finally, GroES and GroEL were required to
mediate the in situ folding of a large multidomain polypeptide, the luciferase-GFP protein
in E. coli.

xi

I.

Introduction

A.

Protein folding in vitro and in vivo
Proteins, the molecules that allow all living organisms to exist, are composed of

amino acid chains folded into distinct conformational three-dimensional structures. The
essential statement that structure equals function probably applies best to protein folding;
the native conformation of a protein dictates its function. Protein folding pioneer and
Nobel laureate Christian Anfmsen established that the primary amino acid sequence of
globular proteins contains all the information necessary to direct the linear chain of
amino acids into the correct tertiary structure producing a native, functional protein
(Anfinsen, 1973). A polypeptide sequence must satisfy a thermodynamic and a kinetic
requirement necessary for a protein to become active within a cell (Dobson et al., 1998).
Thermodynamically, the polypeptide must fold into a stable, unique folded structure
under physiological conditions. Kinetically, the unfolded polypeptide must fold into its
native structure on a biologically relevant time scale. A random search of all the possible
conformations of a polypeptide from the linear sequence presents an insurmountable
barrier to efficient protein folding because of the very high number of conformations to
search (Levinthal, 1969). If one assumes that each amino acid has three possible
configurations, then a 100 amino acid polypeptide could form 1049 conformations. If
only 10"11 seconds were allowed for each conformational change to occur, it would take
approximately 1026 years to search for all conformations (Dobson et al., 1998). The
paradox between time and complexity is known as Levinthal’s paradox. To solve it, he
proposed that a polypeptide could have ordered “pathways” that lead to folding on a
biological time scale (Levinthal, 1968).

1

The classical view of protein folding utilizes three models based on
phenomenological kinetics (Dorrington and Tanford, 1968; Pace and Tanford, 1968).
The off-pathway model analyses unfolded polypeptides that form the native state or an
intermediate state that is different from the unfolded or native state. The on-pathway
model analyzes the change of unfolded polypeptides into the native state, with usually
one normative intermediate in-between. The sequential model addresses the order that
several normative folding intermediates (I) pass through in a sequence from unfolded
polypeptide (U), U

Ii

I2

N, until the polypeptide is folded (N) (Anfmsen,

1972). The classical models are tested, based on decaying optical properties that change
after switching to folding or unfolding conditions (Kuramitsu and Hamaguchi, 1980; Dill
and Chan, 1997). Essentially, polypeptides are viewed as moving step-wise through
defined, individual intermediates like a path. However, a paradigm shift is starting to
take place in the theoretical protein folding field in conjunction with new experimental
systems and data (Baldwin, 1994; Bryngelson e/«/., 1995; Dobson

<2/., 1998). The

new view of protein folding kinetics uses language like ‘folding funnels’ and ‘energy
landscapes’ to describe the folding of denatured polypeptides as they move down an
energetic funnel to the lowest energetic minima, the native state (Thom et al., 2000;
Nakajima et al., 2000). An energy funnel or landscape represents the amount of free
energy that each conformation has as a function of the number of degrees of freedom,
such as the dihedral angles along the peptide backbone that determine its conformation
(Dill and Chan, 1997). Instead of defined pathways, the new view proposes that a
polypeptide consisting of many different conformations is present at the beginning of a
folding reaction. The directedness towards the functional folded protein is like a skier
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moving down a mountainside or an energy landscape. The energetic aspects of a
particular intermediate direct it toward the position of lowest energy. So-called “dead
end” intermediates ski into alcoves that have a high energy barrier. They either stay at
the dead end or they receive help to overcome the energetic barrier preventing the
formation of the native conformation (Miranker et al., 1991). The new view offers a
more robust theoretical perspective on protein folding. Combined with the development
of ultra-fast mixers and very sensitive equipment, experiments can be performed that will
allow researchers to make more accurate predictions regarding the process of protein
folding, and how the folding contributes to disease (Jones et al., 1993; Hagen et al..
1996). Protein folding in vitro, which is what much of the theoretical field addresses, is
studied by diluting chemically or thermally denatured preformed proteins into a refolding
buffer at protein concentrations, temperatures, pH and ion concentrations very different
from physiological conditions (Ellis and Hartl, 1996). The preformed denatured protein
folds as a whole structure, without many of the characteristics of folding within a living
cell.
According to molecular biology’s central dogma, a mRNA synthesized from its
corresponding gene contains the order of nucleotides that encode the primary sequence of
amino acids of a polypeptide (Drummond, 1982). Translation of the mRNA produces a
long string of amino acids, folding into a random coil, which collapses quickly into
secondary structures capable of forming various intermediates composed of a helicies
and p sheets with mobile loops joining the two (Hartl, 1996). The character of each
amino acid arranged in a defined sequence directs the organization of the folding
intermediates. Hydrophobic amino acids favor association with each other and eventual
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burial into a core of the folding polypeptide. Hydrophylic amino acids generally favor
exposure to the solvent and create the outer layer of the polypeptide. In vitro analysis of
synthetic peptides has revealed that an a helix can form within several nanoseconds to a
few microseconds, a p hairpin can form in about 1 microsecond and loops can form in 10
microseconds (Hagen et ai, 1996). The initial collapse into secondary structure appears
to be the formation of the loops, ~10 ps. As a polypeptide continues to fold, the
secondary structure becomes more complex as hydrostatic bonds are formed and broken.
Polypeptide intermediates that are nearly folded are known as molten globules and
contain regions of exposed hydrophobic amino acids . The passage through the molten
globule state is often the rate limiting step during protein folding (Hendrick and Haiti,
1993). These intermediates are compact and slightly larger than the protein in the native
state (Christensen and Pain, 1991). They possess extensive secondary structure that
forms a highly unstable tertiary structure (Hendrick and Hartl, 1993). The
conformational space is flexible in the tertiary structure, resembling the unfolded rather
than the native conformation (Kuwajima, 1989; Miranker et al., 1991). The final
structure of a folded polypeptide, the tertiary structure, forms when all the appropriate
amino acid side chains are packed, producing a native mature protein.
Recently, much discussion has been focused on the differences between protein
folding between bacteria and higher eukaryotes (Hartl, 1996; Fedorov and Baldwin,
1997). The proposition that gene shuffling has introduced higher levels of protein
organization in eukaryotes and allowed for diversification and complexity of protein
function is supported by the genome comparison of bacteria and higher eukaryotes
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(Netzer and Haiti, 1997). As proteins became more complex through the linking of
several domains, the difficulty of attaining the proper native conformation also increased.
Netzer and Haiti (Netzer and Haiti, 1997) demonstrated that eukaryotic
translation mixes and COS-7 cells were capable of folding a synthetic two domain
protein, whereas bacterial translation mixes and Escherichia coli were not. The
determining factor was the ability of the eukaryotic system to fold the two-domain
protein cotranslationally, whereas the bacterial systems nonproductively folded the
protein posttranslationally. The authors proposed that most proteins in bacteria fold
posttranslationally, supported by the general size range of polypeptides in E. coli,
suggesting that most polypeptides in bacteria are single domain proteins. E. coli has
4,285 proteins with and average length of 317 amino acids. Only 13% of those proteins
are greater than 500 amino acids (Netzer and Hartl, 1997). In contrast, yeast S. cerevisiae
contains 5,886 proteins with an average length of 484 amino acids, with 37% comprising
proteins greater than 500 amino acids (Netzer and Hartl, 1997). This hypothesis is
somewhat disputed since several other proteins have been shown to fold in a
cotranslational manner in bacteria (Fedorov and Baldwin, 1997).
Many proteins folding in vitro, are prone to aggregation during refolding
experiments, sometimes extensively, even at low protein concentrations (Mitraki and
King, 1989). In contrast, proteins folding in vivo involves folding of polypeptides, whose
concentration within the bacterial cell is as high as 50 pM (the ribosome concentration
within a bacterial cell) (Darnell et al., 1986) and yet the folding efficiency of
endogenous proteins approaches 100% (Mitraki and King, 1989). Even more perplexing
is that the folding occurs faster than the rate of translation, which is ~20 amino
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acids/second in bacteria (Netzer and Haiti, 1997) and ~4 amino acids/second in
mammalian cells (Thulasiraman et al., 1999), thus leaving the extending polypeptide
bound to the ribosome and unable to shield hydrophobic amino acids from interactions
with the crowded molecules within the cell. This sensitive period would seem to favor
aggregation until the exposed region could collapse into more protected secondary
structure like a domain or until the polypeptide was released from the ribosome. In
addition, a cell is crowded with ribosomes synthesizing polypeptides, and other
macromolecules like RNAs and other polypeptides in the process of folding, which all
could form nonproductive bonds with the exposed polypeptide and aggregate. Cells have
adapted to overcome the obstacles resulting from protein folding.
Molecular chaperones, protein molecules with cells, assist polypeptides that have
not reached their native state in several ways. First, they bind and promote favorable
interactions between amino acids within the folding polypeptide. Second, they can
sequester a polypeptide from the cellular milieu, thus preventing irreversible aggregation.
Third, they assist proteins in retaining their proper conformations after being partially
denatured by an exogenous stress. The association with molecular chaperones is a
dynamic process that assists polypeptides, which require some interaction with molecular
chaperones, to fold into the native, active state.
In the process of folding, a polypeptide has four possible pathways within the cell.
First, it can fold to the native state without any assistance. The small protein
staphylococcal nuclease does not associate with chaperones and quickly folds to its native
state (Ewalt et al., 1997). Second, it may form aggregates and be targeted for
proteolysis, such as the temperature sensitive folding mutants of the phage P22 tailspike
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(King et al., 1996). Third, it may fold into a misfolded but soluble state like the V143A
p53 mutant protein. Fourth, it may associate with molecular chaperones that will help it
attain its native conformation. Molecular chaperones associate with unfolded or folding
polypeptides that display regions of hydrophobicity. Most proteins associate with the
Hsp70 chaperones, but approximately 10% of all bacterial cytoplasmic proteins have a
high dependence upon the ringed chaperones. Bovine rhodanese is a protein that exhibits
that kind of dependence (Ewalt et al., 1997).
B.

Molecular chaperones
Molecular chaperones are ubiquitous proteins whose genes are highly inducible

when exposed to heat shock conditions; thus they were first identified as heat shock
proteins or hsp’s (Tissieres et al., 1974). They interact in vivo and in vitro with
polypeptides, providing folding assistance and protection from aggregation. Chaperones
increase the overall total yield of folded protein, but do not become part of the final
product (Coates et al., 1993). Some chaperones are folding catalysts, such as protein
disulphide isomerase (PDI), which catalyzes the thiol/disulphide interchange reaction.
PDI promotes protein disulfide formation, reduction and isomerization depending on the
substrate and redox potential (Gething and Sambrook, 1992). Chaperone activity has
been attributed to PDI and its ability to bind specific substrates like lysozyme,
thyroglobin and procollagen (Otsu et al., 1994; Kim and Arvan, 1993; Kellokumpu et
al., 1997) Another enzyme involved in protein folding is peptidyl prolyl cis-trans
isomerase (PPIase). PPIase activity catalyses the isomerization step of the peptide bonds
between proline and any preceeding amino acid, thus accelerating the in vitro (Fischer
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and Schmid, 1990; Schonbrunner et al, 1991) and in vivo (Bachinger and Compton,
1991) refolding rate of proline containing polypeptides.
There are several families of heat shock proteins that do not catalyse an enzymatic
reaction but can increase the yield of folded protein. The small heat shock proteins
(hsp’s) and a-crystallin, HsplOO/Clp, Hsp90, Hsp70 and Hsp40 represent chaperones that
interact with substrate polypeptides in the early normative stages of folding that need
specialized associations with chaperones (Fink, 1999). The oligomeric chaperones,
known as chaperonins, associate with late stage folding intermediates presumed to be in
the ‘molten globule’ state (Martin et al., 1991) and assist proteins that misfold under
stressful situations within the cell.
1.

Small Hsp's and a-crystallin
Small heat shock proteins and a-crystallin family members consist of proteins

that range from 12- to 43-kDa. They all contain a conserved a-crystallin domain in their
carboxy terminus and are strongly induced during heat shock (Plesofsky-Vig et al..
1992; deJong et al., 1993). Evidence currently is lacking as to whether the small hsp's
participate in protein folding, but they do bind unfolded proteins during heat shock
conditions (Ehmsperger er a/., 1997; Lee e/a/., 1997). Small heat shock proteins form
large oligomeric structures, 200-800-kDa, which may bind unfolded proteins on the
outside of the large oligomers. Small heat shock protein 27 may increase cell survival
against TNFa induced oxidative stress (Mehlen et al., 1997) and apoptotic inducing
agents (Arrigo, 1998). a-crystallin, found in the eye lens, binds to proteins that denature
due to age or injury and therefore assist in preventing cataracts. Small hsp's and a-
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crystallins appear to shield proteins from aggregation, but do not assist them to refold
after heat shock. They most likely deliver bound polypeptides to other chaperones that
then productively assist the polypeptides to fold.
2.

HSP100/Clp
The members of the HsplOO/Clp family share a diverse number of functions that

can all be attributed to their ability to promote the disassociation and disaggregation of
protein aggregates and oligomers in an ATP-dependent manner (Schirmer et al., 1996).
While some chaperones keep proteins from forming aggregates, the HSPlOO/Clp family
is capable of reducing the effects of aggregation by dissolving them. The proteins in this
family form monomers to trimers, but upon addition of ATP, they form ordered hexamer
rings with small central cavities, with a diameter of ~2.5 nm across for the eukaryotic
Hspl04 (Schirmer et al., 1996). Hexamer formation is thought to bring the regions that
interact with a polypeptide close together, which can then bind with the protein substrate,
but not within the small channel, in contrast to the ringed chaperonins (Schirmer et al..
1996). The first member of this family, ClpA, was identified in E. coli in association
with an ATP-dependent protease, Ti (Schirmer et al, 1996), implicating a role in
proteolysis by association. In addition, Hspl04 from S. cerevisiae is a critical factor
conferring thermotolerance at high temperatures (Sanchez and Lindquist, 1990) and
tolerance to high concentrations of ethanol (Sanchez et al., 1992). HSPlOO/Clp has also
been implicated in various other functions, such as the renaturation of a temperature
sensitive fusion bacterial luciferase (Parsell et al., 1994); suppression of defects in
translation termination (Chemoff et al., 1995); high salt tolerance (Kruger et al., 1994);
and degradation of ^0 protein in phage X (Wojtkowiak et al., 1993; Gottesman et al..
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1993). All of these functions can be attributed to the mechanism of HSPlOO/Clp to
dissociate and degrade protein aggregates and oligomers. Intense study of this family of
proteins will undoubtedly reveal more of the mechanisms involved in the chaperoning
activity.
3.

HSP90
Members of the Hsp90 family share homology between species, the most

divergent eukaryotes share at least 50% identity at the amino acid level and greater than
40% identity with Hsp90 homolog of E. coli (Lindquist and Craig, 1988). The various
homologues among prokaryotes and eukaryotes are the E. coli HtpG (Spence and
Georgopoulos, 1989); yeast Hsp83 and Hsc83 (Nathan et al., 1997); Drosophila
cytosolic Hsp83 (Xiao and Lindquist, 1989); mammalian cytosolic Hsp83 and Hsp87
(Wiech et al., 1992); mammalian endoplasmic recticulum Grp94 (Lee et al., 1984),
ERp99 (Mazzarella and Green, 1987) and endoplasmin (Koch et al., 1986). Hsp90 is a
highly abundant protein in eukaryotic cells under non-heat shock conditions (Jakob et al.,
1995). The genes encoding Hsp90 are stress inducible, within the eukaryotic cytosol
(Borkovich et al., 1989; Krone and Sass, 1994), the endoplasmic reticulum (Gething et
al., 1994) and bacteria (Zhou e? <2/., 1988).
Hsp90 performs various functions in vivo. It stabilizes the inactive form of
steroid receptors such as glucocorticoid and estrogen receptors until bound by ligand
(Picard et al., 1988; Picard et al., 1990; Dalman et al., 1989; Reynolds et al., 1999).
Hsp90 also forms a complex with Hsp70 due to the role of Hop, an adaptor molecule that
integrates the interaction of Hsp90 and Hsp70 in steroid receptor maturation (Chen and
Smith, 1998).
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Dimeric forms of Hsp90 also interact with cellular proteins involved with signal
transduction and cell structure, for example, tyrosine kinase (Brugge, 1986), casein
kinase II (Miyata and Yahara, 1992), calmodulin (Minami et al., 1993), actin (Miyata
and Yahara, 1991; Nishida et al., 1986), tubulin (Fostinis et al., 1992; Redmond et al.,
1989) and the heme regulated eIF-2a kinase (Rose et al, 1989). Additionally, Hsp90
can bind thermally unfolded citrate synthase intermediates, which upon releasing from
Hsp90, folds rapidly to the native state in vitro (Jakob et al., 1995).
Recent evidence demonstrated a negligible role for Hsp90 in bulk protein folding
compared to Hsp70 and Hsp60 as general chaperones (Nathan et al., 1997). Hsp90
action in de novo folding is restricted to proteins that have intrinsic difficulty achieving
stable structures exemplified by a temperature sensitive bacterial luciferase (Nathan et
al., 1997). As stress conditions increase Hsp90 concentrations in the cell, where Hsp90
can interact with proteins that already have difficulty in maintaining stability at
permissive temperatures and assist normally stable proteins when they encounter
difficulties in stability and folding (Nathan et al., 1997). The role of Hsp90 proteins in
protein folding as a general or specific chaperone is still a controversial matter and is not
completely resolved, however more experimental evidence will surely refine and
elucidate the in vivo functions clearly.
4.

Hsp70/Hsp40
Hsp70 (70-kDa) is a monomeric protein found in bacteria (DnaK) and most

compartments in eukaryotes including the mitochondrial lumen (Hsp70), the cytosol,
nucleus, golgi and the endoplasmic reticulum (BiP). It functions in several capacities, all
correlated by the ability of Hsp70 proteins to bind hydrophobic regions of polypeptides.
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Hsp70 proteins can protect thermally unfolded proteins from total denaturation and
assists the reconstitution of proteins under thermal stress (Schroder et al., 1993);
promote nascent chain folding on ribosomes (Hard, 1996); assist protein translocation
across membranes (Langer and Neupert, 1991); assemble antibody chains (Morrison and
Scharff, 1975; Haas and Wabl, 1983), and is involved in the replication and growth of
bacteriophage at high temperatures (Georgopoulos et al, 1990).
Hsp70 has a three-domain structure that allows it to perform these diverse
functions: an ATPase domain, a protein substrate binding domain and an as yet
uncharacterized C-terminal domain (Wilbanks et al., 1995). DnaK of E. coli is the best
characterized of the Hsp70 chaperones. It binds small hydrophobic regions from
translating polypeptides or recently translated polypeptides to varying degrees depending
on the strength and amount of hydrophobicity displayed on the polypeptide. The
specificity of substrate binding has been mapped out by screening a cellulose-bound
peptide library (Rudiger et al., 1997). The binding motifs are mostly p sheets that are
usually fully buried in the native, folded protein. The target motif is a hydrophobic core
of four to five residues consisting mostly of leucine, but also of tyrosine, phenylalanine,
isoleucine, and valine. The amino acids flanking the core are mostly basic, while acidic
amino acids are not found in the core and disfavored in the flanking regions.
Statistically, every 36 amino acids of a polypeptide contains a Hsp70 binding site (Fink,
1999), which should allow Hsp70 to protect it from unfavorable interactions with itself
and other macromolecules. Release of the polypeptide from DnaK allows the
polypeptide to fold to the native state, aggregate or rebind to DnaK.
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The role of ATP is very important in the binding and release of substrate
polypeptide by Hsp70 (McCarty and Walker, 1994). ATP binding to DnaK creates a
polypeptide accepting state in DnaK. The DnaK-ATP complex has a low binding affinity
for normative polypeptide with quick rates of exchange if it happens to be bound. The
DnaK-ADP complex, however, is stable, with high binding affinity for substrates and
slow rates of protein substrate exchange (Bukau and Horwich, 1998). The presence of
ATP or ADP controls a hinge-like polypeptide-binding pocket. When ATP is bound, the
pocket is open and it closes when ATP is hydrolysed to ADP. On its own, DnaK
hydrolysis of ATP to ADP is slow, making the chaperone unproductive, requiring some
means to speed up ATP hydrolysis. ATP hydrolysis and nucleotide exchange from DnaK
is assisted and mediated in part by its co-chaperones, DnaJ and GrpE.
DnaJ (40-kDa) of E. coli is homologous to eukaryotic Hsp40 found in all cells
and compartments (Laufen et al., 1997). DnaJ has a dual function in its role as co
chaperone for DnaK. First, DnaJ can bind unfolded polypeptide substrate and deliver it
to the DnaK-ATP complex. Once the folding protein is transferred to DnaK, its ATPase
activity is stimulated through the interaction with DnaJ, hydrolysing ATP to ADP
(McCarty et al., 1995). Second, DnaK-ATP may transiently bind protein substrate,
which if this complex interacts with free DnaJ, the DnaK bound ATP is hydrolysed to
ADP. This coupling of protein substrate to ATP hysrolysis prevents the needless
hydrolysis of ATP by DnaK without substrate polypeptide bound. Once substrate is
transferred to DnaK and ATP is hydrolysed, DnaJ is released to recycle back to bind
more protein substrate.
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The DnaK-ADP-substrate complex binds to the second cochaperone, GrpE (21.8kDa), triggering release of ADP from the DnaK-substrate complex (Lieberek et al..
1991). Once ATP rapidly binds again to DnaK, GrpE and the substrate polypeptide are
then released. DnaK is again primed to bind another normative polypeptide or receive
one from DnaJ. GrpE has been identifed in E. coli (Wu et al, 1994), archaebacteria
(Conway de Macario et al., 1994) and mitochondria (Naylor et al., 1996); however, a
GrpE homolog has not been identified in chloroplasts or in the cytosol, endoplasmic
reticulum or nucleus of eukaryotic cells. It does appear that a nucleotide exchange factor
like GrpE is expendable in some Hsp70 chaperone functions. There may be other factors
that perform specialized cochaperone-like regulatory activities for Hsp70 in eukaryotic
cells, such as Hip, which stabilizes the Hsp70-ADP state (Frydman and Hohfeld, 1997),
or Hop (also known as BAG-1), which may stimulate nucleotide exchange (Hohfeld and
Jentsch, 1997) but is not homologous to GrpE.
Many polypeptides, -50%, interact with DnaK during biogenesis to achieve their
native state (Teter et al., 1999). Some polypeptides are more sensitive to aggregation
and require additional assistance to complete their folding into native, active proteins.
Polypeptides may be released into the bulk cytosol and bound by ringed chaperonins as in
bacteria, or they may be transferred to chaperonins in a more directed pathway through a
protein intermediate without release into the bulk cytosol as in eukaryotes and
archaebacteria.
5.

Ring chaperones: group I and II chaperonins
The distinguishing characteristic of chaperonins is the formation of an oligomeric

ring complex. Hsp60 from bacteria, mitochondria and chloroplasts, the thermosome from
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archaebacteria and TRiC from eukaryotes form high molecular weight complexes of two
rings stacked back-to-back, forming a noncontiguous channel or chamber. Auxiliary
chaperonin HsplO also forms a ring structure and associates with some double ringed
chaperonins to mediate the folding of polypeptides. Group I chaperonins are found in
bacteria, mitochondria and chloroplasts (Zeilstra-Ryalls et al., 1991) and form ringed
structures composed of homologous subunits with seven-fold rotational symmetry.
Group II chaperonins (Willison and Kubota, 1994) are found in archaebacteria and the
eukaryotic cytosol (Trent et al., 1991; Frydman et al., 1992) and are composed of
multiple heterologous subunits of eight- or nine-fold rotational symmetry. They will be
discussed first, since the remainder of the introduction will be focused on the group I
chaperonins.
a)

Chaperonins of archaebacteria and eukaryotic cytosol

(1)

Archaebacteria
Group II chaperonins are found in the cytoplasm of archaebacteria and the cytosol

of eukaryotes. The archaebacterial chaperonin, known as the thermosome, is considered
to be the functional representative of the 60-kDa group I chaperonins (Horwich and
Willison, 1993). The thermosome of archaebacteria form an 8 (Pyrodictium occultum) or
9 (Sulfolobus solfataricus) membered double ring structure (~1000-kDa) composed of
two subunits containing domain folds similar to GroEL (Ditzel et al., 1998). The
subunits of the thermosome are very similar to each other, each with a molecular weight
of ~60-kDa. X-ray crystalography of crystals from the thermosome has revealed
protrusions from the apical domain that may act as a built-in lid, covering the central
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channel, analogous to the GroES co-chaperonin, binding and secluding polypeptides
(Klumpp

a/., 1997; Ditzel

a/., 1998). No GroES-like protein has been discovered

as a co-chaperonin in archaebacteria. The thermosome of Sulfolobus solfataricus can
prevent thermal denaturation and promote refolding of bound polypeptides in vitro
(Guagliardi et al., 1995). Additionally, the levels of the thermosome are dramatically
increased after heat shock in Pyrodictium occultum which grows optimally at 105°C. The
thermosome represents 11% of the total soluble protein at 100°C, however, it increases to
73% of the total soluble protein when the cells are heat shocked at 108°C (Phipps et al.,
1994). Though the thermosome has not been as well characterized as the GroEL
chaperonin of E. coli, additional study is sure to provide some interesting and important
information regarding the group II chaperonins and their divergence from the eukaryotic
chaperonin, TRiC.
(2)

TRiC
The group II chaperonin of the eukaryotic cytosol is known as TRiC (t-complex

polypeptide-1 ring complex)(Li e? a/., 1994). It forms a 960-kDa hetero-oligomeric
double ring structure composed of at least eight related but distinct polypeptides with
molecular weights of 57.5-kDa to 60.6-kDa (Kubota and Willison, 1997). In contrast to
the other chaperonins, synthesis of the TRiC subunits does not appear to be induced upon
heat shock. Relatively little is known about TRiC, with only a few natural substrates
shown to interact with it in vivo, such as actin, tubulin and Ga-transducin (Li et al., 1994;
Farr et al., 1997). Interestingly, in vitro experiments have demonstrated productive
folding of firefly luciferase mediated by TRiC, but not by GroEL (Frydman et al., 1992).
TRiC has the same double ring features similar to GroEL as determined by cryoelectron
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microscopy (Marco et al., 1994). There appears to be extensive homology in the regions
comprising the equatorial domain, especially the conservation of identical residues
comprising the ATP binding site motif (residues 86-91 and 412-416 in GroEL) but
almost no homology exists within the intermediate or apical domains (Kim et al., 1994;
Kubota^ <2/., 1995).
One of the main functions of TRiC is to mediate the folding of actin and tubulin
in a sequestered, compartmentalized protein folding pathway (Siegers et al, 1999). The
protein folding machinery of the eukaryotic cell shelters nascent polypeptides from
nonproductive interactions within the bulk cytosol in a hand-to-hand fashion. Hsp70
initially binds the synthesized polypeptide, masking hydrophobic regions that are
aggregation-sensitive. Prefoldin/GimC, another factor in the protein folding machinery
of eukaryotic cells interacts with TRiC in the folding of nascent polypeptides (Vainberg
et al., 1998). This interaction has been identified in yeast and also mammalian cells and
probably acts as a bridge, transferring the polypeptide from Hsp70 to TRiC (Hansen et
al., 1999; Siegers e/a/., 1999). Complete folding of protein substrate takes place with
the assistance of TRiC and the polypeptide is released to perform its proper function.
Group II chaperonins, the first chaperonins to be identified, are also involved in
mediating protein folding, but much more time and energy has been spent understanding
their function, process and capacity to fold proteins.
b)

Chaperonins of bacteria, mitochondria and chloroplasts
The Hsp60/Hspl0 chaperonins of Escherichia coli, GroEL and GroES, are the

best-characterized members of the group I chaperonin family. Chaperonins GroES and
GroEL were first identified through mutations in E. coli that blocked X phage biogenesis,
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producing large aggregates of head particles (Georgopoulos et ai, 1973; Sternberg,
1973). Mutations in the A, E protein overcame the defect and allowed infectious phage
production, implicating GroEL in protein assembly; hence, the E. coli gene responsible
was named groE and was subsequently identified as part of the two gene groESL operon,
groES, for the small gene and groEL for the large gene. Deletions of the groESL genes
are lethal for E. coli at all temperatures indicating that they are essential proteins in cell
viability (Van Dyk e/a/., 1989; Fayet ^

1989). GroEL interacts with a relatively

small number of polypeptides, -10-15% of the total protein population of E. coli under
normal physiological conditions (Ewalt et ai, 1997). However, when cells are placed
under stress, such as heat shock, approximately 30%-50% of nascent and prefolded
polypeptides transit GroEL (Ewalt et aL, 1997; Parsed and Lindquist, 1993). All
bacterial species examined so far contain proteins homologous to GroES and GroEL.
GroEL also has homologues in both mitochondria and chloroplasts. Homology
between plant chloroplast Hsp60 and GroEL is 46.3% and human mitochondrial Hsp60
and GroEL is 49.1% (Georgopoulos and Ang, 1990). Size exclusion studies (Viitanen et
aL, 1992) and electron micrographs (Horwich et aL, 1998) have indicated that
mitochondrial Hsp60 is a single ring as opposed to the double ring of GroEL, but the
double ring may be the only form that is functional. Mitochondrial Hsp60 and HsplO can
substitute for all the essential functions of GroES/GroEL in E. coli, however, the
mitochondrial proteins cannot compensate for some nonessential functions, such as
GroEL-dependent head assembly of bacteriophage T4 and GroES/GroEL-dependent head
assembly of bacteriophage A (Nielsen et aL, 1999). GroES and GroEL have been the
subject of intense study since they were first shown to assist protein folding.
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(1)

GroES
The groES gene is the first of the two-cistron groE operon (Hemmingsen et al.,

1988). A 291 nucleotide open reading frame encodes the GroES protein, a 10-kDa
protein that forms a single ring of seven homologous subunits (Mande et al, 1996;
Mayhew and Hard, 1996). The crystal structure of GroES from E. coli has been
elucidated at a resolution of 2.8 A (Hunt et al., 1996) and CpnlO from M laprae at 3.5 A
(Mande et al., 1996). GroES binds noncovalently to the apical domain of GroEL, thus
coordinating conformational changes that assist folding of bound nascent polypeptides
and denatured proteins (Xu et al., 1997). The GroELu-GroESy complex secludes the
non-native polypeptide from unproductive molecular interactions (Chen et al., 1994).
(2)

GroEL
The groEL gene (1647 bp) is the second gene of the E. coli groE operon

(Hemmingsen et al., 1988). An individual GroEL subunit has a molecular mass of ~57kDa (Hemmingsen et al., 1988) although it migrates with an apparent molecular mass of
~66-kDa when using SDS-PAGE. GroEL protein forms a 14-mer complex of two
heptameric rings of homologous subunits stacked back-to-back (Braig et al, 1994) with
a total molecular mass of ~812-kDa.
The crystal structure of GroEL has been solved at 2.8 A (Braig et al., 1994).
Each subunit of GroEL contains three domains (Kawata et al., 1999). The apical domain
is responsible for polypeptide binding and association with GroES (Fenton et al., 1994).
The equitorial domain is involved in inter- and intrasubunit contacts as well as contacts
between rings (Braig et al., 1994). The intermediate domain is a flexible region between
the apical and equitorial domains that lifts and swings the apical domain upward, which
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increases the volume of the GroELi4 chamber (Xu et al., 1997). The stacked rings form
a noncontiguous central channel capable of enclosing a polypeptide of ~70-kDa
molecular weight, assuming a very compact folded intermediate (Sigler et al., 1998).
The volume of the noncontiguous cavity is nearly 85,000 A3, based on the crystal
structure of GroEL bound to GroES and ADP (Sigler et al., 1998). GroEL operates in
vivo with the cochaperonin GroES, which increases the volume of the cavity after
binding, creating an enclosed, secluded folding chamber (Xu et al., 1997) with GroEL
forming the floor and walls and GroES forming the roof. This secluded chamber allows a
polypeptide protection from aggregation and an opportunity to fold without any other
interference.
(3)

GroES/GroEL mediated protein folding
GroES/GroEL-mediated protein folding occurs on alternating rings of GroELu

(Kad et al., 1998). One ring of GroELn exists in a polypeptide accepting state while the
other is not (Rye et al., 1997). Polypeptide binds to the inner channel of the polypeptide
accepting ring of GroELu via the apical domain, which contains hydrophobic regions of
amino acids (Braig et al., 1994). These hydrophobic regions interact with the exposed
hydrophobic regions of the non-native polypeptide in a noncovalent manner (Lin et al..
1995). Recent evidence revealed a structural motif, the a(3 sandwich, which is
preferentially bound among the proteins isolated via immunoprecipitation (Houry et al..
1999).
The GroEL ring complexed with the folding polypeptide is known as the cis
GroEL ring. One ATP nucleotide binds per GroEL subunit on the cis GroEL ring
(Ostermann et al., 1989), followed by GroES docking. The cooperativity of GroES and
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GroEL allows ATP to be hydrolyzed to ADP and Pi in a coordinated manner causing a
conformational change in GroEL. The apical domains of the cis GroEL complex raise
60° upward and 90° to the left (viewing the monomer GroEL from the inside of the
chamber). This conformational shift stretches the polypeptide and partially unfolds it, as
determined by deuterium exchange experiments (Shtilerman et al., 1999) and switches
hydrophobic regions of the GroEL apical domain with regions of hydrophilicity (Xu et
al., 1997). The polypeptide, no longer bound by the walls of GroEL, can fold in an
exclusive microenvironment, free from nonproductive interactions and favors the burial
of hydrophobic regions on the polypeptide.
The hydrolysis of ATP sets a “timer” for the cis GroES/GroEL-polypeptide
complex association. Binding of ATP to each GroEL subunit on the cis GroEL ring
blocks ATP binding on the trans GroEL ring. Subsequent hydrolysis of ATP to ADP
then allows binding of ATP to the trans GroEL ring and results in another conformational
shift that promotes the release of GroES, ADP and polypeptide from the cis GroEL ring,
taking ~15 seconds. The released polypeptide then folds completely to its native state, or
is rebound by GroEL for another round of folding. There is considerable discussion,
however, as to the state of the trans GroEL after the dissociation of the cis GroEL
complex with polypeptide and GroES. The general consensus now forming is that very
soon after the dissociation of the cis GroEL complex, the trans GroEL ring is in a high
polypeptide accepting state and that non-native polypeptide is bound immediately to the
trans GroEL ring followed by GroES, which then becomes the cis ring complex. The
GroEL-GroES-ATP/ADP cycle has been throughly studied and is constantly being
refined, as more data becomes available. Of course, the whole purpose of the reaction
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cycle is to assist proteins fold into their conformationally active structure. Although
GroEL is very promiscuous, it does not recognize a specific sequence of amino acids, but
can bind many protein substrates with various functions.
(4)

Substrates of GroEL
Since the demonstration that GroEL could mediate the folding of the protein

Rubisco (Hemmingsen et al., 1988), many protein substrates have been described that
interact with GroEL in vitro and in vivo. Figure 1 is representative of the substrates that
have been described in the available literature. Many studies with various protein
substrates have revealed that GroEL does not recognize a single polypeptide sequence,
indeed it can interact with an all a helical polypeptide (Landry and Gierasch, 1991) as
well as an all p sheet polypeptide (Schmidt and Buchner, 1992). Ulrich Haiti’s group
recently published the largest in vivo search for GroEL protein substrates using
immunoprecipitation of GroEL and identifying coimmunoprecipitants (Houry et al.,
1999). They determined that -300 polypeptides interact with GroEL in E. coli, which
may be actually higher given that immunoprecipitation may not identify protein
substrates that transit GroEL quickly or are not stable on GroEL via the
immunoprecipitation procedure. The identity of 52 polypeptides described and classified
the proteins into the following categories: amino-acid metabolism, sugar metabolism and
other metabolisms, transcription and translation, and other miscellaneous activities such
as stress response, DNA manipulation and cell division. GroEL showed no bias for any
gene family; however, most of the proteins that associated with GroEL were less than 60kDa. The wide variety of substrate proteins interacting with GroEL in vivo confirms its
promiscuous capacity to bind proteins. Indeed, GroEL can assist a wide variety of
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Figure 1. Substrates that interact with GroEL in vivo and in vitro.
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GroEL Substrate

Mr (K)

Experimental Reference
conditions
In vivo
(Hourye£tf/., 1999)

DNA-directed RNA polymerase P
chain fragment
Phytochrome photoreceptor
E. coli p-galactosidase

150.6
124
116

In vitro
In vitro

Ketoglutarate dehydrogenase
DNA gyrase subunit A
Phenylalanyl-tRNA synthetase P
chain
Plant P-glucosidase- glutathione Stransferase fusion protein
Maltose binding protein fused to the
alpha subunit of the decarboxylase
(El) component of the human
mitochondrial branched-chain
alpha-ketoacid dehydrogenase
complex
T etrahydropteroyltriglutamate
methyltransferase
P-Glucosidase
Methylmalonyl CoA mutase

105.1
97.0
87.4

In vivo
In vivo
In vivo

87

In vitro

86

In vitro

84.5

In vivo

(Roury et al., 1999)

83.4
79

In vitro
In vitro

Human propionyl-CoA carboxylase
alpha subunit
Polynucleotide phosphorylase
Phosphate acetyltransferase
Glycyl-tRNA synthetase b chain
Bacterial luciferase

77.3

In vitro

(Machida e/a/., 1998)
(Weissman et al.,
1994)
(Kelson et al., 1996)

77.1

In
In
In
In

Imidazoleglycerol phosphate
dehydratase-histidinol phosphate
phosphatase
Alcohol oxidase
Threonyl-tRNA synthetase
Phage P22 coat protein
Alpha-glucosidase
RNA polymerase, sigma subunit
NiFe hydrogenase 3 precursor
Acetolactate synthase isozyme III
large subunit
Non-glycosylated invertase
Firefly luciferase

77.0

76.7
76

vivo
vivo
vivo
vivo

(Grimm et al., 1993)
(Ayling and Baneyx,
1996)
(Horwich et al., 1993)
(Hourye/a/., 1999)
(Roxxry et al., 1999)
(Keresztessy et al.,
1996)
(Huang and Chuang,
1999)

(Horwich et al., 1993)
(Houry et al., 1999)
(Houry e/a/., 1999)
(Escher and Szalay,
1993)
(Van Dyk <?/., 1989)

75

In vivo

74.1

68.5

In vitro
In vivo
In vivo
In vitro

66
65
63.0

In vitro
In vitro
In vivo

(Ewgxs etal., 1993)
(Houry ^<2/., 1999)
(Gordon et al., 1994)
(Holl-Neugebauer et
al, 1991)
(Browns a/., 1992)
(Rodrigue et al, 1996)
(Houry et al, 1999)

60.5
60

In vitro
In vivo

(Kerne/a/., 1992)
(Schroder e/a/., 1993)

74.0
72
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Human propionyl-CoA carboxylase
beta subunit
2-Isopropylmalate synthase
NUSA protein
Glucose-6-phosphate
dehydrogenase
Taka-amylase A
Tryptophanase
Glutamate decarboxylase-a
RUBISCO
Dodecameric glutamine synthase
Citrate synthase
Protein- tyrosine kinase p50csk
Dihydrolipoamide dehydrogenase
Tubulins
Prion protein PrPc
6-hydroxy-D-nicotine oxidase
Pro-urokinase
D-amino acid dehydrogenase small
subunit
Tagatose-6-phosphate kinase gatZ
Yeast enolase
E2 inner core bovine mitochondrial
branched chain a-keto acid
dehydrogenase
Medium-chain acyl-CoA
dehydrogenase
ATP-dependent Clp protease ATPbinding subunit ClpX
Aspartate aminotransferase
Histidinol dehydrogenase
E. coli Enolase
THIH protein
Elongation factor Tu
UDP-galactopyranose mutase
Human cyclin dependent kinase
inhibitor pi6 fused with glutathione
S-transferase
Plant ferredoxin-NADP+ reductase
S-adenosylmethionine synthetase
Capsid protein gp5of bacteriophage
HK97
8-Amino-7-oxononanoate synthase

58.2

In vitro

(Kelson e/a/., 1996)

57.2
54.9
54.3

In vivo
In vivo
In vitro

54
52.8
52.7
52.7
51.7
51.6
50.7
50.6

In vitro
In vitro
In vivo
In vitro
In vitro
In vitro
In vitro
In vivo

50
49

In vitro
In vitro

48.7

48.5
47.6

In vitro
In vitro
In vivo

(Houry^a/., 1999)
(Hourye/a/., 1999)
(Hansen and Gafhi,
1993)
(Kawata ^ <3/., 1994)
(Mizobata e? <2/., 1992)
(Roury et al., 1999)
(Viitanen et al., 1990)
(Fisher, 1998)
(Buchner et al., 1991)
(Amrein et al, 1995)
{Romy et al., 1999;
Houry et al., 1999)
(Phadtare et al., 1994)
(Edenhofer et al.,
1996)
(Brandsch et al., 1993)
(Xu et al., 1997)
{Roury et al., 1999)

47.1
46.6
46.5

In vivo
In vitro
In vitro

(Roury et al., 1999)
(Kubota/., 1993)
(yiyrmet al., 1994)

46.5

In vivo

(Bvoss etal., 1993)

46.2

In vivo

(Houry et al., 1999)

46.2
45.7
45.5
43.3

In vitro
In vivo
In vivo
In vivo

(Mattingly ^ a/., 1995)
(Van Dyk et al., 1989)
{Roury et al., 1999)
(Roury et al., 1999)

43.2
43.0
43

In vivo
In vivo
In vitro

(Roury et al., 1999)
(Roury et al., 1999)
(Luo and Hua, 1998)

42.3
42.0
42

In vitro
In vivo
In vitro

(Dionisi e/<2/., 1998)
(Roury et al., 1999)
(Dinged/., 1995)

41.6

In vivo

(Houry ^<2/., 1999)
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P-lactamase precursor
Granulocyte Rnase

41.5
~40

In vitro
In vitro

Protein in OXMY-DEOC intergenic
region
Histidinol-phosphate
aminotransferase
Glycerol dehydrogenase

39.8

In vivo

(Laminet et al., 1990)
(Rosenberg et al.,
1993)
(Houry^a/., 1999)

39.7

In vivo

(VanDyke^tf/., 1989)

39.5

In vitro

Phospho-2-dehydro-3deoxyheptonate aldolase, Trpsensitive
Phospho-2-dehydro-3deoxyheptonate aldolase, Phesensitive
RecA protein
Galactitol-1-phosphate 5dehydrogenase
Threonine 3-dehydrogenase
DNA-directed RNA polymerase a
chain

38.7

In vivo

(Krauss and Gore,
1996)
(Roury et al., 1999)

38.0

In vivo

(Romy et al., 1999)

37.8
37.4

In vivo
In vivo

(Houry et al., 1999)
(Houry et al., 1999)

37.2

36.5

In vivo
In vivo

(Houry ^<3/., 1999)
(Roury et al., 1999)

Malate dehydrogenase
Lipoic acid synthetase
Phenylalanyl-tRNA synthetase a
chain
Ornithine transcarbamylase
Glyceraldehyde 3-phosphate
dehydrogenase A
Lactate dehydrogenase
Pho spho fructokinas e

36.3
36.1
36.

In vitro
In vivo
In vivo

(Miller et al., 1993)
(Roury et al., 1999)
(Houry et al., 1999)

36
35.4

In vitro
In vivo

(Zheng ^ a/., 1993)
(Houry et al., 1999)

34.8
34.7

In vitro
In vitro

Asparatate carbamoyltransferase
catalytic chain
5,10-Methylenetetrahydrofolate
reductase
Rhodanese
Bovine deoxyribonuclease I
Tagatose-bisphosphate aldolase
gatY

34.3

In vivo

(Badcoe ^ <3/., 1991)
(Melegh and Minami,
1997)
(Roury et al., 1999)

33.1

In vivo

(Houry et al., 1999)
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31.3
31.1

In vitro
In vitro
In vivo

(Mendoza a/., 1991)
(Teshima ^ «/., 1997)
(Roury et al., 1999)

31

In vitro

29.7
29.5
29.1

In vivo
In vivo
In vitro

(Sherman and
Goldberg, 1991)
(Houry et al., 1999)
(Roury et al., 1999)
(Persson et al., 1995)

CRAG
THIG protein
Cell division inhibitor minD
Carbonic anhydrase II
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Phosphate transport ATP-binding
protein
Green fluorescent protein
Phosphomethylpyrimidine kinase
NAGD protein
Protein in XERC-UVRD intergenic
region
Phosphoribosylaminoimidazolesuccinocarboxamide synthase
Trichosanthin
3OS ribosomal protein S2
Chloramphenicol acetyltransferase
Protein YCFV
Capsular-synthesis regulator
component
Lysozyme
Uracil phosphoribosyltransferase
Heat-shock protein GrpE
Dihydrofolate reductase
NUSG protein
Chloroplast precursor protein

29.0

In vivo

(Houry^tf/., 1999)

29
28.6
27.1

In vitro
In vivo
In vivo
In vivo

(Makino et al., 1997)
(Hourye/fl/., 1999)
(Hourye^tf/., 1999)
(Hourye^a/., 1999)

27.0

In vivo

(Hourye^tf/., 1999)

27

In vitro
In vivo
In vitro
In vivo
In vivo

(Lauefa/., 1998)
(Houry e/<2/., 1999)
(Kim and Kang, 1991)
(Hourye/a/., 1999)
(Houry^fl/., 1999)

20.2

In vitro
In vivo
In vivo
In vitro
In vivo
In vitro

(Coyle ^<3/., 1999)
(Hourye/a/., 1999)
(Romy et al., 1999)
(Viitanen et al., 1991)
(Romy et al., 1999)
(Dessauer and Bartlett,
1994)
(Hwang et al., 1998)

27.2

26.6
25.6
24.9
23.7
23.2

22.5
21.8
21.4
20.5

Tobacco mosaic virus coat protein
for ribonucleocapsid
Ferritin
Stringent starvation protein B
Cyclophilin
Cu,Zn superoxide dismutase
Bamase
Interferon-gamma

20

In vivo

19.4
18.3
17.7
17.6
17.5
17

In vivo
In vivo
In vitro
In vitro
In vitro
In vitro

5OS ribosomal protein L9
Alpha-lactalbumin

15.8
14.2

In vivo
In vitro

Bovine adrenodoxin
5OS ribosomal protein L7/L12
Cytochrome C
DNA-directed RNA polymerase 0
chain
F(ab) fragments

14
12.2
11.5
10.2

In vitro
In vivo
In vitro
In vivo

Not
given

In vitro
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(Roury et al., 1999)
(Roury et al., 1999)
(Zahne^tf/., 1994)
(Battistoni #/., 1993)
(Gray et al., 1993)
(Vandenbroeck et al.,
1998)
(Houry et al., 1999)
(Hayer-Hartl et al.,
1994)
(Grunau et al., 1995)
(Roury et al., 1999)
(Hoshino ^ <2/., 1996)
(Romy et al., 1999)
(Schmidt and Buchner,
1992)

polypeptides to attain their native conformation, explaining the necessity of this
chaperonin for cell viability at all temperatures (Van Dyk et al., 1989; Fayet et al..
1989).
(5)

Large polypeptides bound by GroEL
Several large proteins form stable complexes with GroEL but are not productively

folded, either with or without GroES (phytochrome photoreceptor [124-kDa] (Grimm et
al, 1993), p-galactosidase [116-kDa] (Ayling and Baneyx, 1996), methylmalonyl Co A
mutase [79-kDa] (Weissman et al., 1995), tailspike protein of phage P22 [72-kDa]
(Gordon e/a/., 1994) and firefly luciferase [60-kDa] (Schroder ^ a/., 1993)). The act of
binding and subsequent release by GroEL may be enough of a kinetic stabilizer to allow
these large proteins to fold to their conformationally active state. However, these studies
were done in vitro, so the effect of physiological conditions cannot be stated or how
GroES may interact in vivo to assist the folding of these proteins.
There has been some evidence suggesting that GroES and GroEL can fold a large
polypeptides. The first example was in vitro work demonstrating the need for GroES,
GroEL and Mg2+-ATP to productively fold a large 86-kDa polypeptide fusion. The
protein was a fusion of the mature maltose-binding protein (MBP) linked to the Nterminus of the alpha subunit of the decarboxylase (El) component of the human
mitochondrial branched-chain alpha-ketoacid dehydrogenase complex (Huang and
Chuang, 1999). GroES binding to GroEL was compared in the presence of the alpha
subunit moiety of El or the full fusion of MBP-alpha EL GroES could cap either end of
GroEL in the presence of the alpha subunit of El, however in the presence of MBP-alpha
El, GroES could only cap the non-polypeptide bound trans GroEL ring. The authors

28

conclude that productive folding of large proteins can only occur on the GroEL ring that
does not have GroES sequestered.
The second investigation explored the size of a protein that could fit into the
folding cavity of GroEL and still be capped by GroES in vitro (Sakikawa et al., 1999).
The green fluorescent protein (GFP) and a variant, the blue fluorescent protein (BFP)
were fused together creating a 54-kDa protein fusion. In vitro experiments demonstrated
GFP-BFP fusion protein was protected from proteinase K digestion by GroES
encapsulation. The encapsulated GFP-BFP fusion was functional within the GroELGroES chamber. Frequency resonance energy transfer probed the activity of both
fluorescent proteins encapsulated under GroES. Energy was transferred from BFP to
GFP, indicating activity of both proteins sequestered inside the GroEL chamber covered
with GroES. A triple fluorescent protein fusion (82-kDa) was susceptible to proteinase K
digestion, suggesting that GroES could not encapsulate it. However, it was not specified
if activity was retained from the third GFP of that fusion. It could have been active
without being capped by GroES. These experiments provided evidence for a probable
maximum polypeptide size that could fit within the GroEL cylinder capped with GroES.
The third investigation demonstrated the necessity of GroES and GroEL to rescue
a large protein in vivo, temperature sensitive bacterial luciferase (76-kDa). Bacterial
luciferase is a heterodimer of LuxA and LuxB subunits and in the presence of long-chain
aldehyde and oxygen, the enzyme emits a photon of light. The fusion of the bacterial
luciferase subunits LuxA and LuxB resulted in temperature sensitivity at 37°C in E. coli
(Escher et al., 1989) and was due to polypeptide misfolding (Nathan et al., 1997). The
bacterial luciferase was also used as a model substrate that demonstrated the propensity
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of the luciferase to aggregate in yeast cells deficient in Hspl04 (Parsell et al., 1994).
Escher and Szalay (Escher and Szalay, 1993) demonstrated that E. coli cells
overexpressing the groEL gene displayed luciferase activity lower than basal levels from
cells that contained no excess chaperonins. The overexpression of both groES and groEL
genes overcame the temperature sensitivity and greatly increased the activity of the
fusion luciferase (Escher and Szalay, 1993). This was previously the only in vivo work
that was done which demonstrated the requirement of GroES and GroEL for the folding
of a large two-domain protein.
GroEL appears to be much more promiscuous than group II chaperonins,
especially TRiC, assisting a wide variety of proteins to fold correctly, large and small.
Overexpression of the genes encoding GroES and GroEL is capable of rescuing several
proteins that misfold within E. coli. The following studies address the ability of GroEL
to suppress temperature sensitive folding of polypeptides, and of GroEL to keep proteins
from forming insoluble aggregates or inclusion bodies.
(6)

GroES and GroEL rescue of misfolding proteins
The overexpression of the groESL genes has been used to abrogate the

misfolding propensity of many proteins within E. coli, which may consequently indicate
a means of rescuing misfolding proteins that result in human disease. Several examples
illustrate the capacity of GroESL overproduction to rescue various diverse proteins.
Early genetic studies of GroESL demonstrated the essential requirement for
chaperonins at all temperatures in E.coli also revealed that overexpression of the groESL
genes could suppress the mutations of several diverse proteins. They included
acetolactate synthase II, transaminase, histidinol dehydrogenase, histidinol-phosphate
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aminotransferase and imidazoleglycerol phosphate dehydratase-histidinol phosphate
phosphatase (Van Dyk et ai, 1989).
The protein medium chain acyl-CoA dehydrogenase (MCAD) is involved in
mitochondrial beta-oxidation (Andresen et al., 1997). A prevalent point mutation,
K304E, is responsible for a life threatening disease condition (Andresen et al., 1995) due
to misfolding (Bross et al, 1995). Coexpression of the groESL genes and K304E
MCAD increased the solubility and amount of activity of the mutant MCAD in E. coli
(Bross et al., 1993). We tried to synthesize MCAD in the cytosol of COS-7 cells as a
possible protein substrate for GroESL rescue, but we were not able to detect the protein
from cells transfected with either the wild type of mutant mead genes (details are found
in the appendix).
An important enzyme that plays a role in cellulose biodegradation, pglucosidase, was overproduced in E. coli comprising 80% of the total cellular protein, but
had little activity because it had aggregated into inclusion bodies (Machida et al., 1998).
Concurrent overexpression of the groESL genes increased the soluble protein from <1%
to 70% of the protein substrate and increased the enzymatic activity 20-fold when grown
at 25°C and compared to solubility and activity at 37°C without excess GroESL.
Jonathan King and associates isolated temperature sensitive folding mutants of
the phage P22 coat protein (Gordon et al., 1994). Overexpression of the groESL genes
was able to suppress the temperature sensitive folding of 17 different point mutations in
the coat protein that were thermolabile at high temperature, indicating the capacity of
GroEL to give folding assistance to the same protein with different mutations that result
in misfolded protein.
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GroEL assists protein folding in E. coli and may assist it in eukaryotic cells.
Mammalian cells can also prevent protein misfolding with a variety of chaperones
previously discussed. What happens when a protein misfolds in mammalian cells that the
endogenous protein folding machinery cannot assist? Most of the time the protein is
degraded, but occasionally the misfolded protein is stable and may contribute to a
pathological condition resulting in disease.
C.

Protein misfolding and diseases
Protein misfolding is the cause of several known human diseases (Thomas et al.,

1995). Polypeptide misfolding can destroy the function of the protein, cause the protein
to aggregate, form pathogenic plaques, or direct the improper trafficking of the protein.
Several examples of each of these misfolding characteristics will be described.
For example, cystic fibrosis results from a mutation in the cystic fibrosis
transmembrane conductance receptor that does not allow it to fold correctly, resulting in
the aggregation or degradation of the mutant protein in the endoplasmic reticulum (Ko et
al., 1993). Mutation in the p53 gene can also result in a greater incidence of cancer due
to prolonged association of this transactivator with its target sequences or blocking the
activity of wild type protein from a nonmutated allele (Hainaut and Milner, 1992).
Marfan syndrome, an autosomal dominant connective tissue disorder, results from
mutations in the epidermal growth factor-like domains of fibrillin, causing them to fold
incorrectly (Wu et al., 1995). These, among others are examples of diseases in which a
protein function is altered due to misfolding and results in a nonfunctional or
malfunctional protein.
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Some misfolding proteins form insoluble plaques of homogenous protein
aggregates. For example, Alzheimer’s disease (Soto et al., 1995), prion diseases,
Parkinson’s disease and Huntington’s disease are due to aggregation of specific proteins
and plaque formation (p-amyloid, prion protein, a-synuclein and huntingtin,
respectively). There are more than 31 amyloid diseases that are characterized by
mendelian inheritance fhttp://www.ncbi.nlm.nih.gov/Omim/searchomim.html ,search for
“amyloid”). By far the most common of the amyloid diseases is Alzheimer’s disease. It
has been estimated that 10% of those over 65 years of age are effected by it and possibly
one-half of people over 85 years old (Thomasson, 2000). Alzheimer’s disease kills
100,000 people/year with a cost of ~$82.7 billion dollars to care for its victims
(Thomasson, 2000). There is currently no therapy for this disease.
Finally, the misfolding of some proteins alter their destination within the cell. For
example, familial hypercholesteromia is due to mutations in the low density lipoprotein
(LDL)-receptor, the misfolding resulting in proteins that do not functionally mature, and
whose transport is blocked between the ER and the Golgi complex (Hobbs et al, 1990).
Tay-Sachs disease is due to a mutation in the p-hexosaminidase protein, the resultant
misfolded protein does not fully mature and is degraded rapidly (Lau and Neufeld, 1989).
Each of these diseases is detrimental to the health of the individual and costly to
society as a whole. Understanding the mode of action and the dynamics of protein
misfolding undoubtedly will reveal more answers to the questions that will arise in the
treatment of diseases resulting from a misfolded protein. One possible approach to the
problem may be through gene therapy.
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1.

Gene therapy approach to misfolding disease
Most gene therapy methods focus on overexpressing the wild type form of a

dysfunctional gene or controlling regulatory elements involved in various diseases.
These approaches may not be applied in cases in where the mutant protein, for example
the tumor suppressor protein p53, is dominant negative because the dominant nature of
the mutation abrogates the effect of any native protein in the cell. Overexpressing more
wild type protein may alter the balance, but possibly not enough to overcome the
dominant negative effect. The wild type form of the genes that encode the proteins
leading to the formation amyloid diseases, which form aggregates, also cannot be
overexpressed since they are usually native proteins that change conformation, leading to
aggregation and disease (Dobson, 1999). There is currently no clinical therapeutic
alternatives involving gene therapy of misfolding diseases in which the misfolding
protein is rescued. However, there are several promising alternatives on the horizon for
the treatment of amyloid diseases that were discussed at an EMBO workshop in 1998,
such as suppressing the production of the amyloid precursor, increasing amyloid
degradation and preventing amyloid formation (Dobson and Ellis, 1998). Pharmacologic
intervention was also proposed and investigated for the treatment of amyloidosis of
transthyretin protein by using analogs of its natural ligand, thyroxine, to stabilize the
tetrameric form (Dobson and Ellis, 1998). Stresses that effect cell viability, such as
ischemia, have been examined recently. The induced synthesis of Hsp70 in cells treated
under hypoxic conditions has been observed (Heads et al., 1994) and overexpression of
the genes encoding Hsp70 conferred a protective effect upon cells challenged with
hypoxia (Heads et al., 1995). Transgenic mice expressing the hsp70 gene constituatively
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in the heart had enhanced metabolic recovery from postischemic injury (Radford et al..
1996). The use of chaperones in the protection of transplant organs has taken a dramatic
surge. The heart has a maximum of ~4 hours of viability before it can no longer be used.
Inducing hsp70 is being examined as a means to lengthen the time a heart may be used by
reducing injuries to the heart muscle from ischemia and reperfiision (Gray et al., 1999).
We wanted to investigate whether GroES and GroEL could be functional in
mammalian cells to determine if they might be able to assist proteins that pathologically
misfold. One advantage of GroE therapy would be that since GroES and GroEL are not
part of the final product, physiological amounts of proteins would be kept within the
treated cell, provided there would be no regulatory control augmenting the disease. To
our knowledge, the only previous study using a chaperonin in this context examined the
role of mycobacterial Hsp65 as an immunoadjuvant in the treatment of tumors by
increasing tumor immunogenicity. Highly malignant J774 murine macrophage tumor
cells transfected with the mycobacterium hsp65 gene were innoculated into syngenic and
athymic mice and did not form tumors (Lukacs et al., 1993). Subsequent challenges of
syngenic mice with the J774 parent cells were fully protected from tumor formation;
however, challenged athymic mice all developed tumors, indicating that the protection
was mediated by T cells. Similarly, the mycobacterial hsp65 gene was transferred in vivo
to tumors via liposomes (Lukacs et al., 1997) and tumor regression was observed in
immunocompetent and immunodeficient SCID mice, but complete tumor regression only
occurred in immunocompetent mice, confirming the role of T cells. A tumor-specific
cytotoxic T cell response and J774-specific antibodies in mice that had received the
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hsp65 gene transfer indicated that there was an increased in vivo recognition of tumor
antigens.
An elevation in the levels of p53 was also seen in hsp65-transfected cells, which
the authors suggest may be due to chaperoning activity of Hsp65. The tumor suppressor
protein p53 is an essential protein for cell cycle control, thus Hsp65 may have mediated
the folding of p53 and reduced the tumoriginicity of the transfected cells. The authors
were currently investigating the possibility of Hsp65-p53 interaction and folding (Lukacs
et al., 1993). Only the highly immunogenic Hsp65 was used in these experiments,
however E. coli GroEL has 58.3% amino acid similarity to mycobacterial Hsp65
(Zeilstra-Ryalls et al., 1991). It may have also played a role in protein stabilization
within the tumor cells that allowed apoptotic signals to kill the cell. Indeed, GroES and
GroEL have been shown to interact with diverse proteins.
One disadvantage that may exist in the use of GroES/GroEL is the possibility of
eliciting a humoral immune response arising from the cross-reactive epitopes of E. coli
GroEL and human mitochondrial Hsp60 (Handley et al., 1996). Patients with
rheumatoid arthritis and systemic lupus erythematosus exhibited a positive correlation
between IgG levels of mitochondrial Hsp60 and IgG levels of GroEL. Genetic
replacement of nonimmunogenic regions of Hsp60 to GroEL could be explored, which
may alleviate the cross-reactive nature of GroEL. However, this research focused on
investigating if it were possible to use GroES and GroEL to rescue a biologically
significant protein in mammalian cells as a proof of principle.
We chose GroEL for our experiments instead of mitochondrial Hsp60 or TRiC
because so much work has been done with GroEL, demonstrating its interaction with
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many varied protein substrates. The protein substrate interaction with TRiC is limited
and the level of promiscuity for mitochondrial Hsp60 was not known. Another reason
GroEL was chosen was because the functional GroELn unit is composed of homologous
subunits, encoded by one gene. Technically, it would be very difficult to use TRiC
overexpression because TRiC requires 8 genes that encode the subunits for functional
double-ringed structure assembly. GroEL coupled with GroES was chosen as the most
viable alternative available. We chose a mutant p53 protein as our model for the rescue
of a biologically and medically relevant protein.

a)

Function of p53
Certain forms of cancer have been linked to mutations in a particular protein

transcription factor, p53. Dominant negative mutations of p53 could provide a viable
model system to evaluate the efficacy of GroESL-mediated gene therapy. Several tumor
suppressor proteins have been discovered in recent years, yet p53 is by far one of the
most important in regards to its impact on cancer progression. The p53 protein has been
dubbed the “guardian of the genome” (Lane, 1992). It controls the cell cycle by inducing
genes that cause an arrest in the Gi phase after extensive DNA damage (Ginsberg et al..
1991; Reich and Levine, 1984). If the DNA damage is not severe, cellular genes are
expressed and the damage repaired (Janus et al., 1999). If the DNA damage is too great,
then genes are induced that are involved in apoptosis, thus eliminating the damaged cell
from the population (Wani er«/., 1999; Yam et al., 1999; Janus ^

1999). It is the

most frequently mutated gene in human tumors, with >50% of all tumors containing a
mutation in the p53 gene with “hot spots” in the DNA binding domain (Friend, 1994).
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Several important genes are suppressed by the action of p53: Human cFos (Chin
et aL, 1992), human cJun (Ginsberg et al., 1991) and human P-actin (Santhanam et al..
1991). Additionally, p53 also acts to induce the expression of several other genes:
GADP45 (Kastan et al., 1992) and MCK (Weintraub et al., 1991). Indeed, p53 plays an
active role in DNA repair after endogenous DNA damage and acts as a potent response
element following exogenous DNA damage (Janus et al., 1999). When DNA damage is
too severe, p53 induces the apoptotic pathway via its interaction with pro-apoptotic Bax
and anti-apoptotic Bcl-2 proteins (Zambetti and Levine, 1993).
The tetramerization domain in the C-terminal region of p53 is responsible for
homo-tetramer formation, the complex capable of binding DNA. The N-terminal region
of p53 contains a transactivation domain capable of inducing the expression of
downstream genes in conjunction with other transcriptional factors. The DNA binding
consensus sequence has been determined and a reporter assay has been developed to
determine the transactivational activity of p53 (Chen et al, 1993). This reporter
construct has the DNA consensus sequence, p53CON, located upstream of a minimal
hsp70 promoter that controls transcription of the downstream firefly luciferase cDNA.
b)

The V143A p53 mutant
One of our goals was to use a dominant negative mutant of p53 as a model system

for testing the function of GroES/GroEL in mammalian cells and to determine if
GroES/GroEL could be used as therapeutic proteins by monitoring the restoration of p53dependent reporter gene activity. A dominant negative mutant inhibits the action of the
wild-type gene product. When a protein is multimeric, the variant should be capable of
having a functional domain responsible for interaction with the wild-type gene product,
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but be defective in some other aspect, thus creating non-functional multimers
(Herskowitz, 1987). The V143A mutant p53 fits the definition of a dominant negative
mutant (Zambetti and Levine, 1993).
The VI43 A mutation is located in the core region of p53 responsible for DNA
binding (Friend, 1994). The p53 protein induces or suppresses protein synthesis by
binding specific DNA sequences located in the promoter regions of specific downstream
genes. The change of valine to alanine at codon 143 (VI43 A) is a disease causing
mutation (Baker et al., 1990). V143Ap53 exhibits temperature-sensitive activity (Chen
et al., 1993), increased transformation frequency (Hinds et al., 1990), conformational
alterations (Gannon et al., 1990; Bartek et al., 1990), binds the molecular chaperone,
Hsc70 (Hinds et al., 1990) and has a half-life of hours compared to minutes for wild type
p53 (Iggo et al., 1990). These properties led us to hypothesize that the endogenous
chaperone systems could not correct the mutation presented by V143A p53 at
non-permissive conditions. We hypothesized that the coexpression of the groESL genes
and V143A p53 gene could rescue the V143A p53 mutant protein to fold correctly in
cells devoid of p53, NCI-H1299, a human lung cell line. The rescue of a mutant p53 by
GroES/GroEL was an objective of this research that would demonstrate the functionality
of GroES and GroEL in mammalian cells and be a proof of concept for the use of
GroES/GroEL chaperonins in a gene therapy context.
2.

GroEL as a molecular probe
DNA mutations are obviously not the only source of misfolded proteins. Folded

proteins that partially denature due to exogenous stress also adopt the molten globule
state. GroEL, in contrast to its ability to assist proteins to fold, could be used as a
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molecular probe to find proteins that misfold during their initial tries at folding or
proteins that are structurally unstable under various environmental conditions or disease
states. Individual proteins that may misfold, contributing to the pathology of a disease,
could be probed in tissue culture models of disease, such as comparing normal and
cancerous cells. The global state of protein stability in vivo could be addressed in several
situations, such as protein misfolding during stresses, such as heat, cold, ischemia, and
exposure to alcohol or heavy metals. Almost any perturbation to the normal growth
condition of a cell, ie. viral infection or radiation exposure, could be probed to determine
if there were global changes in the folding state of proteins or if there were any specific
proteins that misfolded under the given conditions.
Coimmunoprecipitation or other methods that are developed in the future that
detect GroEL-protein interactions with greater sensitivity could be used to discover
binding partners with GroEL in adverse conditions. Probing the state of individual or
global protein folding with GroEL offers the distinct advantage of GroEL's promiscuity.
Under normal cell culture growth conditions, GroEL does not appear to interact with
many proteins, however, it may interact with a wide variety of proteins when cells are
treated with environmental stress or pathological situations (Thulasiraman et al., 1999).
Once a protein is isolated, it could be sequenced, and its corresponding gene determined.
Gene sequencing may lead to the detection of mutations that affect the health and
viability of the cell under the specific conditions tested or further elucidate the means of a
pathological condition. Replacement of the mutant gene with the wild type version could
be one way to determine if the mutant protein really effected cell viability. Additionally,
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it may be determined whether a pathway was perturbed because of the loss of normal
protein function or a gain of function by the misfolding protein, such as p53 in cancer.
Two previous studies established that GroEL could be used to probe the
partitioning of polypeptides during synthesis or during stress. A polypeptide releasedefective GroEL mutant was synthesized in yeast and assayed for its ability to bind
nascent actin chains (Siegers et al., 1999). Mutant GroEL did not bind actin within the
intact yeast system, indicating that polypeptides are not released into the bulk cytosol of
eukaryotic cells after synthesis on ribosomes. In fact, approximately only 1% of the total
newly synthesized polypeptides in yeast was accessible or associated by the trap GroEL
compared to the ~15% in the E. coli cytoplasm (Ewalt et al., 1997). However, when the
cytosolic chaperonin TRiC was mutated, ~25% of the previously unavailable actin
polypeptides were then able to associate with GroEL. Folded actin was reduced in the
TRiC mutant yeast cells and GroEL associated with about half of the misfolded actin
present (Siegers et al., 1999), indicating that GroEL can be used as a sensitive tool to
analyze the partitioning of misfolded polypeptides in the cytosol of eukayotic cells.
Another report investigated the ability of wild type GroEL and the trap GroEL
mutant to bind actin in the bulk cytosol of mammalian cells. It appeared that the TRiC
chaperonin in mammalian cells mediated the folding of nascent actin also without the
release of the non-native polypeptide to GroEL in the bulk cytosol (Thulasiraman et al..
1999). However, in cells treated with heat shock or incubated in ethanol, GroEL was
able to bind and coimmunoprecipitate polypeptides that were previously unavailable. In
yeast and mammalian cells, GroEL has been shown to at least bind polypeptides in cells
lacking some chaperonin activity or when placed under stress.
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3.

Research aims
The work discussed in this dissertation addresses our interest in (1) GroESL-

mediated protein folding within bacterial and mammalian cells, (2) using GroEL as a
molecular probe to identify proteins that misfold in mammalian cells, and (3) determining
if GroESL could be used as a theraputic proteins to treat misfolding diseases. Protein
folding within bacterial and mammalian cells has some obvious differences, such as the
speed of protein synthesis. Prokaryotic ribosomes translate mRNAs at a rate of ~20
amino acid/s (Ewalt et ai, 1997) compared to eukaryotic ribosomes at a rate of ~4 amino
acids/s (Thulasiraman et al., 1999). Prokaryotic cells also contain on average smaller
protein compared to eukaryotes (Netzer and Haiti, 1997). This research confirms some
recent findings regarding the pathway of assisted polypeptide folding polypeptides within
mammalian cells (Thulasiraman et al., 1999), but with some additional insights not
discussed in that paper. The course of this research also provided the opportunity to
compare and contrast the capacity of the protein folding machineries of both bacterial and
mammalian cells to fold a large protein substrate containing in vivo reporter activity, a
fusion of bacterial luciferase and green fluorescent protein.
Additionally, we investigated whether GroEL could be used as a molecular probe.
This would allow the future analysis of cellular conditions that contribute to stress or to
identify unknown proteins that misfold and contrubute to disease. Finally, we
investigated whether GroES and GroEL could rescue a medically relevant, temperature
sensitive protein in mammalian cells and whether they can contribute to the survival of
mammalian cells challenged by extended heat shock. The investigation into the practical
use of GroES and GroEL as theraputic agents was promising considering the promiscuity
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of GroEL and the severe diseases resulting from pathological protein misfolding within
cells and the limited ability of current medicine to treat these diseases.
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II.

Materials and Methods

A.

DNA cloning, restriction analysis and general reagents
All DNA manipulations were performed using restriction enzymes from Promega

(Madison, Wis.) and Boehringer Mannheim Biochemicals (Indianapolis, Ind.). Klenow
filling was performed with enzyme from New England BioLabs (Beverly, Mass.). PCR
was performed using pwo DNA polymerase and dNTP’s from Boehringer Mannheim
Biochemicals (Indianapolis, Ind.). ATP-Mg2+ salt and antibiotic/antimycotic solution
was obtained from Sigma Chemical Co. (St. Louis, Mo.). All chemical used in making
reagents were purchased from Fisher Scientific Co. (Pittsburg, Pa.) unless otherwise
noted.
B.

Media
Luria-Bertani (LB) (Sambrook et al., 1989) broth was prepared in the following

manner per liter of media: 10 g NaCl; 10 g tryptone; 5 g yeast extract and distilled water
to 1 liter. 15 g agar was added if agar plates were to be made. LB and/or LB-agar was
sterilzed by autoclaving. Antibiotics, if used, were added to LB-agar when the solution
had cooled to ~45°C.
M63 media (Ewalt et al., 1997) used for radiolabeling of E. coli was prepared in
the following manner per liter: 13.6 g KH2PO4; 2 g (NLLOiSCL; 0.5 mg FeSCWFLO; pH
adjusted to 7.0 with KOH and brought to 1 liter volume in double distilled water and
autoclaved.
Dulbecco's Modified Eagle's Medium (Dulbecco and Freeman, 1959) (DMEM,
Bio Whittaker, Walkersville, Md.) with 4.5 g/1 glucose and 2 mM L-glutamine. DMEM
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was supplemented with 10% fetal calf serum (FBS, Difco Laboratories Detroit, Mich.)
and IX antibiotic/antimycotic solution (Sigma Chemical Co., St. Louis, Mo.). This
media was used for the growth of COS-7 cells.
Ham's F-12 with 2 mM L-glutamine (Ham, 1965) (CellGro, Freiburg, Germany)
was supplemented with 10% FBS and IX antibiotic/antimycotic solution. This media
was used for the growth of CHO cells.
RPMI 1640 (Moore et al., 1967) (CellGro, Freiburg, Germany) was
supplemented with 10% FBS, 2 mM L-glutamine and IX antibiotic/antimycotic solution.
This media was used for the growth of NCI-H1299 cells.
C.

Cell lines and strains used
DH5cc: Escherichia coli strain used in all bacterial experiments: F

(|)80d/<2cZAM15A(/tfcZYA-argF) U169 endKX recKX hsdK\l{r k’ niK+) deoK thi-\
supE44 X~gyrA96 relAl
COS-7: ATCC CRL-1651. This fibroblast cell line comes from Cercopithecus
aethiops, an African green monkey, and was derived from the CV-1 cell line (ATCC
CCL-70) by transformation with an origin defective mutant of SV40 which codes for
wild-type T antigen.
CHO: Chinese hamster ovary cells isolated from Cricetulus griseus, exhibiting
epithelial morphology.
NCI-H1299: Epithelial cells isolated from a lymph node metastasis taken from a
43 year old Caucasian male. It is a non-small cell lung carcinoma.
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1.

Plasmid constructions

a)

Plasmid Vectors
pBluescript: Plasmid pBluescript KS and pBluescript SK (Stratagene, La Jolla,

Calif.) are bacterial cloning and expression vectors derived from the pUC19 vector.
These plasmids contain the bla gene, which confers ampicillin resistance to transformed
bacterial cells. The ColEl origin of replication allows 100-150 copies/cell of the plasmid
(Minton et al., 1988).
pACYC184: Plasmid pACYC184 (Chang and Cohen, 1978) is the vector used
for the expression of the luciferase-gfp fusion gene. It carries the chloramphenicolresistance gene from Tn9 and the tetracycline-resistance gene from pSClOl. It is a low
copy number plasmid, ~10 copies/cell due to the origin of replication from plasmid pi 5 A
(Sambrook et al., 1982), which allows it to coexist in bacterial cells with vectors
carrying the ColEl origin of replication.
pcDNA3.1(+): Plasmid vector (Invitrogen, San Diego, Calif) that carries an
ampicillin resistance gene and the ColEl origin of replication for cloning and propagation
in bacterial cells. The human cytomegalovirus (CMV) immediate-early
promoter/enhancer controls transcription of cloned genes, followed by the bovine growth
hormone polyadenylation signal. Plasmid pcDNA3.1(+) containing a gene DNA insert is
abbreviated as p3.1 followed by the designation of the DNA insert.
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b)

groE plasmids
pbl+skx-: Plasmid vector pBluescript KS was digested with Xbal and blunt

ended with Klenow enzyme (New England BioLabs, Beverly, Mass.), destroying the
Xbal site.
pbl+groE: All groE nucleotide numbering is based on the previously published
sequence (Hemmingsen et ah, 1989). The groE operon of plasmid pOF39 (Fayet et al..
1986) was fragmented into three DNA segments to facilitate Ml3 site directed
mutagenesis of the Escherichia coli groE genes. Previous work indicated that the
complete operon was deleted in E. coli, when cloned in Ml3, probably due to
GroES/GroEL interference with efficient phage assembly (A. Escher, personal
communication). Separating the operon into three fragments disrupted groES and groEL
into nonfunctional genes thereby eliminating this problem. Fragment I consists of an
EcoRl-Kspl DNA fragment cloned into plasmid pBluescript SK resulting in plasmid
bl+skgroE-EK. Fragment II consists of a Kspl-Hindl DNA fragment cloned into
pBluescript KS resulting in plasmid bl+ksgroE-KH. Fragment III consists of a HindlHin<\\\\ DNA fragment cloned into MP19 resulting in vector MP19groE-HH. A Xbal site
was introduced upstream of the groEL gene via Ml 3 site directed mutagenesis (A.
Escher, unpublished work). The primer sequence used was 5,-456TAAGGAATATCT
AGAATGGCA476-3'. The mutations were confirmed by restriction analysis and
sequencing. Fragment III Hincll-Hin&lll was cloned into bl+skx- resulting in plasmid
bl+skx-groE-HH. Plasmid pbl+skgroE-EK was digested with Apal-Kspl, releasing
fragment I and bl+ksgroE-KH was digested with Kspl-Hincll releasing fragment II.
Fragments I and II were ligated into bl+skx-groE-HH digested with Apal-Hincll resulting
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in the creation of plasmid bl+groESL. Sequence analysis of the groEL gene revealed a
mutation of C-+A at nucleotide 2017, resulting in a nonsense mutation of threonine to a
glutamic acid (T516N). This mutation is implicated in GroEL subunit-subunit interaction
vital for GroEL function (Fenton et al., 1994). To recover the wild type coding sequence
of this region, an EcoRl-HincW fragment from bl+groESL and a i7mcll-//z>zdlll fragment
containing the wild type sequence was released from pOF39 and were ligated into
bl+skx- digested with EccRl-Hin&lll, resulting in plasmid bl+groE. The groE operon is
under transcriptional control of the groE promoter.
pGEL7: The plasmid pGEL7 contains the groEL gene under the transcriptional
control of the groE promoters cloned into vector pT3T7-19 as previously described
(Escher and Szalay, 1993).
pbl+groES: pbl+groES plasmid contains the groES gene under transcriptional
control of the groE promoters. Plasmid pbl+groEP was digested with Xbal-Hindlll,
removing the groEL gene. 5' ends were filled in with Klenow enzyme and religated,
resulting in plasmid bl+groES.
p3.1groES: To facilitate increased translation efficiency of the groES and groEL
genes in mammalian cells, a Kozak sequence (Kozak, 1986) was engineered for groES
using PCR and cloning the PCR product into the pGEM-T vector (Promega, Madison,
Wis.). PCR was performed withpwo polymerase (Boehringer Mannheim Biochemicals,
Indianapolis, Ind.). The 5' primer introduced a Nhe\ site upstream of the groES AUG and
brought the -3 to -1 sequence in line with the optimal Kozak sequence for high level
protein synthesis in mammalian cells. The upstream primer IVe was
S'-^GGAGAGCTAGCAATGA137^'. The downstream primer IVio was 5'-475GCC
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ATTCTAGATATTCC459-3'. The 353-basepair PCR product was cloned into pGEM-T,
resulting in plasmid pGEM-TgroESNX. The construct orientation was determined by
restriction analysis. The groEL gene was cloned in by digestion of bl+groE with XbalApal and ligating the fragment into plasmid pGEM-TgroESNX digested with Xbal-Apal,
resulting in plasmid pGEM-TgroESL. The groES and groEL genes were introduced into
pcDNA3.1(+) by digestion of pGEM-TgroESL with Notl-Apal and ligating into
pcDNA3.1(+), resulting in plasmid p3.1groESL. The groEL gene was removed, leaving
the groES gene, by digestion of p3.1groESL W\\hXbal-Xhol followed by Klenow filling
in of the 5' overhangs and ligation of the free ends, resulting in plasmid p3.1 groES.
p3.1 groEL: The groES gene was removed, leaving the groEL gene, by digestion
of p3. IgroESL with Nhel-Xbal and religation resulting in plasmid p3.1 groEL.
p3.1groE-IRES: The plasmid pBS-ECAT containing the encephalomyocarditis
virus internal ribosome entry site (IRES) sequence was obtained from Gary Withered,
University of New York, Stony Brook, N.Y. (Jang et al., 1989). The IRES sequence was
modified by PCR, adding Xbal sites at each end. Primer IV2 hybridizes to the 5' end of
the IRES sequence: 5 '-TTTTCTAGAAATAC GACT C ACTATAGGGC-3'. The 3' primer
for the 3’ end of the IRES sequence was IVA: 5 '-TTTTCTAG AGGC AAT ATAATAAT
CGTGTTTTTC-3', which changes two upstream ATG sequences to ATT sequences and
adds a GCC just prior to the Xbal site for enhanced expression of the downstream gene
(Davies and Kaufman, 1992). The PCR product was ligated into the pGEM-T vector and
sequenced resulting in plasmid pGEM-T-IRES-A. The IRES sequence was introduced
between the groES and groEL genes by digestion of pGEM-T-IRES-A WAhXbal and
cloning out the 607 basepair IRES fragment and ligating into Xbal digested pGEM-
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TgroESL resulting in plasmid pGEM-TgroE-IRES. The groES-IRES-groEL construct
was cloned into vector pcDNA3.1(+) by releasing groES-IRES-groEL genes from
pGEM-TgroE-IRES with digestion by Nhel-Xhol and ligating into pcDNA3.1(+)
digested with Nhel-Xhol resulting in plasmid p3.1groE-IRES.
c)

Bacterial luciferase and GFP plasmids
plx403fab9: A fusion of the Vibrio harveyi luxA and luxB genes (Escher et al.,

1989) designated fab9, was cloned into plasmid pACYC184, which carries a
chloramphenicol resistance gene. The luciferase gene was under transcriptional control
of the tef promoter.
pACGNl: The gfph cDNA, encoding the 26,000 Mr-green fluorescent protein,
contains a mutation in nucleotide 193 A-»T, creating a serine to threonine substitution at
position 65, which increases fluorescence 6X more than the wild type GFP and shifts the
maximal excitation peak from 395 nm to 490 nm (Heim et al, 1995). This cDNA was
also “humanized,” due to the >190 silent mutations which represent human codon usage
preference. The gfp cDNA was excised from vector pBS-GFPh2 (Zolotukhin et al..
1996) with a Notl digest and ligated into pcDNA3.1(+) digested with the same enzyme,
resulting in plasmid p3.1GFPh. Plasmid p3.1GFPh was digested with Kpnl and the 3'
termini were removed, creating blunt ends. A fragment of the temperature sensitive
bacterial luciferase gene, fab9, encoding the monomeric luciferase protein, was released
from plasmid pCEP4fab9 with a BsrBl digest and ligated into blunt-ended p3.1GFPh,
resulting in plasmid p3.1FG. The ifarBI digest of pCEP4fab9 removed the last 44
basepairs from the 3' end, representing 15 amino acids from the C terminal end of the
LuxB moiety of the LuxA-LuxB fusion. The orientation was confirmed by restriction
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digest analysis. The bridging region between fab9 and gfph is 72 basepairs, representing
24 amino acids in the fusion protein between Fab9 and GFP. The fab9-gfph fusion gene
was removed from p3.1FG with a HindlWXbal digestion followed by filling in with
Klenow enzyme. The vector pACYC184 (Chang and Cohen, 1978) was digested with
T/mdlll and filled in with Klenow enzyme and ligated to the fab9-GFPh gene fragment in
the forward orientation as confirmed by restriction digest analysis, yielding plasmid
pACFG. A Shine-Delgamo sequence was engineered into pACFG by removal of the
AseVHpal fragment of pACFG and replacement with the 5' region offab9 containing a
Shine-Delgamo sequence by AseVHpal digestion of plx403fab9-l (Escher et ai, 1989),
yielding plasmid pACFG-SD. Site directed mutagenesis was performed on p3.1FG to
mutate the GFP starting methionine to a lysine in order to remove the possibility of internal
translation of the GFP portion of the luciferase-GFP mRNA resulting in p3.1FG-lys. The
AUG was successfully mutated to an AAA and confirmed by DNA sequencing. The
p3.1FG-lys plasmid was digested with HpaVXhol, releasing a 1252 basepair fragment
encoding the luciferase-GFP region that contains the methionine to lysine mutation, which
was isolated and cloned into pACFG-SD, replacing the AUG-containing fragment for the
AAA-containing fragment by HpaVXhol digestion resulting in pACFG-SD-lys. The
missing 44 bp from the 3' end of the fab9 gene was cloned by PCR amplifying a 460
basepair fragment spanning the Mini site in the fab9 gene to the Spel site in the linker
region. A mutation was introduced that changed the TAA stop codon in the fab9 gene to a
lysine, AAA, and &Xhol site was introduced to confirm that the PCR amplified DNA was
inserted into the fab9-gfp gene. The PCR fragment was cloned first into pBluescript where
it was sequenced. The MluVSpel fragment was released by digestion and ligated into
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pACFG-SD digested with the same enzymes. The plasmid was digested with Spel, blunt
ended with Klenow enzyme, digested with Smal and ligated. The linking region was
confirmed to be in frame by DNA sequence analysis and the plasmid was named pACGNl.
The fab9-GFPh gene is under transcriptional control of the tetracycline resistance promoter
found in pACYC184 (Chang and Cohen, 1978).
d)

p53 plasmids
pC53-SN3 and pC53-SCX3: Eukaryotic expression vectors containing wild type

p53 (pC53-SN3) and mutant p53 cDNA’s (pC53-SCX3 containing the V143A mutation)
were obtained from Bert Volgelstein, Johns Hopkins University School of Medicine
(Baker et al., 1990). The p53 cDNA’s are under transcriptional control of the human
CMV immediate-early promoter/enhancer.
p53CON-LUC and pGUP.PA.8: Plasmid p53CON-LUC contains the firefly
luciferase structural gene linked to the Hsp70 minimal promoter with the p53 DNA
binding element known as the p53 consensus sequence (p53CON), in the 5’ regulatory
region (Chen et al., 1993). Plasmid pGUP.PA.8 does not contain the p53CON target
sequence. Plasmids were obtained from Jeou-Yuan Chen, University of Taiwan (Chen et
al., 1993).
e)

MCAD plasmid construction
MCAD cDNA’s were obtained from Peter Bross, Aarhus University Hospital,

Denmark. Primary plasmids contained the mature wild type or K304E mutant cDNA’s
(Bross et al., 1995) cloned in pBluscript with an artificial initiator methionine. In order
to achieve higher protein synthesis levels in mammalian cells, an adenine in the -3
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position from the start AUG was engineered, increasing translation initiation (Kozak,
1986). pbl+MCAD plasmids were digested with SpeVNotl followed by Klenow filling of
the 5' ends and ligation, removing aXhal restriction site necessary for further cloning.
The plasmid DNA’s were then digested with Xbal/Ndel, filled in with Klenow enzyme
and religated, resulting in bl+MCAD-wt.K and bl+MCAD-K304E.K, creating an
AGUstartAUG from CAUstartAUG. The change was confirmed by DNA sequencing. The
plasmids were digested W\\hAspl\%IBamY{l releasing the full cDNA MCAD sequence
and ligating it into pcDNA3.1(+) digested WiihAspllZIBarriRl, resulting in p3.1MCADwt.K and p3.1MCAD-K304E-K. The orientation and positioning was confirmed by
restriction analysis.
D.

Blunt ending
DNA’s were blunted with Klenow enzyme in the following manner for 5'

overhangs: ~100 ng of digested DNA, 2pl of Klenow buffer, 0.5 pi of lOmM dNTP's
(final concentration was 0.25 mM), 1 pi of Klenow enzyme and double distilled water
raising the volume to 20 pi were mixed together. The mixture was incubated for 30
minutes at room temperature and ethanol precipitated to a dried pellet, ready for the next
proceedures, ie. restriction, ligation or transformation.
For 3’ termini removal the following reagents were mixed: ~100 ng of digested
DNA, 2 pi of Klenow buffer, 1 pi of Klenow enzyme and double distilled water to 20 pi
volume. The mixture was incubated at 37°C for 15 minutes. 0.5 pi of 10 mM dNTP's
were added and the mixture incubated for 30 minutes, then ethanol precipitated and dried,
ready for any further manipulation.
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E.

PCR
Polymerase chain reaction (PCR) products were produced using pwo DNA

polymerase (Boehringer Mannheim Biochemicals, Indianapolis, Ind.) for PCR reactions
andpfu DNA polymerase (Sigma Chemical Co., St. Louis, Mo.,) for site directed
mutagenesis reactions. Prior to PCR, 100 pg of each primer was mixed with 5 ng of
template, 5 pi of DNA polymerase buffer and sterile double distilled water to 50 pi. 5
units ofpwo DNA polymerase were added when the reactants had reached 95°C in the
first step. The reaction settings on the thermal cycler were as follows: 1)1 minute at
95°C; 2) 30 cycles of the following three temperatures, i) 95°C for 30 seconds, ii) 550C
for 30 seconds and iii) 72°C for 1 minute; 3) after the 30 cycles, the reaction was cooled
to 4°C until removed from the thermal cycler. Site directed mutagenesis was done
exactly as described in the protocol for the QuickChange Mutagenesis system
(Stratagene, La Jolla, Calif).
F.

Ligation
T4 DNA ligase was purchased from New England BioLabs (catalog #202S,

Beverly, Mass.) or was a gift from Marina Zemskova. 2 pi (1.33 Weiss units/pl) of
ligase was mixed with a plasmid vector to insert ratio of ~1:3, (the plasmid vector never
greater than 500 ng), 2pl of T4 DNA ligase buffer and water to 20 pi. The reaction was
incubated for 2 hours at room temperature or overnight at ~15°C. Reaction mixtures
were used immediately after incubation, stored at 4°C for 24-48 hours or stored for longer
periods at -20°C.
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G.

Visualization ofGFP fluorescence in Escherichia coli cells
DH5a cells transformed with the appropriate plasmid constructs were grown at

37°C in Luria-Bertani (LB) media containing the appropriate antibiotic (ampicillin [100
pg/ml] and/or chloramphenicol [30 pg/ml]) to an approximate O.D.600 of 1.0 and placed
on ice for 15 minutes. Cells were pelleted and 5 pi of cells resuspended in 20 pi LB
media were then transferred to microscope slides. Cells were visualized with UV
fluorescent microscopy using a FITC filter under 1000X magnification. Digital
photographs were captured with a cooled CCD camera (Princeton Instruments, Trenton,
NJ.) and imaged in black and white with MetaMorph software (Universal Imaging Corp.,
West Chester, Pa.). Images were acquired for 2500 milliseconds.
H.

Microscopy of mammalian cells
Mammalian cells were subcultured and grown on glass coverslips inside of tissue

culture dishes 24 hour prior to the transfection. Transfections were performed by various
methods. Approximately 48-72 hours post transfection the cells were washed three times
with cold Dulbecco's phosphate buffered saline (DPBS, Sigma Co., St Louis, Mo.). The
cells were then incubated at room temperature for 30 minutes in a 4% formaldehyde/PBS
solution. A single wash was performed after removal of the formaldehyde solution. The
coverslip was removed from the plate and placed on a microscope slide that had a small
drop of mounting solution placed on it which contained DAPI, a DNA staining agent
(Vectashield, Vector Laboratories, Burlingame, CA). The cells were visualized by UV
microscopy and images captured with a cooled CCD camera directed by MetaMorph
software.
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Differential centrifugation and immunoblot analysis
DH5a cell lysates were separated into soluble and insoluble fractions as described

previously (Siemering et al., 1996). Briefly, cells were grown in LB broth supplemented
with ampicillin (100 pg/ml) and chloramphenicol (30 pg/ml) to an O.D.6oo= ~1 and
placed on ice for 15 minutes. 1.5 ml cultures were centrifuged at 15,500 X g for 2
minutes, resuspended in 500 pi of resuspension solution (50 mM Tris-HCl [pH 8.0], 2
mM EDTA, lysozyme [100 pg/ml], 0.1% Triton X-100) and incubated for 15 min at
30°C. Cells were then lysed by sonication (5X15 seconds) and protein concentrations
were normalized for each set of cotransfections according to instructions for the BioRad
Dc Protein Assay Kit (Bio-Rad Laboratories, Richmond, Calif). Cell lysates were then
centrifuged at 15,115 X g for 15 minutes at 4°C. The supernatant (soluble fraction) was
removed and stored at -70°C. The pellet was washed once with 500 pi washing buffer (50
mM Tris-HCl [pH 8.0], 10 mM EDTA, 0.5% Triton X-100) resolubilized in 500 pi
solubilization buffer for 1 hour at room temperature (8 M urea, 0.1 M Na^PCL, 10 mM
Tris-HCl [pH 6.3]) and stored at -70°C. Immunoblot analysis was performed with 10 pi
of soluble and insoluble fractions prepared in 5 pi of 2X gel loading buffer and boiled for
5 minutes. Proteins separated by SDS-PAGE using 12% gels were transferred to
Immobilon-P PVDF membrane (Millipore Corp., Bedford, Mass.) and subsequently
reacted with a mixture of polyclonal rabbit anti-LuxAB antibody (dilution of 1:15,000)
and polyclonal rabbit anti-GroEL antibody (Epicenter Tech., Madison, Wis., dilution of
1:30,000). Antibodies were detected with horseradish peroxidase conjugated secondary
anti-rabbit IgG antibody (Sigma Chemical Co., St. Louis, Mo., dilution of 1:30,000) and
reacted with enhanced chemiluminescent substrate (Pierce Co., Rockford, Ill.).
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J.

LipofectAMINE PLUS transfection of mammalian cells
COS-7 cells were transiently transfected using the LipofectAMINE PLUS

cationic lipid reagent (GIBCO BRL, Grand Island, N.Y.). The COS-7 cells were
subcultured the day before the transfection into 10 cm tissue culture plates at ~70%
confluence. Each transfection used 4 pg of DNA. The DNA was mixed with 25 pi
PLUS reagent in DMEM media up to 750 pi, lacking serum or antibiotics and incubated
at room temperature for 15 minutes. At the same time, 20 pi of LipofectAMINE reagent
was diluted into 730 pi DMEM media lacking serum or antibiotics and incubated for 15
minutes at room temperature. After incubation the DNA-PLUS reagent-media mixture
was added to the LipofectAMINE- media mixture and incubated for 15 minutes at room
temperature. During that time, the growth media was removed from the cells and 5 ml of
DMEM media lacking serum and antibiotics was added to the cells and they were
returned to the 37°C humidified CO2 incubator. The LipofectAMINE PLUS-DNA
complexes were added to the cells, making 6.5 ml total volume. The cell-transfection
mix was incubated in the humidified CO2 incubator for three hours. Fetal bovine serum
to 10%, IX antibiotic/antimycotic solution and DMEM (2.5 ml) were added after the
incubation and cells were allowed to grow until harvesting as previously described.
K.

Calcium phosphate transfection of cultured mammalian cells
One day before transfection, CHO or COS-7 cells were subcultured 1 to 5 from a

confluent plate into DMEM media supplemented with 10% FBS and IX
antibiotic/antimycotic solution to -50-60% confluency. Transfection was performed
using the calcium phosphate method with reagents and following the instructions from
Promega (Madison, Wis.) A 10 cm tissue culture dish of cells was usually used for the
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transfection method described. Plasmid DNA was added to a tube at the appropriate
amount followed by double distilled H2O adjusted to a volume of 500 pi after addition of
62 pi CaCb. The mixture was vortexed thoroughly and then added drop wise to 500 pi
2X HEPES buffered saline, vortexing. All solutions were equilibrated to room
temperature before mixing. The CaPC^/DNA complexes were incubated for 30 minutes
at room temperature. The mixtures were resuspended by vortexating briefly, added drop
wise to cells, and incubated for 20 minutes at room temperature, rocking every 5 minutes
to keep the cells moist. Cells were then given warmed supplemented DMEM and
incubated for 8-18 hours with the media/transfection mix after which the media was
replaced by fresh media and the cells were allowed to grow according to the experiment.
L.

Preparation of 35S-methionine radiolabeled mammalian cell lysates

and immunoprecipitation

1.

Radiolabeling
Transfected cells were washed IX with warmed DMEM not supplemented with

FBS or methionine and glutamine (ICN Pharmaceuticals Inc., Irvine, Calif.). Cells were
then incubated for 20 minutes at 37°C at 5% CO2 with 5 ml of DMEM supplemented
with dialysed serum but not containing either methionine or glutamine. 1 ml of media
and 35 S-methionine was added at the concentration as dictated in the individual
experiment and the specified time length.
2.

Harvesting and immunoprecipitation
Immunoprecipitation is advantagous when protein-protein interactions are being

investigated. It is specific for the target protein and when coupled with radiolabelling
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with S-methionine, it becomes a very sensitive tool, though controls should be put in
place to determine if the antibody that is used cross-reacts with nontarget proteins. Minor
protein-protein interactions can be detected as well as strong protein-protein interactions.
The interactions that occur in the midst of the cellular milieu compete with all the other
proteins in the lysate creating built-in specificity control (Phizicky and Fields, 1995).
Transfections of cells with the empty plasmid vector serve as a control for nonspecific
antibody interaction with cellular polypeptides. Coimunoprecipitated protein complexes
are in their natural state after any posttranslational modifications have taken place
(Phizicky and Fields, 1995).
GroEL protein has the major function to bind and assist the folding of nascent
polypeptides and polypeptides whose structure becomes unstable under various
environmental circumstances in E. coli. We have investigated whether GroEL and
GroES proteins are synthesized in cultured mammalian cells and if GroEL has the
capacity to coimmunoprecipitate bound polypeptides.
Cells were washed IX with cold DPBS and removed by scrapping with a rubber
policeman into 1 ml of DPBS. Cell pellets were kept on ice until resuspended and lysed
as previously reported (Beckmann et al., 1990) in lysis buffer (0.1% Triton X-100, 5
mM MgCh, 100 mM KC1, ImM phenylmethylsulfonyl fluoride [PMSF, Sigma Chemical
Co., St. Louis, Mo.] and Complete protease inhibitor, a cocktail of protease inhibitors
with specificity for serine-, cysteine-, metalloproteases, and calpains [Boehringer
Mannheim Biochemicals, Indianapolis, Ind.] in cold DPBS). 10 units of apyrase (Sigma
Chemical Co., St. Louis, Mo.) per ml was added to the lysis buffer to hydrolyse free ATP
upon lysis and kept on ice for 15 minutes. The lysates were clarified by room
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temperature centrifugation at 15,500 X g for 5 minutes. The supernatant was collected
and 50 pi of protein A-agarose or protein G-agarose (Boehringer Mannheim
Biochemicals, Indianapolis, Ind.) was used to preclear the lysate for 3 hours at 4°C, on a
rocking platform. After the preclear, the cell lysates/protein A/G-agarose mixture was
centrifuged for 30 seconds at 12,000 X g to separate the precleared cell lysate from the
preclearing protein A/G-agarose. 5 pg of mouse monoclonal anti-GroEL antibodies
(SPA-870, StressGen Biotechnologies Corp., Victoria, B.C., Canada), rabbit polyclonal
anti-GroEL antibody from StressGen Biotechnologies Corp. (SPA-875, Victoria, B.C.,
Canada), rabbit polyclonal anti-GroEL antibody from Epicenter Tech. (Madison, Wis.) or
rabbit anti-GFP (Molecular Probes, Eugene, Oreg.) was added to the precleared cell
lysate to form immune complexes between GroEL and anti-GroEL antibodies or
luciferase-GFP fusion protein and anti-GFP antibodies. The mixture was incubated for 1
hour at 4°C on a rocking platform. 50 pi fresh protein A/G-agarose was added to the
precleared cell lysate/ antibody mixture and incubated for 3 hours or overnight at 4°C on
a rocking platform. After the incubation was complete the supernatant was removed and
the immune complexes pelleted by centrifugation for 20 seconds at 12,000 X g.
Alternatively, instead of preclearing with the protein A/G-agarose, the protein A/Gagarose was washed with lysis buffer and resuspened into bovine serum albumin (BSA,
10 mg/ml, Jackson ImmunoChemicals, West Grove, Pa.). After incubating the lysate
with the primary antibody for one hour, the protein A/G-agarose in BSA was added to the
immune complexes and incubated for another hour. Both procedures worked equally
well. The pelleted complexes was washed twice with 1 ml of washing buffer 1 (Final
concentration in 50 ml: 50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Nonidet P-40 [NP-
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40], 0.5% DOC, 1 Complete tablet), centrifuging 20 seconds at 12,000 X g between each
wash. Complexes were then washed twice with 1 ml of washing buffer 2 (Final
concentration in 50 ml: 50 mM Tris-HCl [pH 7.4], 500 mM NaCl, 0.1% NP-40, 0.05%
DOC) and centrifuged as before. The final wash was done once with washing buffer 3
(Final concentration in 50 ml: 50 mM Tris-HCl [pH 7.4], 0.1% NP-40, 0.05% DOC).
Complexes were pelleted and all of the final wash was removed. The pelleted complexes
were resuspended in 2X gel loading buffer (100 mM Tris-HCl [pH 6.8], 4% SDS; 20%
glycerol, 10% 2-mercaptoethanol, bromphenol blue) and boiled for 5 minutes. The
boiled complexes were centrifuged and the supernatant collected and used immediately
or frozen at -80°C.
M.

One dimensional SDS-PAGE
Fresh polyacrylamide gels were prepared for protein electrophoresis. 4% stacking

gels (pH 6.8) and 12% separating gels (pH 8.8) were used in most separations unless
otherwise indicated. SDS-PAGE gels were loaded with the sample protein and the
current was applied until the bromophenol blue leading edge exited the gel (Laemmli,
1970). Radiolabeled gels were soaked in 1 M salicylic acid (pH 6.0) for 30 minutes
which acted as a scintillant. Alternatively, the scintillant Entensify (NEN Life Science,
Boston, Mass.) was used. Gels were transferred to filter paper, dried, exposed to X-ray
film and developed. For proteins transferred to Immobilion P, PVDF membrane for
immunoblots, gels were incubated in IX transfer buffer (0.025 M Tris [pH 8.3], 0.132 M
Glycine, 0.0013 M SDS, 10% methanol) for 10 minutes with gentle agitation on a
platform shaker at room temperature. The PVDF membrane was wetted with 100%
methanol and then washed twice with distilled water followed by incubating the
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membrane for 10 minutes in transfer buffer with gentle agitation on a platform shaker at
room temperature. The gel bound proteins were transferred to PVDF membrane using a
9

semi-dry blotter (C.B.S. Scientific, Del Mar, Calif.) ran at 0.8 mA/cm for 90 minutes.
Three sheets of filter paper, cut to the same size of the membrane, were soaked in IX
transfer buffer, laid together on the bottom plate of the semi-dry blotter, and rolled with a
tube to remove air bubbles. The membrane was laid on top of the filter paper followed
by the protein containing gel. Next, three more precut sheets of filter paper were soaked
in IX transfer buffer and laid on top of the gel and rolled again to remove bubbles. The
semi-dry blotter top plate was laid on top and screwed to the bottom plate snugly
sandwiching the membrane and gel between the filter papers. Electric leads were
attached and the current was applied at constant amperage for the length of the run.
N.

Immunoblot procedure
The immunoblot procedure or commonly called Western blotting allows detection

of protein antigens based on the reactivity of antigen specific antibodies with antigen that
is blotted onto a membrane like nylon or polyvinylidene fluoride (PVDF) (Towbin et al.,
1979).The membrane was removed after the length of the transfer on the semi-dry blotter.
Membranes were incubated for one hour or overnight with 1% gelatin, type B from
bovine skin (Sigma Chemical Co., St. Louis, Mo.) or 5% skim milk to block nonspecific
binding of antibodies to the membrane. The membrane was then rinsed with IX TEST
(20 mM Tris-HCl [pH 7.5], 137 mM NaCl, 0.1% Tween-20) and then washed once for 15
minutes in IX TEST on a shaking platform at room temperature. All subsequent washes
and incubations were done at room temperature on a platform shaker set to ~50 rpm.
The primary and secondary antibodies were diluted in IX TEST. Secondary antibodies
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against polyclonal primary antibodies were sheep anti-rabbit antibodies conjugated to
horseradish peroxidase (Sigma Chemical Co., St. Louis, Mo.). Secondary antibodies
against mouse monoclonal antibodies were sheep anti-mouse antibodies conjugated to
horseradish peroxidase (Amersham Pharmacia Biotech., Piscataway, N.J.). Incubation
with the primary antibody was done for one hour followed by three washes with an
excess of IX TEST for 15 minutes, 10 minutes and 5 minutes. The secondary antibody
was added and incubated for 30 minutes followed by the same regimen of washes with
IX TEST. During the final wash, the SuperSignal West Pico Chemiluminescent
Substrate solution (Pierce Co., Rockford, Ill.) was prepared by mixing the Stable
Peroxide Solution with the Luminol/Enhancer Solution in a 1:1 ratio in a separate tube.
The membrane was removed from the IX TEST wash and residue was removed by slight
shaking, then placed on a sheet of saran wrap. Substrate solution was added and
incubated motionless for 5 minutes. The membrane was wrapped in saran wrap, exposed
to autoradiography film under safe light and developed with a Kodak M3 5 A X-Omat
automatic processor (Eastman Kodak Co., Rochester, N.Y.). Images were prepared for
presentation using Adobe Photoshop (Adobe, San Diego, Calif).
O.

Electroporation of NCI-H1299 cells
Transient transfections of NCI-H1299 cells were done as previously described

(Chen et al., 1993). Cells were purchased from ATCC and maintained in RPMI 1640
supplemented with 10% FES, L-glutamine and IX antibiotic/antimycotic solution. Cells
were seeded and then trypsinized 48 hours later. Cells were washed twice in media
without serum or antibiotic/antimycotic solution and resuspended to a final concentration
n

of 1 x 10 cells (0.5 ml). Cells were mixed with the indicated amounts of DNA,
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incubated for 5 minutes at room temperature and electroporated at 960 pF, 210 volts
(time constant ~25ms). Cells were immediately resuspended in prewarmed media
complete with 10% FBS and antibiotic/antimycotic solution. The cells were allowed to
grow for 24 hours and then harvested.
P.

Mammalian cell lysates preparation for Firefly Iucif erase and Ren ilia

luciferase assay
Cell lysates were prepared according to the Luciferase Assay System with
Reporter Lysis Buffer (Promega, Madison, Wis.): Cells in 10 cm plates were washed
twice with cold PBS. 440 pi of IX Cell Lysis Reagent (25 mM Tris-phosphate [pH 7.8],
2 mM DTT, 2 mM 1,2-diaminocyclohexane-N, N, N’jN’-tetraacetic acid, 10% glycerol,
1% Triton X-100) was added to the cells which were then scraped and transferred to
microfuge tubes. Cell lysates were centrifuged at 12,000 X g for 5 seconds to pellet cell
debris. The supernatant was collected and an aliquot was analyzed.
1.

Analysis of Firefly luciferase activity
An aliquot of cell lysates was assayed for bioluminescence for 10 seconds in a

luminometer (Turner TD-20e) after addition of 100 pi room temperature Luciferase
Assay Reagent (Promega, Madison, Wis.).
2.

Analysis of Renilla luciferase activity
An aliquot of cell lysate was assayed for bioluminescence for 10 seconds in a

luminometer (Turner TD-20e) after rapid injection of 500 pi 1 pM coelenterazine hep
(Molecular Probes, Eugene, Oreg.) in Renilla assay buffer (0.5 M NaCl, 1 mM EDTA,
100 mM potassium phosphate [pH 7.4]).
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Q.

E. coli radiolabeling
E. coli strain DH5a was transformed with the pbl+groE plasmid and grown in

M63 media (13.6 g/liter KH2PO4, 2 g/liter (NH^SO^ 0.5 mg/liter FeSOWHhO, pH
adjusted to 7.0 with KOH) supplemented with ampicillin (100 pg/ml), 0.0005% thiamine,
0.5% glucose, 1 mM MgS04'7H20 and L-amino acids (lucine, histidine and threonine
[40 pg/ml] each). The cells were spheroplasted (Ausubel et ai, 1994) and radiolabeled
with 35S-methionine for approximately 2-3 minutes (Ewalt et al., 1997).
Cells were spheroplasted in the following manner: 5 ml of cells were centrifuged
into a pellet and the media removed. The pellet was resuspended in 250 pi of 20%
sucrose/50 mM Tris-HCl (pH 8.0), ice cold. 25 pi of lysozyme (10 mg/ml) prepared
fresh in 250 mM Tris-HCl (pH 8.0) was added to the cells and incubated for 5 minutes on
ice. 50 pi of 0.5 M EDTA (pH 8.0) was added and incubated on ice for another 5
minutes. 100 pi of 50 mM Tris-HCl (pH 8.0) was added and the cells were placed in a
37°C water bath for 5 minutes. A sample of the cells was taken to see if they were
clumpy. The procedure was stopped if the cells had clumped. If the cells were not
clumpy, they were pelleted and then resuspended in complete M63 media without
methionine and containing 0.25M sucrose. 75 to 100 pCi/ml of 35S-methionine was
added to the cells for ~2-3 minutes. The cells were pelleted at 21,000 X g for 5 minutes.
The media was removed and the cells were resuspended in 100 pi of hypotonic solution
(10 mM NaCl, 25 mM Tris-HCl [pH 7.4], 5 mM MgCh, ImM PMSF) for 5 minutes on
ice. 100 pi of hypertonic solution (200 mM NaCl, 25 mM Tris-HCl [pH 7.4], 5 mM
MgCh, ImM PMSF) was then added to restore the NaCl concentration to 100 mM. The
cell lysate was then brought to a 1 ml volume with cell lysis buffer (0.1% Triton X-100, 5
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mM MgC^, 100 mM KC1, ImM PMSF and Complete protease inhibitor in cold DPBS).
The cell debris was pelleted and soluble proteins were separated by centrifugation at
21,000 X g at room temperature. Following lysis, cell extract containing ATP or apyrase
was incubated for 30 minutes at 37°C followed by immunoprecipitation at room
temperature. One wash was done with each washing buffer already described in chapter
two. The Complete EDTA-free protease cocktail (Boehringer Mannheim, Indianapolis,
Ind.) and PMSF were added to the lysate for the incubations. The EDTA-free protease
inhibitor was used because EDTA chelates magnesium that is necessary for the ATPase
function of GroEL. EDTA containing Complete was used in all the wash buffers and
allowed any residual ATPase activity to be quenched. Equal volumes of the cell lysate
were apportioned for each reaction and immunporecipitated with polyclonal anti-GroEL
antibodies.
R.

Immunocytochemistry of COS-7 cells
Cells were transfected by the calcium phosphate method as previously described

after the cells were subcultured into a Lab-Tek 8 chambered slide (Nalge Nunc
International, Naperville, Ill.). 48 hours posttransfection, the cells were washed with
DPBS twice. The cells were fixed in 4% formaldehyde/PBS at room temperature for ~15
minutes (Fanger et al., 1997). Three washes with PBS/0.1% Triton X-100 were
performed. The cells were blocked with 0.5% BSA in PBS for one hour to overnight.
The primary antibody was diluted in 0.1% BSA in PBS, incubated for one hour and
washed once for 5 minutes with TBS (20 mM TRIS base, 137 mM NaCl, .38% HC1, pH
adjusted to 7.07 with NaOH). Cells were washed three times with PBS and washed again
with TBS for 5 minutes. The secondary antibody was diluted 1:2000 in 0.1% BS A/PBS
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and incubated for one hour. The cells were washed in TBS/0.01% Triton X-100.
Mounting solution was added to the cells containing DAPI and a coverslip was placed on
top of the cells.
S.

Heat shock treatment of CHO Cells, analysis of Hsp70 induction and

radiolabeling
CHO cells were grown in Hams F-12 media (CellGro, Freiburg, Germany)
supplemented with L-glutamine, IX antibiotic/antimycotic solution and 10% FBS. To
determine the amount of Hsp70 accumulation after heat shock, cells were subcultured
and grown to -70% confluency. Two 10 cm plates of cells were wrapped in parafilm,
one was placed in a 45°C prewarmed water bath and the other was placed in a 37°C
incubator for one hour. Following the incubation, the media was replaced with
prewarmed media at 37°C, and the cells were allowed to recover for 24 hours (Fanger et
aL, 1997). Following the recovery time, cells were washed with DPBS three times,
scraped in 1 ml of DPBS, and placed in a microfuge tube. Cells were centrifuged for 5
minutes at 1600 X g. The DPBS was removed and the cells were lysed by adding 100 pi
of lysis solution (1% Triton X-100-Complete protease inhibitor-DPBS) and incubated for
10 minutes. Cellular debris was pelleted and soluble proteins were collected by
centrifugation at 21,000 X g for 5 minutes at room temperature. Protein concentration
was determined using the Bio-Rad Bradford protein assay (Bio-Rad Laboratories,
Richmond, Calif). Equal concentrations of total protein were mixed with 2X gel loading
buffer and boiled for 5 minutes. Purified Hsc70 (SPP-751, StressGen Biotechnologies
Corp., Victoria, B.C., Canada) was used as a positive control for the western blot
analysis. The SDS-PAGE and western blot transfer was performed exactly as previously
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described. Protein samples were fractionated on two SDS-PAGE gels. Exactly the same
amount of protein sample was added per gel. One gel was stained with coomassie blue
(Fisher Scientific Co., Pittsburg, Pa.) for one hour and placed in destaining solution (30%
methanol, 10% glacial acetic acid in distilled water) until there was no blue background.
The fractionated proteins from the other gel were transferred to PVDF membrane,
blocked with 5% skim milk in TEST for 1 hour. The blot was probed with monoclonal
anti-Hsp70/Hsc70 (SPA-820, StressGen Biotechnologies Corp., Victoria, BC, Canada) at
a 1:1000-2000 dilution. The secondary antibody was sheep anti-mouse antibody
conjugated to horseradish peroxidase (Amersham Pharmacia Biotech., Piscataway, N.J.).
The western blot bands were quantified by spot densitometry. Four separate protein
bands from the destained coomassie blue stained gel were used to quantify the
equivalence of gel loading by spot densitometry. The relative amount of protein was
normalized to 100% of the untreated cells at 37°C and fold induction calculated.
Radiolabeling of CHO cells was done exactly the same manner as previously
described. After the 20 minute incubation in 35S-methionine-media, the radioactive
media was replaced with complete Hams-F12 media containing nonradioactive 50 mM
methionine. The plates were sealed with parafilm and placed in a 45°C water bath or a
37°C incubator for one hour. Following the incubation, the media were removed and the
cells were scraped in 1 ml of DPBS and centrifuged for 5 minutes, 1600 X g, +4°C. The
rest of the procedure was done exactly as previously described.
T.

Heat shock survival of CHO cells
CHO cells were transiently transfected with plasmid vector only, the groEL gene

or the groESL genes by the calcium phosphate precipitation method already described.
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48 hours post-transfection cells were washed three times with DPBS to remove any dead
floating cells. Cells were then detatched from plates by trypsinization and resuspended in
5 ml of complete media. 200 pi aliquots of cells were placed in 1.5 ml micro frige tubes
in triplicate for each time point and temperature. Cells were placed in a 37°C water bath
or a 45°C water bath for one to four hours. Each hour, three identical samples of each
transfection were removed. Cell viability was determined by adding 50pl of trypan blue
(Sigma Chemical Co., St. Louis, Mo.) to the 200pl aliquot of cells. Cells were counted
on a hemocytometer; trypan blue excluding cells were counted and divided by the total
number of cell counted to calculate the percent viable cells. Each transfection was
counted from the triplicate samples and the average taken and the standard deviation
calculated.
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III.

Results

A.

Construction of groE mammalian expression vectors
Several plasmids were constructed that contained the groES and groEL genes

either alone or bicistronically, allowing expression and synthesis of the respective
encoded proteins in mammalian cells. Figure 2 shows maps for the plasmid constructs.
The bacterial groE operon is the structural model used for the bicistronic groES and
groEL (Figure 2 A, B). The groE operon is under transcriptional control of the groE
promoter. Shine-Delgamo sequences precede each gene in the bacterial operon, allowing
both GroES and GroEL polypeptides to be translated from a single groE mRNA. The
mammalian bicistronic expression vector contains the groES and groEL genes under
transcriptional control of the strong CMV immediate-early promoter/enhancer (Figure
2B). The genes are separated by a DNA element known as an internal ribosome entry
site (IRES) from the encephalomyocarditis virus (Jang et al., 1989). The IRES sequence
allows for ribosomal initiation of translation of the downstream gene of the transcript,
which permits the GroES and GroEL polypeptides to be synthesized from the same
mRNA, analogous to the bacterial operon. We did not know if it were important to have
both GroES and GroEL synthesized in the same vicinity, but this allowed us to deliver
both genes into the same cell from a single plasmid. The groES and groEL genes were
also cloned individually into the mammalian expression vector with each gene under the
CMV immediate-early promoter/enhancer for synthesis of a single protein from a single
transcript (Figure 2C, D).
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Figure 2. Bacterial groE operon and major plasmid constructions used in this
work. (A) The E. coli groE operon. The groES and groEL genes are under the
transcriptional control of the groE promoter. Shine-Dalgamo sequences are at the 5'
end of each gene. (B-D) Mammalian expression vectors containing the chaperonin
gene(s) based on the plasmid vector pcDNA3.1(+). (B) Plasmid p3.1groE-IRES. The
groES and groEL genes are under transcriptional control of the constitutive
cytomegalovirus (CMV) intermediate-early promoter/enhancer. The IRES sequence
dividing the two genes allows internal translation initiation of the groEL gene. (C)
Plasmid p3.1 groES. The groES gene is under transcriptional control of the constitutive
cytomegalovirus (CMV) intermediate-early promoter/enhancer. (D) Plasmid
p3.1 groEL. The groEL gene is under the transcriptional control of the constitutive
cytomegalovirus (CMV) intermediate-early promoter/enhancer. SD, Shine-Delgamo
sequence; CMV, constitutive cytomegalovirus (CMV) intermediate-early
promoter/enhancer; groE, groE promoter; IRES, encephalomyocarditis virus internal
ribosome entry site sequence.
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groEL

1.

groESL genes are expressed in mammalian cells
Escherichia coli proteins GroES and GroEL were synthesized in mammalian cells

from their respective genes. Figure 3 is an immunoblot of total cell extracts from COS-7
cells that were transfected with various plasmid constructions. The immunoblot was
reacted with both polyclonal anti-GroES and polyclonal anti-GroEL antibodies. The
absence of a GroES correlating band indicates that GroES synthesized from the
bicistronic vector or a single gene was undetectable by immunoblot analysis. In contrast,
GroEL is synthesized and detectable in mammalian cells; however, the negative control
cell extracts, from cells transfected with the empty plasmid, showed considerable cross
reaction of mitochondrial Hsp60 with the anti-GroEL antibody (StressGen
Biotechnologies Corp., 2000). The SDS conditions of the gel probably exposed more
epitopes than are exposed on the native protein, as will be shown later using
immunoprecipitation. GroEL is synthesized in levels above that shown for the negative
control using the single gene and the bicistronic vectors. The bands below GroEL may
be degradation products of Hsp60 or GroEL or a nonspecific cross-reaction of the
antibody with another protein because they are present in the negative control and in the
lane of cell extract from cells transfected with the groES gene.
We felt that a more sensitive method was necessary to determine whether the
groES gene was expressed, so radiolabeling with 35S-methionine and
immunoprecipitation with specific antibodies was employed. Figure 4 represents an
autoradiogram of fractionated immunoprecipitates from cell extracts of radiolabeled
COS-7 cells that had been transfected with empty plasmid vector (Figure 4, V), the groES
gene (Figure 4A, ES) or the groEL gene (Figure 4B, EL). Immunoprecipitations were
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Figure 3. Simian COS-7 cells express the groES and groEL genes of is. coli.
Immunoblot of COS-7 cell extracts fractionated on a 12% SDS-PAGE and
reacted with anti-GroES antibodies (1:15,000) and anti-GroEL antibodies
(1:30,000). Cell extracts were obtained from COS-7 cells transiently transfected
for 48 hours. Left to right: V, cells transfected with the pCEP4 vector; ES/EL,
cells transfected with plasmid containing the bicistronic groE construct; ES, cells
transfected with the groES gene; EL, cells transfected with the groEL gene;
purified GroES and GroEL protein as positive controls for migration and antibody
specificity. Anti-GroEL antibody has cross-reactivity to mitochondrial Hsp60
{StressGen Biotechnologies Corp. 2000 ID: 1457}.
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Figure 4. GroES and GroEL immunoprecipitated from COS-7 cells. Transiently
transfected COS-7 cells were radiolabeled with 35S-methionine (200 pCi/ml) for 20minutes. Immunoprecipitates were fractionated on a 12% SDS-PAGE gel and
exposed to x-ray film to produce the autoradiograms. (A) Cells were transfected
with left, plasmid vector pcDNA3.1(+) or right, plasmid p3.1groES. Cell extract was
immunoprecipitated with polyclonal anti-GroES antibodies. The GroES protein is 10
kDa. (B) Cells were transfected with left, plasmid vector pcDNA3.1(+) or right,
plasmid p3.1groEL. Cell extract was immunoprecipitated with monoclonal antiGroEL antibodies. The GroEL protein is ~58 kDa.
IP, immunoprecipitation; MWr, relative molecular weight standards; V, plasmid
vector pcDNA3.1(+); ES, cell extract immunoprecipitated from cells transfected with
the groES gene; EL, cell extract immunoprecipitated from cells transfected with the
groEL gene.
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done with either anti-GroES or anti-GroEL antibodies. The presence of the intense band
at ~10-kDa in the groES lane and the absence of the band in the empty vector lane
indicated that the GroES protein was synthesized and specifically immunoprecipitated
(Figure 4A). The additional radioactive bands detected in the lane are most likely cross
reactive proteins the antibody is recognizing, since those bands are found in the vector
control also. This could be explained by the fact that the polyclonal anti-GroES
antibodies are not affinity purified from Sigma Company. The migration of the
radioactive 10-kDa band corresponds with a Coomassie Blue stained band of purified
GroES protein (data not shown). Similarly, a radioactive band of ~ 60-kDa migrates at
the same molecular weight as purified GroEL on a coomassie blue stained gel (data not
shown). A monoclonal antibody specific for GroEL and not cross-reactive with
endogenous Hsp60 of mitochondria was used in this immunoprecipitation (Figure 4B),
indicating that the groEL gene was expressed and the GroEL protein was synthesized in
mammalian cells. There is no detectable band in the empty plasmid vector lane
corresponding to Hsp60, confirming the specificity of the GroEL monoclonal antibody.
In addition, we used an additional approach to demonstrate the synthesis of
GroES in mammalian cells. COS-7 cells were transiently transfected with the groES
gene, fixed and reacted with anti-GroES antibodies (Figure 5). Secondary antibodies
conjugated with cy3 were reacted with the primary anti-GroES antibodies. UV
microscopy using a rhodamine filter revealed that cells appearing red represent those
cells that contain GroES, which reacts with anti-GroES antibodies. The apparent
transfection efficiency based on this analysis was approximately 20-40%.
Immunocytochemistry of cells transfected with the plasmid vector did not show any
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Figure 5. GroES is synthesized in COS-7 cells. Immunocytochemistry of
COS-7 cells transiently transfected with plasmid p3.1groES. Cells were probed
with polyclonal anti-GroES antibodies followed by goat anti-rabbit antibodies
conjugated with the fluorescent label cy3. The mounting medium contained
DAPI that stains the DNA blue when viewed with an ultraviolet microscope and a
DAPI filter. Cy3 stains red when viewed under ultraviolet microscopy and a
rhodamine filter. Two images were combined to form this composite image. The
red signal indicates those cells that have synthesized the GroES protein. Negative
control cells, transfected with the pcDNA3.1(+) vector did not show a similar
signal.
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stained cells (data not shown). GroES was synthesized in mammalian cells, confirmed
by immunoprecipitation and immunocytochemistry. Now that we have shown the
presence of at least monomeric GroES and GroEL, we next examine whether they form
oligomeric structures, the fundamental units of chaperonin activity.
2.

GroEL forms a 14-mer
One of the hallmark features of chaperonins is the formation of oligomeric

structures. GroEL forms a large ~800-kDa double ringed complex of homogenous
subunits, which is necessary for function, although some examples of assisted folding by
an isolated apical domain have been reported (Kobayashi et al., 1999). We investigated
whether GroEL associated into the large oligomeric structure by comparing monomeric
or oligomeric HPLC purified GroELn with GroEL synthesized in mammalian cells by
native PAGE and immunoblot analysis (Figure 6). HPLC purified GroELn dissociates
into monomers in the presence of 4 M urea (Azem et al., 1998). There is a small fraction
of the protein still in the single-ring state, GroEL? found in the middle of the immunoblot
representing the dissociation of double rings into single rings. HPLC purified GroELu
without urea treatment migrated at a slow rate in the native PAGE, and represents double
ringed GroEL. A minor fraction of the protein migrated characteristically as a single
ringed GroEL? complex and some of the protein migrated in the GroELi monomeric
form. COS-7 cells transfected with the groEL gene were homogenized by physical
disruption. Lysates were fractionated using native PAGE, transferred to membrane and
probed with polyclonal anti-GroEL antibodies. Compared to the purified HPLC
GroELi4, GroEL synthesized in COS-7 cells migrated at the same position as GroELu.
This indicates that GroEL formed an oligomeric structure similar to purified HPLC
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Figure 6. GroEL forms a large oligomeric complex in COS-7 cells. Native
PAGE was performed using a 4% stacking gel and a 6% separating gel. Native
immunoblot compares the purified GroELn complex formation in the presence or
absence of 4 M urea to GroEL synthesized in COS-7 cells. Left, HPLC purified
GroEL in 4 M urea; middle, HPLC purified GroEL without 4 M urea; right total cell
lysate of COS-7 cells transiently transfected with the plasmid p3. IgroEL. The
immunoblot was probed with polyclonal anti-GroEL (1:30,000). The secondary
antibody conjugated to horseradish peroxidase was used at a 1:30,000 dilution.
GroELi4, double ring GroEL; GroELy, single ring GroEL, GroELi, monomeric
GroEL; HPLC GroEL14, GroEL double ring structure purified by high pressure
liquid chromatography.
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GroELn, which is the functional unit capable of binding polypeptides within the central
channel of the complex. In contrast, similar experiments with purified GroESy and
GroES synthesized in COS-7 cells were unsuccessful. The GroES protein was
undetectable by immunoblot analysis in both SDS- and native PAGE analysis from cell
extracts from COS-7 cells transfected with the groES gene (data not shown). It may be
that GroES is labile in mammalian cells and immunoblot analysis is not sensitive enough
to detect the levels of GroES available. The most likely reason that we were able to
detect the GroES protein by radioactive immunoprecipitation of GroES was that the
method is much more sensitive than immunoblotting and we specifically enriched for the
GroES protein. Using this method, we cannot determine with the methods that we have
used whether the GroES? formed in mammalian cells; however, we have demonstrated
that the protein is synthesized in mammalian cells by immunoprecipitation (Figure 4) and
immunocytochemistry (Figure 5). Additionally, we have demonstrated that GroEL is
synthesized and forms a large oligomeric structure in COS-7 cells. It is known that
GroEL 14 can bind proteins in vivo and in vitro and that it is the primary function of the
GroEL i4 complex. Demonstration of protein binding to GroEL is therefore a
fundamental property that must be made evident in mammalian cells.
3.

GroEL coimmunoprecipitates with proteins
Figure 7 is an autoradiogram of monoclonal and polyclonal anti-GroEL

immunoprecipitates from cell lysates of cells transfected with the vector only or with the
'JC

groEL gene. Transfected cells were radiolabeled with S-methionine to label newly
synthesized proteins. The polypeptide spectrum illustrated by Figure 7 (EL lanes)
demonstrates the ability of anti-GroEL antibodies to coimmunoprecipitate other proteins
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Figure 7. GroEL coimmunoprecipitates with a wide range of polypeptides in
COS-7 cells. COS-7 cells transiently transfected with the plasmid vector
pcDNA3.1(+) or p3.1groEL were radiolabeled with 35S-methionine (200 pCi/ml) for
20-minutes and harvested. The cell extracts were divided equally and 5 fig of
monoclonal anti-GroEL or polyclonal anti-GroEL was added. The
immunoprecipitates were fractionated on a 12% SDS-PAGE gel, scintillated, dried
and exposed to x-ray film producing the autoradiogram. The most intense band is
GroEL.
V, cell extract immunoprecipitated from cells transfected with the plasmid vector
pcDNA3.1(+); EL, cell extract immunoprecipitated from cells transfected with the
groEL gene; IP, immunoprecipitation; MWr, relative molecular weight standards.
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which may interact with the GroEL protein. The use of a polyclonal antibody against
GroEL compared to the monoclonal antibody indicates that there is an increased amount
of GroEL immunoprecipitated under exactly the same conditions. This is most likely due
to greater affinity of the antibodies for the GroEL protein because of the additional
number of epitopes that the polyclonal antibody mixture recognizes. There are more
polypeptides that are fractionated from immunoprecipitated cell extracts of cells
transfected with the groEL gene when immunoprecipitated with polyclonal anti-GroEL
antibodies, but they are not present in the empty plasmid vector transfected cells.
Are the bands present in the GroEL containing lane polypeptides that were bound
by GroEL and coimmunoprecipitated, or are they degradation products of GroEL that the
anti-GroEL antibodies are recognizing and immunoprecipitating? Comparison of cell
extract from cells transfected with the groEL gene and immunoprecipitated with either
the monoclonal or polyclonal anti-GroEL antibodies reveals that a majority of the bands
in the lanes are of the same molecular weight but with variable intensity. This suggests
that the polypeptides are actual coimmunoprecipitated polypeptides that were bound to
GroEL. The use of the monoclonal anti-GroEL antibody is advantageous because it
recognizes only one epitope on GroEL. If the monoclonal antibody can recognize all the
degradation products of GroEL, then the epitope must be in a very conserved core that is
highly resistant to proteolysis. However, this seems highly unlikely since the polypeptide
spectrum ranges from ~60-kDa to 21-kDa, the size capable of being encapsulated by
GroES and GroEL . This represents a large span of molecular weights that have different
intensities. If the polypeptide spectrum were GroEL degradation products, the bands
would be expected to be progressively less intense for the lower molecular weight
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polypeptides because they would not have as many methionines as the full length GroEL.
Figure 7 shows that there is a variety of intensities represented with the
coimmunoprecipitating polypeptides.
There does appear to be two major bands that could be degradation products of
GroEL. Two polypeptides, 51-kDa and ~48-kDa, were immunoprecipitated by the
polyclonal anti-GroEL antibody but were not immunoprecipitated by the monoclonal
anti-GroEL antibody. They apparently have an epitope(s) that is recognized by
polyclonal anti-GroEL antibodies, but not by the monoclonal anti-GroEL antibodies.
Although the other polypeptides appear to be coimmunoprecipitated proteins bound by
GroEL, further evidence was needed to support this conclusion.
4.

GroEL coimmunoprecipitates are not GroEL protein degraded in vitro
The argument that the polypeptide spectrum is due to degradation of GroEL post

lysis was investigated by immunoprecipitating cell extracts in the presence or absence of
the protease inhibitor cocktail Complete, containing inhibitors of calpains, serine-,
cysteine- and metalloproteases. PMSF was added to all samples as a general protease
inhibitor at the lysis step. Figure 8 is an autoradiogram of fractionated
immunoprecipitates from cell extracts of COS-7 cells transfected with the vector plasmid
or the groEL gene. The same spectrum of polypeptide fractionation occurs with or
without the presence of the protease inhibitor cocktail. There is no increase in the
number or intensity of the coimunoprecipitating bands in the presence of the protease
inhibitors. This result suggests that there is little degradation of GroEL post-lysis unless
there is an unknown protease that is not inhibited by the inhibitors used; however, these
protease inhibitors are widely used and accepted as generally comprehensive. An
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Figure 8. GroEL coimmunoprecipitates are not degraded GroEL polypeptides
from the immunoprecipitation procedure. COS-7 cells transiently transfected with
the plasmid vector pcDNA3.1(+) or plasmid p3.1groEL were radiolabeled with 35Smethionine (200 pCi/ml) for 20-minutes and harvested. The cell extracts were divided
equally and 5 pg of polyclonal anti-GroEL was added. The immunoprecipitates were
fractionated on a 12% SDS-PAGE gel, scintillated, dried and exposed to x-ray film
producing the autoradiogram. Left two lanes. Complete protease inhibitors were
omitted from the lysis buffer; right two lanes. Complete protease inhibitors were
added to the lysis buffer.
V, plasmid vector pcDNA3.1(+); EL, plasmid p3.1groEL containing the groEL gene.
MWr, relative molecular weight standards.
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alternative explanation of the coimmunoprecipitating polypeptides with GroEL is that
they represent GroEL degradation in vivo. Upon lysis, anti-GroEL antibodies may
specifically immunoprecipitate GroEL fragments.
5.

GroEL coimmunoprecipitates are not GroEL protein degraded in vivo
The possibility of in vivo degradation of GroEL protein within transiently

transfected cells prior to lysis was examined by pulse-chase analysis. Cellular proteins
were metabolically labeled with 35S-methionine for one minute, the time to efficiently
label one round of protein synthesis in mammalian cells (Thulasiraman et al., 1999;
Netzer and Haiti, 1997) and chased with complete media containing excess nonlabeled
methionine for several time points. If the polypeptides are degradation products of
GroEL, then the lower molecular weight species should increase in their intensity over
time while the GroEL band should decrease in intensity over time. Figure 9 is an
autoradiogram of immunoprecipitated cell extracts from cells that had been pulse-chased
for various time points. The signal at the zero time point indicates that GroEL is
synthesized in one minute and labeled efficiently. GroEL already exhibits lower
molecular weight radiolabeled coimmunoprecipitating species. Over the following hour,
the levels of GroEL remain constant relative to the lower molecular weight bands. The
30-minute lane represents a difference in loading but is of the same intensity when
compared to the other bands in that lane. Results from this experiment indicated that
degradation of the GroEL protein was not occurring in vivo prior to cell lysis.
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Figure 9. GroEL is not degraded in vivo. COS-7 cells transiently transfected with
the plasmid pS.lgroEL or the plasmid vector pcDNA3.1(+) were pulsed for 1 minute
with S-methionine (400 pCi/ml). Chase times for pS.lgroEL transfected cells are as
follows, left to right, zero minutes, 10 minutes, 20 minutes, 30 minutes, 60 minutes.
Far right, 60 minutes chase of cells transfected with the vector pcDNA3.1(+). After
the chase, cells were harvested, immunoprecipitated, fractionated on an 8% SDSPAGE gel, dried, scintillated and exposed to x-ray film, producing an autoradiogram.
Variation in the 30 minute chase lane was due to unequal loading, however the relative
ratios of the GroEL band to the other bands is the same compared to the other lanes.

92

p3.1groEL

rtnw

10

20

p3.1
39

60

60

GroEL

—51 *2

—33-6
“28.$
“21.1

93

6.

Polypeptides bind to GroEL in vivo
The bulk of the evidence supports the conclusion that the polypeptides

immunoprecipitated and fractionated from cell lysates from cells transfected with the
groEL gene are polypeptides bound by GroEL. It appears that polypeptides are
coimmunoprecipitated, but do they represent the natural association of polypeptides with
GroEL within the living cells or an artifact due to the association of the polypeptides with
GroEL after the cells are lysed? We addressed this problem with a competition
experiment between radiolabeled polypeptides within the cell and a cold competitor
added post-lysis. asi-casein is a protein that has high binding affinity for the polypeptide
binding region of the inner walls of the GroEL chamber, even when completely folded to
its native state, as previously demonstrated for Hsp60 of mitochondria (Martin et ai,
1992). Another competitive sample that could have been used was nonradiolabeled cell
extracts instead of asi-casein. If the binding of polypeptides occurs within the cell, the
cold competitor, upon cell lysis, should have few GroEL sites to bind. The polypeptides
bound to GroEL will be coimmunoprecipitated and visualized by SDS-PAGE and
autoradiography. However, if the binding of polypeptides to GroEL occurs post-lysis,
then the excess asi-casein should bind to the available sites of GroEL, excluding the
radiolabeled polypeptides. Very little radiolabeled polypeptides should be bound to
GroEL, drastically reducing the signal obtained after immunoprecipitation, fractionation
on SDS-PAGE and autoradiography. Fifty micrograms of asi-casein was added to
metabolically S-methionine labeled cells prior to lysis. Figure 10 illustrates that
asi-casein does not compete for the available GroEL binding sites upon lysis of cells
transfected with the groEL gene. There is no difference between the intensity and
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Figure 10. GroEL binds polypeptides in vivo. Immunoprecipitation with antiGroEL antibodies of COS-7 cell extract from cells transiently transfected with
pS.lgroEL or pcDNA3.1(+) and radiolabeled with 100 pCi/pl of 35S-methionine for
1 hour. Left to right: pB.lgroEL transfected cells lysed and immunoprecipitated
without asi-casein; pcDNA3.1(+) vector transfected cells lysed and
immunoprecipitated without asi-casein; p3.1groEL transfected cells lysed and
immunoprecipitated with 50pg of nonradioactive asi-casein. 12% SDS-PAGE
without scintillation exposed for 1 month.
MWr, relative molecular weight standards; EL, cells transfected with p3.1groEL;
V, cells transfected with the pcDNA3.1(+) vector.
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number of bands coprecipitated with the anti-GroEL antibodies. Therefore, the binding
of polypeptides appears to occur within the living cell.
We also examined the spectrum of bound polypeptides after various methods of
transient transfection to see if that effected the number or intensity of bound polypeptides
(Figure 11): calcium phosphate precipitation, electroporation and Lipofectamine Plus (a
cationic lipid material). Each method revealed a very similar array of polypeptides that
were coimmunoprecipitated by GroEL. Electroporation killed many of the COS-7 cells,
resulting in less cell lysates immunoprecipitated by anti-GroEL antibodies, but the overall
spectrum is the same as the calcium phosphate and LipofectAMINE transfection
methods. The polypeptides may represent unstable polypeptides with a structure that
GroEL is capable of binding. Induction of genes due to the transfection of plasmid DNA
may result in a greater abundance of proteins newly synthesized that may interact with
GroEL, which are not detectable using a stable cell line capable of inducing the synthesis
of GroEL (Thulasiraman et al., 1999). Thus, we established that GroEL is synthesized
and can coimmunoprecipitate polypeptides from the cytosol of mammalian cells. Next,
we want to investigate the similarities/differences that might exist in the folding
environments between E. coli, the natural source of GroEL, and mammalian cells by
comparing their coimmunoprecipitated polypeptides based on relative band intensity and
number.
B.

Difference in spectrum of bound proteins between bacterial and

mammalian cells
A fundamental feature of GroEL-mediated protein folding is the ability to
hydrolyse ATP. Each monomer of GroEL contains a weak ATPase that triggers
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Figure 11. The same polypeptide spectrum is coimmunoprecipitated with
GroEL independent of the transfection method. An autoradiogram from antiGroEL immunopreciptated cell extracts from cells transfected with p3.1groEL or
pcDNA3.1(+) and radiolabeled for 20 minutes with 200 pCi/ml of 35S-methionine.
Three transient transfection methods were utilized, left to right: calcium phosphate
precipitation, LipofectAMINE Plus and electroporation. The electroporated cells
did not handle the transfection procedure well resulting in a loss of viable cell
numbers compared to the other two methods. Immunoprecipitates were fractionated
on a 12% SDS-PAGE and scintilated with Entensify.
MWr, relative molecular weight standards; V, pcDNA3.1(+) vector transfected cells;
EL, p3.1groEL transfected cells.
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conformational shifts in the GroELn complex allowing the bound polypeptide to be
released into the central channel space for a chance at folding. We examined the ability
of GroEL synthesized in E. coli cells to release polypeptides in the presence of ATP and
compared it to the ability of GroEL synthesized in COS-7 cells to release polypeptides
(Figure 12). GroEL synthesized in E. coli binds a wide range of polypeptides in the
absence of ATP (Figure 12A). Polypeptides range from >200-kDa to 7-kDa, indicating
the capacity of GroEL to interact with many polypeptides, including those larger than
GroEL itself. It has been recently demonstrated that most of the high molecular weight
polypeptides that bind to GroEL remain associated for an extended period, while those of
lower molecular weight transit GroEL quickly, the majority of which pass through
GroEL within ~100 seconds (Ewalt et ai, 1997). The majority of the polypeptides were
released from GroEL in the presence of ATP, with some polypeptides incompletely
released.
In contrast, although GroEL synthesized in mammalian cells can bind and release
polypeptides (Figure 12B), the spectrum of polypeptides bound was relatively restricted.
From prior immunoprecipitations, there appeared to be only 10-20 individual
polypeptides that are coimmunoprecipitated with GroEL. In the presence of 5 mM ATP
several polypeptides are not coimmunoprecipitated with GroEL compared to the GroEL
in the absence of ATP. These results indicate that GroEL synthesized in mammalian
cells has restricted access to polypeptides that are synthesized in the cell or GroEL may
not interact as well with proteins modified in the endoplamic reticulum or golgi and
located on the cell membrane. It may also be possible that GroEL is modified in some
way that makes it incapable of binding the large polypeptide spectrum in mammalian
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Figure 12. GroEL coimmunoprecipitates a different polypeptide spectrum in
E. coli and COS-7 cells. Immunoprecipitation with anti-GroEL antibodies of cell
extracts from (A) E. coli, and (B) COS-7 cells transfected with the groEL gene,
radiolabeled with 35S-methionine and incubated with or without 5 mM Mg2+-ATP.
(A) Inununoprecipitates of E. coli cell extract incubated with (left) 10 units of
apyrase and (right) 5 mM ATP. Cells were radiolabeled with -100 pCi/ml of 35Smethionine. (B) Immunoprecipitates of COS-7 cell extracts from cells transfected
with, left to right. pcDNA3.1(+) vector and 10 units of apyrase; pcDNA3.1(+)
vector and 5 mM Mg2+-ATP; p3.1 groEL and 10 units of apyrase; p3.1 groEL and
Mg2+-ATP. Cells were radiolabeled with 200 pCi/ ml of 35S-methionine.
Immunoprecipitates were fractionated on a 12% SDS-PAGE and scintillated with
Entensify.
MWr, relative molecular weight standards; kDa, kilodaltons; V, cell extract from
cells transfected with pcDNA3.1(+); EL, cells transfected with p3.1 groEL.
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cells. GroEL binds folding proteins in the bulk cytosol of E. coli, thus gaining general
access to them. It was recently hypothesized that protein folding in mammalian and yeast
cells occurs in a sequestered manner, because the folding polypeptide was bound by
chaperone factors, rarely being released into the bulk cytoplasm (Siegers et al., 1999;
Thulasiraman et al., 1999). Thus, GroEL may not have access to folding polypeptides in
mammalian cells because they are not released into the bulk cytoplasm. However,
GroEL may have access to native proteins denatured by stress. We therefore examined
the spectrum of the polypeptides associated with GroEL in mammalian cells under heat
shock.
C.

Increased polypeptide binding to GroEL in heat shocked cells
Many of the same proteins that assist protein folding are also involved in

protecting polypeptides from stress. Many of the heat shock proteins were
serendipitously discovered after examining cells that had been subjected to heat shock
and were later described as chaperones of protein folding. We investigated whether
GroEL could bind previously unavailable proteins after heat shock. This could indicate
that 1) the stress response machinery of mammalian cells could be saturated, 2) GroEL
could act as a molecular probe for misfolding proteins and 3) GroEL or GroESL could
possibly provide thermotolerance to cells subjected to heat shock.
The induction of the heat shock response was determined by comparing the
increase or accumulation of HspTO protein levels between treated and nontreated control
cells by western blot analysis. CHO and COS-7 cells were incubated for 1 or 2 hours for
CHO cells and 3 hours for COS-7 cells at 37°C or 45°C and then recovered for 24 hours.
Total cell lysates from the treated and nontreated cells was collected, fractionated and
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proteins transferred to PVDF membrane for immunoblot analysis using anti-Hsp70
antibodies. CHO cells displayed a nearly 16-fold increase of Hsp70 protein in cells heat
shocked for 1 hour compared to the cells incubated at 37°C (Figure 13), still maintaining
their morphological shape (data not shown). The Hsp70 accumulation indicated that the
cells were under stress that effected protein stability. Cells heat shocked for 2 hours
displayed a 30% decrease of Hsp70 protein compared to the untreated cells and were
noticeably more rounded and shrunken (data not shown). Heat shock longer than one
hour at 45°C appears to be therefore detrimental to the health of the CHO cells. In
contrast, COS-7 cells did not show any accumulation of Hsp70 protein in response to
heat shock at 45°C compared to control cells.
Having established that 1 hour was sufficient for inducing the heat shock response
in CHO cells, the groEL gene or the empty vector was transfected into CHO cells and
allowed to grow for 24 hours. COS-7 cells were also transfected and treated in the same
manner as CHO cells in order to investigate the possibility that the cells were undergoing
heat shock and proteins were misfolding, but without the concommitment response from
Hsp70. CHO and COS-7 cells were radiolabeled and then chased to produce a pool of
radioactive folded proteins. The plates were sealed with parafilm and placed in either a
45°C water bath or in a 37°C incubator for 1 hour for CHO cells and 3 hours for COS-7
cells (based on previous preliminary experiments). Following the chase, cell extracts
were collected, immunoprecipitated with polyclonal anti-GroEL antibodies, fractionated
on a 12% SDS-PAGE gel, scintillated, dried and exposed to x-ray film. Figure 14 for
CHO cells and Figure 15 for COS-7 cells show the results of the experiments. Cells that
were transfected with the vector only served as a control for any nonspecific binding and
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Figure 13. Induction of Hsc70/Hsp70 protein after heat shock at 45°C. CHO cells were incubated for 1 hour at 37°C
and 45°C and allowed to recover for 24 hours. COS-7 cells were heat incubated for 3 hours at 37°C and 45°C and allowed
to recover for 24 hours. Equal amounts of cell extracts were loaded onto a 12% SDS-PAGE in dublicate and fractionated.
One gel was stained with coomassie blue and destained and the other gel was transferred to memberane for immunoblot
analysis with anti-Hsc70/Hsp70 monoclonal antibodies. Protein loading equivalency was determined by densitometry of
five averaged coomassie blue stained bands. Hsc70/Hsp70 accumulation was determined by densitometry of the
immunoblot film and normalized according to loading equivalence. Fold induction was compared to the 37°C control,
which was set at 1.
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Figure 14. GroEL coimmunoprecipitates from CHO cells heat shocked at 45°C.
Immunoprecipitation with anti-GroEL antibodies of cell extracts from cells transfected
with pcDNA3.1(+) or pB.lgroEL, radiolabeled with 400 pCi/ml of 35S-methionine
and fractionated on a 12% SDS-PAGE followed by scintillation with Entensify. Cells
were radiolabeled for 20 minutes to create a pool of labeled proteins after which fresh
media with 50 mM nonlabeled methionine was added and the cells were incubated for
one hour at either 37°C or 45°C, scraped, lysed and immunoprecipitated.
MWr, relative molecular weight standards; p3.1, pcDNA3.1(+) vector.
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Figure 15. GroEL coimmunoprecipitates from COS-7 cells heat shocked at
45°C. Immunoprecipitation with anti-GroEL antibodies of cell extracts from cells
transfected with pcDNA3.1(+) or p3.1groEL, radiolabeled with 400 pCi/ml of 35Smethionine and fractionated on a 12% SDS-PAGE followed by scintillation with
Entensify. Cells were radiolabeled for 20 minutes to create a pool of labeled proteins
after which fresh media with 50 mM nonlabeled methionine was added and the cells
were incubated for one hour at either 37°C or 45°C, scraped, lysed and
immunoprecipitated.
kDa, kilodalton relative molecular weight standards; V, pcDNA3.1(+) vector; EL,
p3.1groEL.
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association with the anti-GroEL antibodies at either temperature. GroEL in CHO cells
was able to coimmunoprecipitate many more proteins under heat shock conditions than
were available for interaction at 37°C (Figure 14). The polypeptides had a wider range of
distribution, with polypeptides greater than 60-kDa associating with GroEL. It appears
that incubation of cells for 1 hour at 45°C could saturate the endogenous stress response
proteins in CHO cells because GroEL had access to proteins that were destabilized, yet
not bound by other proteins. However, the situation is somewhat different in COS-7
cells. GroEL was able to coimmunoprecipitate polypeptides at 37°C, but there was no
enrichment of the polypeptides compared to cells incubated at 45°C. This indicates that
COS-7 cells might contain factors, possibly endogenous heat shock proteins that were not
saturated by the heat shock conditions. We next investigated whether the presence of
GroEL or GroES/GroEL could effect the viability of CHO cells under heat shock
conditions, since GroEL can bind proteins that presumably were denatured by the heat
shock.
D.

Increased thermotolerance of mammalian cells expressing the groEL

gene
Three populations of CHO cells transiently transfected with plasmid vector, the
groEL gene, or the groESL bicistron were analyzed. Cells were incubated for up to four
hours at 37°C and 45°C and aliquots were examined every hour for the ability to exclude
the dye trypan blue, indicating cell viability. Figure 16 represents the viability of the
transfected cell populations at 37°C and 45°C. The cells synthesizing GroEL have an
increased amount of thermotolerance when exposed to prolonged heat shock compared to
cells not expressing the groEL gene (Figure 16). Cells incubated at 37°C were -100%
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Figure 16. Heat shock survival of CHO cells transiently transfected with various chaperonin plasmids. CHO cells were
transiently transfected with the pcDNA3.1(+) plasmid, the p3.1groEL plasmid or the p3.1groE-IRES plasmid. The cells were
allowed to grow for 48 hours posttransfection, washed extensively, aliquoted into 1.7 ml microfuge tubes and placed in a 37°C
or 45°C water bath for the times indicated. At each time point, triplicate tubes containing cells of each transfection were
removed and cell viability was measured by the ability of the cells to exclude the dye trypan blue.
p3.1, pcDNA3.1(+) plasmid vector; p3.1groEL, pcDNA3.1(+) vector containing groEL gene; p3.1groE-IRES, pcDNA3.1(+)
vector containing the groES and groEL genes.
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viable through the entire experiment indicating the killing effect was due to the heat
shock. The population of cells transfected with the groEL gene are consistently more
viable than those without the groEL gene. Cells transfected with the groESL genes are
less viable than cells containing the groEL gene, but more viable than those transfected
with the vector only. After one and two hours, there is no great difference between the
viability of cells containing the vector, groEL or groESL genes. However, after three
hours at 45°C, 58% of the cellular population transfected with the groEL gene is viable
compared to 29% of the cellular population transfected with the plasmid vector. Even the
cellular population transfected with the groESL genes is 42% viable. Unfortunately, after
four hours, the cell viability drops greatly with only ~5% difference between the groEL
and vector transfected cell population. The groESL transfected cell population is ~2%
lower than the vector transfected cell population.
GroEL has a positive effect on the viability of cells subjected to heat shock. The
viability curve generated over time shows that the groEL transfected cell population
survives better, yet the curve is not that much different than for the vector control cells.
However, the cell survival effect may be due to the variable extent of transient
transfection of the cells, with only a smaller population actually containing the groEL
gene. Some of the dying cells may not have had the gene. Though the cells were
transfected transiently, the general effect demonstrates that GroEL did confer a degree of
thermotolerance to cells that were transfected with the groEL gene. The concurrent
synthesis of GroES and GroEL did not offer a distinct advantage to the cells. This could
have been due to the lower production level of GroEL protein when it is translated from
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the bicistronic vector. Optimization of GroES and GroEL synthesis from the bicistronic
vector may reveal the same or greater thermotolerance to heat shock.
Our data indicate that mammalian cells have the capacity to express the groES
and groEL genes and synthesize the respective proteins. Fundamental properties of
GroEL, such as forming large oligomeric structures and binding proteins in vivo, the
majority of which do not appear to be degradation products of GroEL itself were all
maintained in mammalian cells. Additionally, the protein folding machinery in
mammalian cells generally sequesters folding polypeptides away from the bulk cytosol,
whereas the E. coli protein folding machinery allows release of folding polypeptides into
the bulk cytosol where GroEL can bind and interact with them. Considering the different
pathway of protein folding between bacteria and mammalian cells, we wanted to use a
model protein substrate that misfolded in E. coli and produce it in mammalian cells to
investigate whether GroES and GroEL were functional as protein folding machines in
mammalian cells. If the protein misfolded in mammalian cells, then we could coexpress
the groESL genes and determine their effect on protein folding in mammalian cells. The
next section describes the model protein substrate, the rationale for its use and the
questions that can be answered by its use.
E.

Overexpression of a luciferase-gfp fusion gene construct and folding

of its product in Escherichia coli and COS-7 Cells
A fusion of the bacterial luciferase alpha and beta subunits, which is dependent on
GroES/GroEL for activity in E. coli at 37°C, was engineered for production in
mammalian cells; however, the luciferase was not active at permissive or nonpermissive
temperatures in mammalian cells (data not shown). We investigated whether the fused
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luciferase was active by coexpressing the genes coding for the individual alpha and beta
subunits of the luciferase in mammalian cells, which likewise did not result in activity,
indicating that bacterial luciferase is inactive in mammalian cells. This was quite
unexpected because, in contrast, a temperature resistant fused bacterial luciferase is
active in plant tissue (Arakawa et al., 1998). Previous reports had demonstrated that the
monomeric luciferase misfolds and forms aggregates in Hspl04 deficient yeast (Parsell et
al., 1994; Nathan ef <2/., 1997). To investigate whether the temperature sensitive
monomeric luciferase was also aggregating in mammalian cells, we fused a green
fluorescent protein to the monomeric luciferase for analysis by fluorescence microscopy.
This luciferase-GFP fusion protein not only allowed us to determine if aggregates were
formed, but led us to ask several other questions as well. Can the high level expression
of a gene coding for a large multidomain protein saturate the endogenous protein folding
machinery in mammalian cells? Can the overexpression of the groESL genes assist the
folding of a large multidomain protein in E. coli in vivo?
The synthesis of foreign proteins in bacteria and mammalian cells could have an
effect on the endogenous protein folding machinery. Medically important proteins are
synthesized in bacteria and gene therapy trials mostly seek to overexpress genes encoding
therapeutic proteins in humans. Understanding the requirements for the endogenous
protein folding machinery may increase the yield of folded protein in E. coli and avoid
saturation in human cells. It has been shown that many mammalian proteins misfold and
form aggregates in E. coli, though less is known regarding this situation in mammalian
cells (Yasukawa et al., 1995). A luciferase-GFP fusion gene was expressed in E. coli
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and mammalian cells and the luciferase-GFP fusion protein solubility, aggregate
formation and association with GroEL was determined to answer the questions above.
We have compared the capability of the endogenous protein folding machinery
from E. coli and COS-7 cells to mediate the folding of the luciferase-GFP fusion protein,
a large multidomain protein. Its molecular weight is 104-kDa, closer to the size of
proteins found in eukaryotic cells (Netzer and Haiti, 1997). E. coli has 4,285 proteins
with an average length of 317 amino acids. Only 13% of those proteins are greater than
500 amino acids (Netzer and Haiti, 1997), the approximate theoretical size limit of a
poplypeptide that can fit within the GroES/GroEL encapsulated space (Xu et al., 1997).
In contrast, S. cerevisiae contains 5,886 proteins with an average length of 484 amino
acids, with 37% comprising proteins greater than 500 amino acids (Netzer and Haiti,
1997). Our model protein, the luciferase-GFP fusion protein, is encoded by a 2,862 bp
gene fusion composed of 954 amino acids including a 27 amino acid linker between the
two moieties that have different biochemical activities, bacterial luciferase and green
fluorescent protein. This is almost double the size of the average protein in yeast and
three times the size of an average E. coli protein.
1.

Construction of the luciferase-GFP fusion gene plasmids
Wild type bacterial luciferase [alkanal monooxygenase (FMN-linked); alkanal,

reduced-FMN:oxygen oxidoreductase (1- hydroxylating, luminescing), EC 1.14.14.3]
isolated from Vibrio harveyi, a bioluminescent marine bacterium, is a heterodimeric
enzyme composed of an a (40-kDa) and a p (36-kDa) subunit, catalyzing the reaction:
FMNH2 + 02 + RCHO

FMN + RCOOH + H20 + 0.1 /*v49o nm- The crystal structure of

the ap heterodimer was solved to 1.5 A (Fisher et al, 1996). The fusion of the luxA
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(1056 bp) and luxB (972 bp) genes encodes for a monomeric temperature sensitive
luciferase (76-kDa) that is dependent on GroE chaperonins for activity at the
nonpermissive temperature in E. coli (Escher and Szalay, 1993), which also aggregates in
yeast (Parsed et al., 1994). The luciferase was fused to the green fluorescent protein
(GFP), which does not have a strict requirement for chaperonin-mediated folding, but
GroESL can mediate its folding in vitro (Makino et al., 1997).
GFP is a 26-kDa monomeric protein, encoded by a 720-bp cDNA (Chalfie et al..
1994). We used a modified GFP, whose cDNA is codon optimized for expression in
human cells (Zolotukhin et al., 1996) and contains a serine to threonine mutation at
amino acid position 65 (S65T) that increases fluorescence six times that of wild type
GFP, excites at 489 nm and emits at 509-511 nm (Heim et al., 1995). The crystal
structure was solved at 1.9 A llustrating that GFP forms an 11 stranded p barrel with a
single a helix threaded through the middle containing the chromophore, placed almost in
the center of the barrel (Yang et al., 1996), Protein Data Bank 1GFL. GFP requires only
atmospheric oxygen (Heim et al., 1995) and excitation with UV light to be functional, so
visualization of its fluorescence in E. coli and cultured mammalian cells is a direct
indication of its native state.
The GFP “tag” of the luciferase-GFP fusion protein allows the in vivo
examination of cells that contain the luciferase-GFP fusion protein via GFP fluorescence.
Characteristic aggregates of recombinant proteins in bacteria, known as inclusion bodies,
have been viewed by light microscopy (Carrio et al., 1998), yet the activity of such
aggregates had not been previously determined in vivo. GFP fluorescence and bacterial
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luciferase activity allowed us to determine the capacity of bacterial and mammalian cells
to mediate the folding of three distinct domains containing two active moieties.
The plasmid DNA construct of the luciferase-GFP fusion gene is illustrated in
Figure 17. The luciferase-GFP fusion protein contains a methionine to lysine mutation at
the codon encoding the first amino acid of the GFP portion of the fusion. This was
introduced as a control to demonstrate that any GFP fluorescence was due to fusion with
the bacterial luciferase and not to internal translation of the GFP protein within the
luciferase-GFP fusion mRNA. The bacterial expression vector is pACYC184 and the
luciferase-GFP fusion gene is under transcriptional control of the tetracycline resistance
promoter. The mammalian expression vector is pcDNA3.1(+) and the luciferase-GFP
fusion gene is under the transcriptional control of the strong CMV immediate-early
promoter/enhancer.
2.

Expression of the luciferase-gfp gene construct in E. coli

a)

Rescue of the luciferase moiety of the luciferase-GFP fusion protein

by expression of the groESL genes
Luciferase activity is an indication of the state of the luciferase-GFP fusion
protein in vivo. Monomeric bacterial luciferase protein exhibits temperature sensitive
folding that excess GroES and GroEL can overcome at 37°C in E. coli (Escher and
Szalay, 1993). This protein (76-kDa) is already over the size range that should interact
with GroES and GroEL (Xu et al., 1997). GFP was used to visualize the state of the
fusion luciferase-GFP protein in vivo. However, we first investigated whether the
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Figure 17. Abbreviated plasmid construction of the luciferase-gfp fusion
gene constructs. (A) pACGNl: Plasmid construction for the expression of the
luciferase-gfp fusion gene in bacteria. The gene is cloned into the pACYC184
vector and is under transcriptional control of the tetracycline resistance promoter.
(B) p3.1FG: Plasmid construction for the expression of the luciferase-gfp fusion
gene in mammalian cells. The gene is cloned into the pcDNA3.1(+) vector and is
under transcriptional control of the human CMV immediate-early
promoter/enhancer. The luciferase-gfp gene is a fusion of the monomeric
temperature sensitive luciferase gene, a fusion of the luxA and luxB subunits,
which was then fused to the green fluorescent protein cDNA. The gene product is
~104-kDa on a SDS-PAGE.
luxA, a subunit gene from Vibrio harveyi; luxB, p subunit gene from Vibrio
harveyi\ gfp, green fluorescent protein cDNA.

120

A.

Bacterial Cell: pACGNI: Bacterial luciferase fused
to gfp (Luciferase-GFP, 104 kDa)
tef

W/////////A
luxA

luxB

gfp

B.
Mammalian Cell: p3.1FG: Bacterial luciferase fused to
gfp (Luciferase-GFP, 104 kDa)
CMV

V//////////A
luxA

luxB

121

gfp

luciferase-GFP fusion protein still required excess GroES and GroEL proteins for the
rescue of luciferase activity as it does for the monomeric luciferase.
E. coli cells were cotransformed with the luciferase-GFP fusion gene and vector
plasmid, the groEL gene, or the groES and groEL genes. Bacterial colonies were grown
at 37°C for approximately 18 hours on LB agar plates with the appropriate antibiotics. Ndecyl aldehyde was spread onto the cover plate and allowed to diffuse to the colonies.
Luciferase activity was visualized using a low light imager that detects photon emissions,
digitally captured on computer and the image pseudocolored red for presentation (Figure
18). Analysis by this method demonstrated that the temperature sensitive activity of the
bacterial luciferase when fused to the GFP protein was still chaperonin dependent.
Colonies containing the luciferase-GFP fusion gene and the vector, without chaperonin
genes, displayed basal luciferase activity (Figure 18A). Basal luciferase activity was
undetectable when the luciferase-GFP fusion gene was cotransformed with the groEL
gene (Figure 18B). When the luciferase-GFP fusion gene was cotransformed with the
groES and groEL genes, the colonies were more bioluminescent compared to the colonies
that were not overexpressing the chaperonin genes. The data indicate that luciferase
moiety of the luciferase-GFP fusion protein was still temperature sensitive and could be
rescued by overexpression of the groESL genes (Figure 18C).
b)

Visualization in situ of soluble and aggregated luciferase-GFP fusion

protein in E. coli
It is known that the monomeric luciferase aggregates in yeast cells deficient in the
Hspl04 chaperone (Parsed et al., 1994). We investigated whether the solubility of the
luciferase could be visualized by fusing the green fluorescent protein with the carboxy
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Figure 18. Luciferase bioluminescence from bacterial colonies grown at 37°C
on agar plates. Bacteria were cotransfected with (A) plasmids pACGNl and
pbl+skx-; (B) plasmids pACGNl and pGEL7 ; and (C) plasmids pACGNl and
bl+groE. Bacterial colonies were selected and propogated on LB-agar plates
supplemented with 100 pg/ml ampicillin and 30 pg/rnl chloramphenicol and grown
in a 37°C incubator until colonies were visible, usually 15 hours after spreading
transformants onto the LB-agar plates. Luciferase bioluminescence was captured
using a low light imager and visualized using MetaMorph software. The
bioluminescent spots were pseudocolored red for presentation. N-decyl aldehyde
was spread onto the inside of the petri plate cover and the aldehyde diffused to the
colonies.
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terminus of the bacterial luciferase. E. coli cells expressing the luciferase-gfp gene at
37°C contain low levels of both diffuse and focused fluorescence (Figure 19), suggesting
that the luciferase-GFP fusion protein was present in a soluble as well as an aggregated
form in these cells. This was corroborated with results obtained after differential
centrifugation and immunoblot analysis of total E. coli cell lysates with anti-GFP and
anti-Luciferase antibodies (Figure 20). The luciferase-GFP fusion protein isolated from
cells not overexpressing chaperonins partitioned mostly into the soluble fraction with low
amounts in the insoluble fraction (Figure 20A, lanes 3 and 4; 20B, lanes 4 and 5). Thus,
GFP can visually “tag” two forms of the luciferase-GFP fusion protein. The fact that
GFP was functional in both of those forms suggested that aggregation and solubility of
the fluorescent fusion protein was partially dependent on its luciferase moiety, as no foci
were observed when the gfp gene alone was expressed (data not shown).
c)

The GFP moiety of the luciferase-GFP fusion protein requires

GroESL for folding
E. coli cells cotransformed with plasmids carrying the luciferase-gfp gene fusion
and the groEL gene showed little increase in GFP fluorescence (Figure 19B) when
comparied to cells overexpressing the luciferase-gfp gene without any overexpressed
chaperonin genes (Figure 19A). However, a significant increase in the amounts of
luciferase-GFP fusion protein was observed in the presence of additional GroEL, both in
the soluble and aggregated forms (Figure 20A, lanes 5 and 6; 20B, lanes 6 and 7). The
increase in fusion protein amounts was not due to increased translation, because
transformation of the firefly luciferase gene with and without the groESL genes in E. coli
did not increase or decrease the amount of firefly luciferase activity (data not shown). It
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Figure 19. GFP fluorescence activity at 37°C of Is. coli cells cotransformed with
plasmid pACGNl and (A) vector only, (B) pGEL7, and (C) pbl+groE.
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Figure 20. Solubility of the luciferase-GFP fusion protein in E.coli at 37°C. (A)
Anti-GFP antibodies and (B) anti-luciferase antibodies were used for immunoblot
analysis of fractionated lysates of cells expressing various DNA constructs. (A)
Lane 1, cells expressing the monomeric luciferase gene from plx403fab9, lane 2,
cells expressing the gfp cDNA from pGFP; lane 3 and 4, cells expressing the
luciferase-gfp gene from pACGNl, and vector, pbl+skx-; lane 5 and 6, cells
expressing the luciferase-gfp gene from pACGNl-full, and the groEL gene from
pGEL7; lanes 7 and 8, cells expressing the luciferase-gfp gene from pACGNl, and
the groES and groEL genes from pbl+groE; lane 9 , cells containing vector
pACYC184 and vector pbl+skx-. (B) Lane 1, cells expressing the monomeric
luciferase gene from plx403fab9; lane 2, cells expressing the luciferase-gfp gene;
lane 3, cells expressing the gfp cDNA from pGFP; lane 4 and 5, cells expressing the
luciferase-gfp gene from pACGNl, and vector, pbl+skx-; lane 6 and 7, cells
expressing the luciferase-gfp gene from pACGNl, and the groEL gene from pGEL7;
lanes 8 and 9, cells expressing the luciferase-gfp gene from pACGNl, and the groES
and groEL genes from pbl+groE; lane 10 , cells containing vector pACYC184 and
vector pbl+skx-.
S, soluble fraction; I, insoluble fraction; FG;. luciferase-GFP protein
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is possible that the luciferase-GFP fusion protein was susceptible to degradation and that
GroEL may protect it. No GroEL protein could be detected in the aggregate fraction
indicating that the presence of the luciferase-GFP fusion protein in this fraction was due
to its misfolding, and not to gene overexpression per se (data not shown). Increased
luciferase-GFP fusion protein amounts without concomitant increased GFP fluorescence
suggested that the GFP moiety of the luciferase-GFP fusion protein also contributed to its
misfolding.
E. coli cells cotransformed with plasmids carrying the luciferase-gfp gene fusion
and the groESL genes showed a drastic increase in both diffuse and focused fluorescence
(Figure 19C). This increase in fluorescence accompanied an increase in fusion protein
amounts when compared to cells expressing the luciferase-gfp gene alone (Figure 20A,
lanes 7 and 8; 20B, lanes 8 and 9). However, when comparing cells expressing the
luciferase-gfp gene and overexpressing the groEL gene alone, lower levels of soluble and
aggregated luciferase-GFP protein amounts were observed. These results suggested that
both GroES and GroEL chaperonins were necessary to fold the luciferase and GFP
moieties of the luciferase-GFP fusion protein. The 1:1 ratio of GroES to GroEL probably
allowed the productive folding of the luciferase and GFP moieties of the luciferase-GFP
fusion protein as indicated by the increase in luciferase bioluminescence and GFP
fluorescence. The overexpression of the groES gene alone together with the
luciferase-gfp gene did not have an effect on the fluorescence of the luciferase-GFP
fusion protein in situ, suggesting that there was no indirect effect of the cochaperonin
GroES on the folding of the GFP moiety (data not shown).
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d)

The luciferase-GFP fusion protein interacts with GroEL in E. coli
Immunoprecipitation of total cell lysates from E. coli cells transformed with the

luciferase-GFP fusion gene indicated a physical association between GroEL and the
luciferase-GFP fusion protein (Figure 21). Cells were transformed with the
luciferase-GFP fusion gene with no additional chaperonin genes, with additional groEL
gene or groESL genes, followed by radiolabeling, lysis and immunoprecipitation with
anti-GroEL or anti-GFP antibodies. Figure 21 is an autoradiogram of the fractionated
coimmunoprecipitates. GroEL could specifically coimmunoprecipitate the
luciferase-GFP fusion protein in E. coli cells, whereas the vector controls displayed no
radioactive bands corresponding to the luciferase-GFP fusion protein. The position of the
luciferase-GFP fusion protein was verified by immunoprecipitation of cell lysates from
cells transformed with the luciferase-GFP fusion gene with anti-GFP antibodies. We
investigated whether the luciferase-GFP fusion protein was immunoprecipitated by cross
reactivity with the anti-GroEL antibody or by the interaction of GroEL with the
luciferase-GFP fusion protein. Differential centrifugation followed by sequential
immunoblot analysis of E. coli total cell lysates demonstrated the specificity of the
coimmunoprecipitation for the GroEL protein and not for the luciferase-GFP fusion
protein (Figure 22). The immunoblot was first reacted with anti-GroEL antibodies used
for the immunoprecipitation, which specifically recognized GroEL, but did not reveal any
detectable reaction with the luciferase-GFP fusion protein.
Next, the same membrane was washed and reacted with anti-Luciferase
antibodies. Detectable luciferase-GFP fusion protein was present only in the soluble cell
extracts without any excess GroEL or GroES/GroEL. It appeared that GroEL directly
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Figure 21. GroEL coimmunoprecipitates the luciferase-GFP fusion protein in
E. coli at 37°C. Cell extracts from cells radiolabeled with -lOOpCi/ml 35Smethionine were immunoprecipitated with either anti-GroEL or anti-GFP antibodies
from cells without the luciferase-gfp fusion gene: bl+skx- and pACYC184, or with
the luciferase-gfp fusion gene: V + FG. The luciferase-GFP fusion protein is 104kDa.
V, pbl+skx-; FG, luciferase-gfp fusion gene; MWr, relative molecular weight
standards.

132

^
Ch

CT) rn

o (N
cs

t-h

Si!

vq

f**

m

oo

o

un
rn

«o

+
>

+

iS>t
cn QJ

;;V':

+

:

i: I
l

Oh
MH

w
2

S': >'-r:';.

-

pH

| o o

m
cn

I

+
O

• lllllll w fe >■?«
•■............. s

m^m
O

'■

+

- o

■Lh<
X) Oh

'
;

OO

t*'

■■

+

,^-

fi

(N

<N

i
■■

O

O)

On

f’l?

•

g xT^

I

'^v •••''.-.-.--VI-'
mZc
• ®K!:i wv?* --y»f.-,,-

Figure 22. No cross-reactivity between anti-GroEL antibodies and the
luciferase-GFP fusion protein. Sequential immunoblot of fractionated E. coli cell
extracts from cells grown under conditions used for radiolabeling and cotransformed
with plasmid pACGNl and left to right, vector only, pGEL7, and pbl+groE. (A)
Immunoblot of fractionated total cell extracts reacted with anti-GroEL antibodies,
revealing the presence of GroEL in the soluble fractions. (B) Reprobe of the same
membrane with anti-luciferase antibodies to show the presence of the
luciferase-GFP fusion protein on the immunoblot and lack of cross-reactivity with
the anti-GroEL antibody.
S, soluble fraction of total cell lysates; I, insoluble fraction of the total cell lysates;
V, pbl+skx-; FG, plasmid encoding the luciferase-GFP fusion protein; EL, plasmid
pGEL7 encoding the GroEL protein; ESL, plasmid pbl+groE encoding the GroES
and GroEL proteins.
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bound to the luciferase-GFP fusion protein and the coimmunoprecipitation of the
luciferase-GFP fusion protein was not an indirect effect of cross-reactive antibodies.
Surprisingly, when cells were visualized with UV microscopy, only those cells that did
not have excess chaperonins contained very bright areas of focused GFP fluorescence
(Figure 23). Those cells containing excess GroEL or GroESL had no detectable GFP
fluorescence. Not surprisingly, there was no detectible luciferase-GFP fusion protein
after probing with anti-GroEL or anti-GFP antibodies in the cells that harbored the
plasmids for excess groEL gene or excess groESL genes by immunoprecipitation (data
not shown). This could indicate that under minimal growth conditions necessary for
radiolabeling, GroEL or GroES/GroEL mediate or shuttle aggregation sensitive proteins
down the degradation pathway. When excess GroEL was present, it appeared to keep the
luciferase-GFP fusion protein in a "holding state," in which the luciferase-GFP fusion
protein is not functional for luciferase activity and weakly active for GFP fluorescence.
Taken together, the soluble and insoluble fluorescent forms of the tagged
luciferase, differential centrifugation and coimmunoprecipitation with GroEL, the
evidence indicates that GroEL in conjunction with GroES can mediate the folding of a
large multidomain protein in Escherichia coli. This provides the first in situ evidence
that there is an exception to the rule that bacteria do not have the capacity to mediate the
folding of a large multidomain protein as has been suggested (Netzer and Haiti, 1997).
F.

Mammalian cell overexpression of the luciferase-gfp gene

The visualization of the luciferase-GFP fusion protein via GFP fluorescence in E. coli
was compared with mammalian cells. We investigated whether the large multidomain
luciferase-GFP fusion protein could be folded in mammalian cells and whether it could
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Figure 23. GFP fluorescence oiE. coli cells grown at 37°C under conditions
used for radiolabeling. The cells were transformed with the plasmid vector
pbl+skx- and plasmid pACGNl that encodes the luciferase-gfp gene.
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saturate the endogenous protein folding machinery. The latter has implications in the
context of gene therapy and the overexpression of proteins in mammalian cells. If the
overexpression of genes encoding therapeutic proteins saturates the protein folding
machinery, then the efficiency of folding may be affected, resulting in more proteins
misfolding and losing function. UV microscopy, centrifugation at 21,000 X g and
immunoprecipitation of coexpressed groEL were used to determine if the luciferase-GFP
fusion protein is released into the bulk cytoplasm as in E. coli and forms aggregates. If
the luciferase-GFP fusion protein forms aggregates, then the coexpression of groESL
genes could be used to abrogate the formation of the aggregates in vivo, suggesting that
GroES/GroEL are functional as protein folding machines in mammalian cells. However,
if the luciferase-GFP fusion protein was soluble, then immunoprecipitation by GroEL
might indicate that the protein was in a non-native state that GroEL could recognize in
the bulk cytosol due to the break down of the compartmentation folding pathway (Siegers
et al., 1999). The breakdown of compartmentalized protein folding has been
demonstrated during stress such as heat shock and ethanol incubation (Siegers et al.,
1999; Thulasiraman et al., 1999). The use of the luciferase-GFP fusion protein may give
additional insight as to whether the overexpression of a gene encoding a protein with at
least three domains can affect the normal folding pathway of mammalian cells.
1.

The luciferase-GFP fusion protein does not form aggregates in

mammalian cells
COS-7 cells were transfected with the luciferase-GFP fusion gene, fixed and
visualized for the presence of protein aggregates, indicated by green speckles (Figure 24).
A diffuse green signal filled the cells, suggesting that the luciferase-GFP fusion protein
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Figure 24. GFP fluorescence activity of COS-7 cells expressing the
luciferase-gfp gene from the p3.1FG plasmid. The green color is the active
green fluorescent protein and the blue color is DAPI stained cell nuclei.
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was soluble in mammalian cells. We investigated whether the soluble diffuse green
signal was masking any aggregates by analysing the solubility of the luciferase-GFP
fusion protein in total cell extracts. Differential centrifugation of total cell lysates from
cells transfected with various expression plasmids was immunobloted and reacted with
anti-GFP antibodies, probing for the presence of insoluble luciferase-GFP fusion protein
(Figure 25). The detectable luciferase-GFP fusion protein was soluble when the
lucifemse-gfp gene was transfected alone and cotransfected with the groEL or
groES-IRES-groEL genes though the amount of the luciferase-GFP fusion protein is
several fold less without the coexpression of the chaperonins (Figure 25, lanes 1-6). No
luciferase-GFP fusion protein signal was detected on the immunoblot of soluble and
insoluble fractions from cells transfected with the vector only (Figure 25, lanes 7 and 8).
The lower molecular weight band was a nonspecific cross-reactive soluble protein that
also appears in the vector only transfected cells (Figure 25, lanes 1, 3, 5, and 7). Lane 9,
a positive control for the immunoblot, contains soluble E. coli cell lysates from cells
transformed with the gfp gene. The same amount of fractionated total cell lysates was
reacted on a separate immunoblot with rabbit anti-luciferase antibodies for which the
same pattern was seen (data not shown). This data suggested that the presence of GroEL
or GroES/GroEL increased the amount of soluble luciferase-GFP fusion protein,
indicating it may interact with GroEL or GroES/GroEL.
2.

GroEL does not interact with the luciferase-GFP fusion protein in COS-7

cells.
Interaction of the luciferase-GFP fusion protein with GroEL or GroES/GroEL was
investigated by immunoprecipitation of radiolabeled total cell lysate from cells
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Figure 25. Solubility of the luciferase-GFP fusion protein synthesized in COS-7
cells. The luciferase-gfp gene was cotransformed with vector (lanes 1 and 2),
pB.lgroEL (lanes 3 and 4), and p3.1groE-IRES (lane 5 and 6). Lanes 7 and 8 were
transformed with the vector only. Lane 9 was cell extracts from E. coli cells
transformed with the gfp gene. Cell extracts were separated into soluble and
insoluble portions and fractionated on a 12% SDS-PAGE and transferred to PVDF
membrane for Western blot analysis. The Western blot was reacted with anti-GFP
antibodies.
S, soluble fraction of the total cell extracts; I, insoluble fraction of the total cell
extracts; V, cells transfected with the pcDNA3.1(+) vector; FG, cells transfected
with the p3.1FG plasmid encoding the luciferase-GFP fusion protein; GroEL, cells
transfected with the pB.lgroEL plasmid encoding GroEL; GroESL, cells transfected
with the p3.1groE-IRES plasmid encoding GroES and GroEL; bt GFP, cell extracts
from E. coli cells transformed with the gfp cDNA.

143

FG +

FG +

FG +

v
GroEL GroESL
V
1__2 3 4 5 6 7 8 9
kDa
207-

S IS

I

S I

SI
.

121-t

-Luciferase-GFP

8151.233.628.622.17.5-

Anti-GFP

144

cotransfected with the luciferase-GFP fusion gene and the groEL or groESL genes
(Figure 26). Radiolabeled cells extracts were immunoprecipitated with either anti-GroEL
or anti-GFP antibodies. Immunoprecipitation with anti-GFP antibodies demonstrated the
presence of the luciferase-GFP fusion protein in transfected cells as seen by comparing
lane 2 and lane 7. GroEL immunoprecipitation with anti-GroEL antibodies probed
whether GroEL could coimmnoprecipitate the luciferase-GFP fusion protein as it did in
E. coli (Figure 21). Lane 1 and lane 2 (Figure 26) are negative controls for the antiGroEL antibody (lane 1) and the anti-GFP antibody (lane 2) immunoprecipitations of cell
lysates from cells transfected with the vector. The bands present are radioactive proteins
that cross-react with the antibodies, which may be a general effect since the same pattern
is seen in the negative controls (lanes 1 and 2). Lane 3 is a positive control for the
synthesis of the GroEL protein. Cell lysates from cells transfected with the groEL gene
were immunoprecipitated with anti-GroEL antibodies. Lanes 6 and 7 are
immunoprecipitations with anti-GroEL antibodies (lane 6) and anti-GFP antibodies (lane
7) of cell lysates from cells transfected with the luciferase-GFP fusion gene,
demonstrating the specificity of the antibodies and the lack of cross-reactivity of the antiGroEL antibodies with the luciferase-GFP fusion protein. A remarkable enrichment of
the luciferase-GFP fusion protein was present at the proper molecular weight for this
protein (lane 7). Immunoprecipitations with anti-GroEL antibodies of cell lysates from
cells transfected with the groEL gene (lane 4) and the groES-IRES-groEL genes (lane 5)
did not contain bands corresponding to the luciferase-GFP fusion protein (lane 7).
GroEL does not appear to interact with the luciferase-GFP fusion protein, or the
interaction was very transient and in amounts that were not detectable by this method. In
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Figure 26. GroEL does not coimmunoprecipitate the luciferase-GFP fusion
protein in COS-7 cells. Cells were transfected with combinations of no chaperonin
genes, vector plasmid and the luciferase-gfp gene, followed by radiolabeling with
200 pCi/ml of S-methionine. Cell extracts were immunoprecipitated with either
anti-GroEL or anti-GFP antibodies. Immunoprecipitates were fractionated on a 12%
SDS-PAGE, scintillated, dried, exposed to x-ray film and developed.
MWr, relative molecular weight standards; V, plasmid pcDNA3.1(+) vector; EL,
plasmid p3.1groEL encoding the GroEL protein; ESL, plasmid p3.1groE-IRES
encoding the GroES and GroEL proteins; FG, plasmid p3.1FG encoding the
luciferase-GFP fusion protein.
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addition, because GroEL did not interact with the luciferase-GFP fusion protein, the
synthesis of the luciferase-GFP fusion protein did not saturate the endogenous protein
folding machinery of COS-7 cells, ie. it was not released into the bulk cytosol. As for the
increased quantity of the soluble luciferase-GFP fusion protein detected by differential
centrifugation that may have been due to an indirect effect of GroEL on translation or
transcription. GroEL may also interact with another protein in COS-7 cells that interacts
to increase the total amount of luciferase-GFP fusion protein.
In conclusion, our results indicate that the GFP protein may be used to visualize
chaperonin-mediated folding directly in situ of Escherichia coli cells. In addition, we
provide evidence suggesting that both GroES and GroEL chaperonins were necessary to
fold the multiple domains of a protein, which was presumably, too large to be entirely
accommodated by the channel formed by GroELi4 in E. coli and encapsulated by GroES.
Finally, the luciferase-GFP fusion protein produced in mammalian cells was soluble, the
GFP moiety was active and the luciferase moiety does not misfold so as to aggregate.
Over production of the luciferase-GFP fusion protein did not saturate the endogenous
protein folding machinery of COS-7 cells. The lack of interaction between the
luciferase-GFP fusion protein with GroEL and GroES/GroEL did not elucidate whether
GroES/GroEL retain protein folding capability in mammalian cells. We next investigated
whether GroES/GroEL could rescue a temperature sensitive p53 protein in mammalian
cells, which if successful would indicate chaperonin activity and the feasibility of
chaperonin-based therapy.
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G.

GroESL and Gene Therapy
The rescue of a protein that is not folded correctly by the endogenous protein

folding machinery was a focus of this investigation. Mutations in enzymatic or
regulatory proteins that results in loss of function can lead to increased morbidity and
mortality. To determine whether the GroES and GroEL chaperonins were functional in
their protein folding capacity in mammalian cells, their genes were coexpressed with the
gene of a temperature sensitive protein involved in human disease. This was begun to
establish the possibility of using GroES and GroEL as proteins that could be used in a
gene therapy setting. The human p53 with a valine to alanine substitution at amino acid
143 (VI43A) was chosen as a model because it exhibits temperature sensitive ability to
transactivate a reporter gene linked to a p53 DNA binding element at 30°C, which is lost
at 37°C (Funk et al., 1992). GroES and GroEL may be able to assist the VI43A mutant
p53 down the proper folding pathway that would lead to phenotypically wild type
protein, thus restoring its wild type function as “guardian of the genome” (Lane, 1992).
Coexpression of the wild type p53 gene with the groESL genes in E. coli had been
previously investigated (Yasukawa et al, 1995). The chaperonins slightly increased the
solubility of the total p53 synthesized compared to endogenous levels of GroES and
GroEL. With such a low yield of soluble wild type protein in E. coli from groESL gene
overexpression, we decided that examining the amount of activity from coexpression of a
temperature sensitive mutant p53 cDNA and groESL genes would be unprofitable in E.
coli. We examined directly whether the coexpression of the groESL genes with a mutant
p53 cDNA could alleviate the misfolding of the mutant p53 protein in mammalian cells.

149

1.

Synthesis of GroES and GroEL does not rescue a temperature-sensitive

p53 mutant V143A at nonpermissive temperature in H1299 cells
Transient transfection assays were performed using wild type p53 and VI43A p53
as the effector proteins. Activity of the p53 gene products was measured as the amount
of activity of firefly luciferase induced from the reporter gene construct, p53CON-LUC.
Figure 27B illustrates the reporter gene construct, p53CON-LUC and its parent plasmid,
pGUP.PA.8 (Figure 27A), not containing the p53 DNA binding element, which were
developed as reporters of p53 transactivational capacity (Funk et al., 1992). The
plasmids contain the structural gene for firefly luciferase under transcriptional control of
a minimal hsp70 promoter. Induction of the firefly luciferase gene is dependent upon the
presence of the p53 DNA binding element, p53CON, found upstream of many p53
responsive genes (Chen et al., 1993). Figure 27A and B illustrates that the p53CON
sequence is necessary for the binding of the p53 tetramer and transactivation of the firefly
luciferase gene and only wild type p53 can bind and transactivate the synthesis of the
firefly luciferase mRNA (Figure 27B and C).
Transfections were normalized for efficiency and growth rate by simultaneous
transfection with Renilla luciferase cDNA under transcriptional control of a strong
human CMV immediate-early promoter/enhancer. Transfections were done in the p53 null
cell line, NCI-H1299 to remove all p53 background (Chen et al, 1993) and placed at the
appropriate temperature for 24 hours. Measurements of the background activity of cells
cotransfected with plasmid pGUP.PA.8 were measured at 37°C (Chen et al., 1993).
Cells were cotransfected with the wild-type p53 cDNA, the V143A p53 cDNA or the
groES-IRES-groEL genes. Figure 28 contains the results of the transient transfection
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Figure 27. Plasmid construct for the p53 responsive reporter. (A) pGUP.PA.8,
the parent plasmid containing the firefly luciferase gene and the minimal hsp70
promoter. This plasmid is not responsive to p53 transactivation. (B) Plasmid
p53CON-LUC, contains the firefly luciferase gene, the minimal hsp70 promoter
and the p53CON sequence, a p53 DNA binding element, which allows p53
transactivation of the luciferase gene. (C) Illustration showing that a dominant
negative p53 oligomerized with wild type p53 destroys the transactivational
activity of wild type p53; hence, there is no induction of the firefly luciferase gene.
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Figure 28. Luciferase activity in response to different plasmid transfections. The hatched bars represent the
luciferase activity from cell extract from NCI-H1299 cells cotransfected with the pGUP.PA.8 plasmid and the wild type
p53 cDNA, the VI43 p53 cDNA and the p3.1groE-IRES construct. The solid bars represent the luciferase activity from
cell extract from NCI-H1299 cells cotransfected with the p53CON-LUC plasmid and the wild type p53 cDNA; the wild
type p53 cDNA and the p3.1groE-IRES construct; the VI43A p53 cDNA; the VI43A p53 cDNA and the p3.1groE-IRES
construct; the p3.1groE-IRES construct. All the cotransfections were also transfected simultaneously with the renilla
luciferase gene. Firefly luciferase activity was normalized to the Renilla luciferase activity to control for loading and
transfection efficiency. RLU, relative light units.

25

*3

H = p53CON-LUC

= pGUP.PA.8

03

!-

20

9

C

£

15

'oi
■£>

03
M

3

10

B

a>

tJ-

P
5

V//////////A

0
wtp53

VI43A p 53

GroES/GroEL

wt p53

Co-transfections

wt p53 +
GroES/GroEL

V143A p53

V143A p53 +
GroES/GroEL

GroES/GroEL

experiments. Cells transfected with pGUP.PA.8 (no p53 DNA binding element) and the
wild type p53 cDNA, the V143A p53 cDNA or the groESL genes produced very low
levels of luciferase, demonstrating the amount of background gene transcription expected
from the minimal hsp70 promoter. Cells transfected with the reporter plasmid containing
the p53 DNA binding element, p53CON-LUC and the wild type p53 cDNA, the V143A
p53 cDNA or the groES-IRES-groEL genes showed different levels of reporter induction.
Only the cells containing wild type p53 had increased luciferase activity, indicating that
the wild type p53 protein transactivates the expression of the firefly luciferase cDNA and
that the system is operational. The cells containing V143A p53 or GroES/GroEL had no
luciferase activity, indicating that the VI43 A cannot transactivate the reporter gene at
37°C and that GroES/GroEL did not indirectly transactivate the reporter gene. The wild
type or VI43 A p53 cDNAs, simultaneously transfected with the groES and groEL genes
did not have a consequential effect on transactivation of the reporter gene, especially with
the VI43 A p53. The levels of firefly luciferase activity were nearly the same as that of
cells transfected with the groES and groEL genes with or without the firefly luciferase
gene.
2.

GroES and GroEL effect on p53 temperature sensitivity
We confirmed that the V143A p53 is temperature sensitive at 37°C by

transfecting cells with the p53CON-LUC reporter gene construct and various
combinations of the p5 3 cDNAs with or without the groEL gene and incubating them at
30°C or 37°C. Figure 29 represents the data obtained from one experiment. Cells
transfected with the p3.1 vector had very low background luciferase activity, indicating
no indirect effect of the p3.1 vector upon the reporter construct and that the NCI-H1299
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Figure 29. Transactivation of the p53CON-LUC reporter gene at 30°C and 37°C. Luciferase activity from cell extracts
from NCI-H1299 cells cotransfected with the vector; p3.1groEL; wild type p53 cDNA; wild type p53 cDNA and p3.1groEL;
V143A p53 cDNA; V143A p53 cDNA and p3.1groEL. Cells were simultaneously transfected with the renilla luciferase
gene. Firefly luciferase activity is expressed as the relative light units of firefly luciferase divided by the normalized amount
of Renilla luciferase activity. Firefly luciferase activity of wild type p53 at 300C and 370C was set as 100%, and all other
luciferase activities are relative to that.
RLU, relative light units.
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cells contained no p53 protein capable of transactivating the reporter gene construct.
Cells transfected with the groEL gene also did not activate the expression of the firefly
luciferase cDNA suggesting that GroEL did not exert an indirect effect on the expression
of the reporter gene at either 30°C or 37°C. Wild type p53 induced the expression of the
firefly luciferase cDNA at both 30°C and 37°C, indicating that the wild-type p53 can bind
the p53 consensus sequence and promote transcription of the downstream gene. The
addition of the groEL gene had the unusual effect of nearly doubling the luciferase
activity levels compared to wild type cells without the GroEL. This effect was not due to
an indirect effect of GroEL on the system since there was only background activity when
the groEL gene is introduced. The NCI-H1299 cells are devoid of any p53 protein,
therefore the luciferase activity increase was most likely due to an effect of GroEL on the
firefly luciferase or the firefly luciferase and Renilla luciferase. It could also represent
interaction of GroEL with an unknown factor that directly or indirectly interacts with
wild type p53. It also appears that the effect is specific to GroEL because there is modest
decreases in luciferase activity when GroES is also present (Figure 28). The object of
this study was to determine the effect that GroES and GroEL had on mutant p53, so this
interesting phenomenon was not pursued in this study.
Expression of the V143A cDNA at 30°C demonstrated a two and a half fold
increase over wild type p53 and nearly a 100-fold increase over V143A p53 cDNA
transfected cells grown at 37°C. The increased half-life and stability of mutant p53 at
30°C, where the protein retains transactivational ability, could explain this finding (Iggo
et al., 1990). Cells transfected with the groEL gene and the V143A p53 cDNA and
grown at 30°C, had lower firefly luciferase activity than cells transfected with the VI43 A
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p53 cDNA without the groEL gene at 30°C. This could be additional evidence that the
mutant p53 at the permissive temperature is not quite wild-type but does retain the
transactivational activity of the wild-type p53 protein. GroEL could also be exerting an
indirect effect on the firefly luciferase or it may transiently bind VI43 A p53, thus
reducing its capacity to interact with the p53 DNA binding element at the permissive
temperature. The cells transfected with the VI43 A p53 cDNA with and without the
groEL gene at 37°C did not display any transactivational capacity.
The mutant VI43 A p53 protein did retain transactivational activity when
transfected cells are grown at 30°C. The results of the simultaneous transfections of the
V143A p53 cDNA and the groES and groEL genes (Figure 28) suggest that GroES and
GroEL cannot rescue mutant p53 at the non-permissive temperature in cultured
mammalian cells.
3.

Probing interaction between GroEL and p53
Even though GroES/GroEL could not rescue V143A p53, we investigated

whether there was a direct interaction between p53 and GroEL by immunoprecipitation
with anti-GroEL antibodies, followed by anti-p53 western blot analysis of cells
synthesizing GroEL and the wild type p53 protein or the VI43 A p53 mutant protein. The
rationale behind this procedure is as follows: Immunoprecipitation of GroEL with a
polyclonal antibody followed by western blot analysis with a monoclonal antibody allows
detection of precipitated proteins in the 45-kDa to 60-kDa range, free of a strong cross
reaction from the heavy chain of the immunoprecipitating immunoglobin which migrates
at ~50-kDa. The principle of Western blotting centers around the reaction of a specific
antibody with a target antigen that has been transferred onto a membrane after being
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separated on a polyacrylamide gel. The primary or antigen specific antibody is incubated
with the membrane containing the antigen and they form a complex. The secondary
antibody is added, reacting with the specific Fc region of a particular species against
which it was raised, i.e. goat anti-rabbit secondary antibody will react with any antibody
raised in rabbits. If an antibody, such as the immunoprecipitating antibody, is separated
in the same gel as the target antigen, then the secondary antibody will recognize the Fc
region of the native primary antibody bound to the target antigen and the Fc region of the
partially denatured immunoprecipitating antibody. This will result in a very strong signal
due to the large amounts of immunoprecipitating antibody on the membrane used for the
immunoprecipitation. However, if the secondary antibody is different from the
immunoprecipitating antibody, then there is a much weaker affinity and only a weak
signal is detected. In this experiment, the immunoprecipitating antibody is a rabbit
polyclonal anti-GroEL, the primary antibody is mouse monoclonal anti-p53, and the
secondary antibody is sheep anti-mouse Ig covalently linked to horseradish peroxidase.
The experiment allowed the detection of proteins in the 45-kDa to 60-kDa ranges without
the strong signal of the immunoprecipitating heavy chain.
Monoclonal anti-GroEL antibodies were used to coimmunoprecipitate any proteins
interacting with GroEL and monoclonal antibodies against p53 (BP53-12, Vector
Laboratories Inc., Burlingame, Calif.) were used to demonstrate the presence of p53 in
the cells. Figure 30 indicates that GroEL did not interact with wild type p53 or V143A
p53 at 37°C. Cell extracts from cells transfected with the gfph gene was used as a
negative control for the GroEL or p53 immunoprecipitation. Cell extract from A1 cells
that overexpress p53 was used as a positive control for the immunoblot. The last lane is
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Figure 30. p53 does not coimmunoprecipitate with GroEL. NCI-H1299 cells
transfected with p3.1groEL and wild type p53 cDNA, p3.1groEL and V143A p53
cDNA, or p3.1GFP were immunoprecipitated with either monoclonal anti-GroEL or
monoclonal anti-p53 antibodies. Immunoprecipitates, p53 positive control A1 cell
extracts and anti-GroEL antibodies were fractionated and transferred to PVDF
membrane for Western blot analysis. The Western blot was reacted with polyclonal
anti-p53 antibodies. The GFP immunoprecipitates were controls for cross-reactivity
during immunoprecipitation and the anti-GroEL antibodies on the Western blot
served as a control for any antibody heavy chain cross-reactivity.
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monoclonal anti-GroEL antibody, which served as a control for any cross reactivity
against the secondary antibody in the immunoblot procedure.
In conclusion, GroES and GroEL do not assist the folding of wild type p53 or
V143A mutant p53 by the methods used here. The reporter assay combined with
coimmunoprecipitation with GroEL suggests that GroEL does not bind or interact with
this mammalian protein in a mammalian expression system. GroEL may simply not
interact with p53; however, the possibility exists that the GroES-GroEL reaction cycle is
not functional in mammalian cells. The possible reasons for the lack of productive
interaction will be discussed forthwith.
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IV.

Discussion
Proteins, the major products encoded by genes, are the functional molecules that

allow all organisms to exist. Folding a protein into its proper three-dimensional
conformation is the key to its function and vital to the survival of a cell. Molecular
chaperones of various molecular weights and complex formations bind polypeptides,
preventing aggregation, adding conformational stability, thus assisting the polypeptides
to fold into functional proteins within cells. Understanding the process and machinery
involved in the folding of proteins within the cell is important. The work presented in
this thesis investigated the aspects of the interaction between GroESL and polypeptides
from E. coli and mammalian cells.
The similarities and differences in protein folding between bacterial and
mammalian cells were investigated. Our results showed that proteins in bacterial cells
have greater access to GroEL than proteins synthesized in mammalian cells, confirming a
previous study (Thulasiraman et al., 1999). However, our data were obtained under
somewhat different conditions and have yielded additional results. To further understand
protein folding in bacteria and mammalian cells, a model protein substrate, the luciferaseGFP fusion protein, was developed and its folding in E. coli and mammalian cells was
analyzed.
Next, we determined whether GroEL could be used as a tool to identify proteins
that misfold under specific conditions in mammalian cells. The cytosol of mammalian
cells appears to be a privileged area regarding protein folding under normal conditions.
Perturbation of the environment, such as heat shock, can have an effect on the stability of
native proteins that can be probed by their interaction with GroEL in treated cells.
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Finally, we determined whether GroEL or GroES and GroEL could protect cells
against thermal injury and whether GroESL could rescue a p53 mutant known to promote
tumor formation due to protein misfolding.
A.

Properties of GroESL in mammalian cells
Protein folding in prokaryotes and eukaryotes occurs by different means. One

major difference between these kingdoms is the size and complexity of the protein
populations. Prokaryotes, exemplified by E. coli, generally have smaller polypeptides
that are released into the bulk cytoplasm after synthesis on the ribosome, associating with
various molecular chaperones (Buchberger et al., 1996) and folding in a posttranslational
manner. Most polypeptides associate with the DnaK/DnaJ/GrpE folding machinery
(Teter et al, 1999). Hsp70 and Hsp40 bind to the most hydrophobic regions of a folding
polypeptide, masking the aggregation sensitive areas from inappropriate interactions in
the cytoplasm. The release of Hsp70 from the polypeptide allows GroEL access to the
folding polypeptide in the bulk cytoplasm in E. coli.
Mammalian cells have acquired more complexity within the organization and
structure of their polypeptide population. A majority of polypeptides in eukaryotes have
more than one domain, thus requiring the need of specialized interactions with the protein
folding machinery of the cell. Many polypeptides are protected from release into the
bulk cytosol, prior to folding, thus avoiding intra- and intermolecular aggregation, due to
the interaction with chaperone proteins. Individual domains fold sequentially in a
cotranslational manner during polypeptide synthesis until the entire polypeptide is
synthesized and folded through the interaction with the Hsp70 machine or if necessary,
the cytosolic chaperonin. The interaction of the chaperone machines occurs in a
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sequestered, compartmentalized manner, which keeps the normative polypeptide away
from the bulk cytosol until the polypeptide has attained its native conformation.
Data presented in this work indicates that wild type GroEL protein can bind
polypeptides under normal growth conditions in mammalian cells. ATP dependent
release of polypeptides from GroEL suggests that the ATPase activity of GroEL was
retained after synthesis in mammalian cells.
In addition, pulse-chase analysis confirmed that GroEL binds polypeptides and
not degradation products of GroEL. Pulse-chase analysis demonstrated that the
polypeptides bound by GroEL are not in vivo degradation products. These polypeptides
are bound by GroEL over at least one hour (Figure 9), suggest that GroEL may be
continually binding and releasing those polypeptides because they cannot maintain a
stable structure once released and therefore are rebound. Alternatively, GroEL may have
been modified in mammalian cells, permanently or transiently, in a way that would not
allow frequent release of the polypeptides in vivo. Reversable phosphorylation of a
fraction of GroEL was described for E. coli cells starved for phosphate (Seeger et ai.
1996) and under heat shock conditions (Sherman and Goldberg, 1994). Incubation of
2_|_

ATP-Mg with the phosphorylated GroEL induced the dissociation of GroEL with the
substrate proteins bound to an affinity column. In mammalian cells, a similar
modification may have occured, but was transient. A fraction of GroEL could be
phosphorylated, allowing it to bind substrates that it would not usually bind under normal
conditions. The incubation of ATP with lysates of cells transfected with the groEL gene
(Figure 12) may also induce conformational changes in GroEL that may not otherwise
occur without the presence of ATP.
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GroEL released bound polypeptides in the presence of ATP and retained them
when the ATP was removed by apyrase treatment, indicating that when synthesized in
mammalian cells, GroEL still maintained the capacity to hydrolyse ATP and release
bound polypeptides. This is an important aspect of GroEL function, since in concert with
GroES, the hydrolysis of ATP sets the timer for releasing the bound polypeptide in vivo
at the end of a round of protein folding (Rye et ai, 1999).
A previous report indicated that GroEL was not able to bind nascent polypeptides
or folded proteins under nonstress conditions in mammalian cells (Thulasiraman et al.,
1999). One reason for this discrepancy with our results may be the mode of gene
expression. We examined cells with transient, high level expression of the groEL gene
(Figure 11) while the other study employed a stable, inducible system. The transient
transfection of plasmid DNA may cause changes in gene expression throughout the cell
that are detectable by their gene products binding to GroEL or more GroELn may be
generated due to higher levels of expression.
Previous investigations lend credence to the possibility that the additional
polypeptides bound by GroEL were due to increased gene expression resulting from
transient transfection. Calcium phosphate precipitation of plasmid DNA into HeLa cells
triggered the cell cycle machinery and induced apoptosis in a significant percentage of a
transfected population independent of the presence of transfection salts (Rodriguez and
Flemington, 1999). Accumulation of wild type p53 was associated with transient growth
arrest and increased levels of transcription from a p53 dependent reporter construct after
cells were incubated with a calcium phosphate precipitate (Renzing and Lane, 1995).
The transient growth arrest was observed whether plasmid DNA was present or absent in
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the precipitates. Transient transfection by the calcium phosphate precipitation procedure
can also activate genes that normally require induction by a-interferon in FS2 cells (a
diploid fibroblast cell line) and HeLa cells (Pine et al., 1988). Cacium phosphate
precipitation has also been implicated in altering the tumorigenic and metastatic
properties of neoplastic cells, which are already genetically instable (Kerbel et al., 1987;
Verrelle et al., 1987). Metallothionein gene expression levels in Hep-G2 cells (a
hepatocellular carcinoma cell line) were altered in the presence of the calcium phosphate
precipitates and copper or zinc (Foster et al., 1989). The induction of genes sensitive to
the transfection of plasmid DNA may be the source of proteins that GroEL is able to
bind. If this is so, this is an example of the usefulness of GroEL in detecting cellular
changes that may not be detected by another method. GroEL is specific to proteins that
may need assistance in folding that may not otherwise be detectable when examining
global protein folding or stability.

a.

Spectrum of proteins bound by GroEL in bacteria and mammalian

cells
We have confirmed that a wide variety of polypeptides interact with GroEL
within E. coli, ranging from 200-kDa to 5-kDa as previously demonstrated by others
(Ewalt et al., 1997). GroEL access to folding polypeptides within a bacterial cell is
restricted only by the hydrophobic exposure in some secondary structure of a given
polypeptide. GroEL can bind almost any polypeptide when they are released into the
bulk cytosol after translation and release from DnaK. However, polypeptides synthesized
in mammalian cells do not have the same general access to GroEL compared to E. coli.
Approximately 30 polypeptides were coimmunoprecipitated with GroEL in mammalian
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cells, ranging from ~60-kDa down to ~5-kDa (Figure 7). There was no association of
polypeptides larger than 60-kDa when compared to E. coli (Figure 12). GroEL may not
interact with polypeptides larger than 60-kDa in mammalian cells because those larger
polypeptides may fold efficiently via the endogenous protein folding machinery.
It was expected that different polypeptides might be coimmunoprecipitated with
GroEL in mammalian cells when compared to E. coli. It was, however, unexpected that
the total number of polypeptides and range would differ so drastically. A possible reason
for this finding, which is supported by several recent reports (Siegers et al., 1999;
Thulasiraman et al., 1999), is that GroEL was not privileged to interact with folding
polypeptides under normal conditions. The eukaryotic cell protein folding machinery
sequesters the folding polypeptide until it is folded and therefore inaccessible to GroEL,
since it has attained its native conformation. Except for ~30 polypeptides, GroEL cannot
bind polypeptides in the bulk cytosol in normal cell growth conditions. Placing cells
under heat shock conditions did allow GroEL to bind more proteins (Figure 14). The
endogenous mammalian protein folding machinery may have had to compensate for the
global instability of folded proteins induced by the temperature increase. The nascent
chain folding activity of the molecular chaperones may have been superceded by the need
to act as elements that suppress the instability of proteins under stress. Chaperones
become ‘safe-havens’ for native proteins that partially denature when the thermal energy
of heat shock causes their hydrogen bonds to break. Since the effect of heat shock is
general throughout the cell, the chaperones act to suppress aggregation and loss of protein
activity until the stress is over or until the misfolding proteins become more abundant
than the available chaperones can protect, resulting in cell death.
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c.

Different folding behavior of a GroEL substrate in bacteria and

mammalian cells
Saturation of the endogenous protein folding machinery is of valuable interest
both from the shared point of basic and applied research. The overexpression of a single
gene may result in either native, active protein or misfolded, inactive aggregates of
polypeptides. We investigated the capacity of both bacteria and mammalian cells to
productively fold a large multidomain protein with and without the presence of the GroE
chaperonins. Our model protein was a fusion of a temperature sensitive bacterial
luciferase and the green fluorescent protein. This model protein was larger than most
proteins predicted to productively fold on GroEL in conjunction with GroES. There may
be a time in the future when polypeptides similar in size or domain organization need to
be either synthesized in bacteria or overexpressed in situ for therapeutic purposes.
Investigation of the effect on the endogenous protein folding machinery is therefore of
interest.
1.

State of the luciferase-GFP fusion protein in E. coli
Bacteria contain the necessary endogenous protein folding machinery to fold a

large multidomain protein such as the luciferase-GFP fusion protein. Low levels of
bacterial luciferase activity and dim green fluorescence without aggregates were detected
without the presence of excess chaperonins (Figure 19). However, the presence of excess
GroES and GroEL increased the levels of luciferase (Figure 18) and GFP activity (Figure
19). E. coli cells coexpressing the luciferase-gfp fusion gene and the groESL genes had
bright green speckles at either pole, and some cells contained multiple speckles
throughout the cell, but also contained diffuse green fluorescence evenly distributed. It
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thus appeared that GroES and GroEL were able to rescue the luciferase moiety as
indicated by the diffuse green fluorescence observed in vivo. GFP was productively
folded when the luciferase was both soluble and aggregated, indicating GroES and
GroEL mediated the folding of GFP. Either GroEL was interacting with GFP before
aggregates formed, thereafter aggregating due to the misfolded luciferase, or GroEL
interacted with GFP after aggregates had formed but still has access to the GFP moiety of
the fusion protein. Our results cannot distinguish the order of GroEL interaction at this
time. Over synthesis of GroEL alone with the luciferase-GFP fusion protein reduced the
luciferase activity to undetectable levels, while GFP activity in cells was only slightly
increased compared to cells without excess groEL gene. The abundance of GroEL over
the endogenous GroES may not have allowed a function cycle to occur and release the
luciferase-GFP fusion protein from GroEL. GroEL may have become a reservoir for
misfolded luciferase-GFP fusion protein, instead of mediating its folding.
Differential centrifugation and Western blot analysis of cell lysates demonstrated
an increase in total soluble and insoluble luciferase-GFP fusion protein when excess
GroES and GroEL were present (Figure 20). However, in the presence of excess GroEL
alone, there was even more soluble and insoluble luciferase-GFP fusion protein. GroEL,
without excess GroES, cannot efficiently rescue the luciferase-GFP fusion protein.
GroEL probably functions in this situation as a misfolding sink for the large misfolding
protein. The available GroES may occasionally interact with a GroEL bound to the
luciferase-GFP fusion protein, but the molar ratio of GroES to GroEL is unequal
compared to wild type cells, so the frequency at which GroES can interact with GroEL
bound to the luciferase-GFP fusion protein is greatly reduced. It thus appears necessary
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for both chaperonins to be present at relatively equal levels for production of active
luciferase-GFP fusion protein. GroES and GroEL are required for productive folding of
the luciferase-GFP fusion protein in E. coli.
GroEL coimmunoprecipitated the luciferase-GFP fusion protein in E. coli,
suggesting that the rescue of the luciferase-GFP fusion protein is not indirect but due to
the direct interaction with GroEL (Figure 21). This is the first example in E.coli of a
large multidomain protein that requires the interaction of both GroES and GroEL to
maintain activity in vivo. Large multidomain proteins of pharmaceutical interest could be
more productively produced if cosynthesized with GroES and GroEL. Of course, this
may not be the case with all large, multidomain proteins synthesized in E. coli, but the
possibility does exist to increase the productive yield of such proteins.
It has been suggested that bacteria fold proteins in a strictly posttranslational
manner without the capacity to fold multidomain proteins effectively (Netzer and Haiti,
1997). Bacterial in vitro translation experiments using a synthetic two domain protein
demonstrated posttranslational folding, even in the presence of 5-10 fold excess of GroES
and GroEL, but the effects of overexpression of the groESL genes were not investigated
in vivo. The requirement for both GroES and GroEL to the folding of the luciferase-GFP
fusion protein challenges, or at least provides an exception, to that hypothesis. The
addition of the GFP moiety to the luciferase does not act to solubilize the luciferase
because GFP fluorescence is in both soluble and insoluble states. The luciferase-GFP
fusion protein increased the size of the luciferase protein to 104 kDa, well beyond the
theoretical 70-kDa to encapsulate a polypeptide with GroES, and yet GroES and GroEL
still could rescue the luciferase and GFP.
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Clearly defined in vitro experiments need to be done to examine if the folding of
the luciferase-GFP fusion protein is folded in a posttranslational or cotranslational
manner. A supply of the luciferase-GFP fusion protein needs to be established for the in
vitro studies, for which ample protocols are available. In vitro transcription and
translation assays in rabbit reticulocyte lysate and E. coli S30 lysate coupled with
functional assays for luciferase and GFP actvity may allow us to determine if the
luciferase moiety is folded and thus functional before the GFP moiety is synthesized or
folded. Additionally, the luciferase-GFP fusion protein succeptibility to various
proteases may also allow monitoring of protein folding by short times of radiolabelling
bacteria or mammalian cells, lysing in the presence or absence of protease followed by
immunoprecipitation with anti-luciferase and anti-GFP antibodies. This would allow
investigation of cotranslational folding of domains or posttranslational folding of the fulllength polypeptide in an in vivo situation also.
Although there are not as many large proteins in bacteria as there are in
eukaryotic cells, there must be some chaperone function that assists these proteins to fold.
The luciferase-GFP fusion protein serves as one example of a large protein that is
dependent on both GroES and GroEL for productive protein folding in E. coli.
2.

State of the luciferase-GFP fusion protein in mammalian cells
The overexpression of a protein in mammalian cells is of interest because of the

various gene therapy protocols and trials that synthesize excess amounts of a particular
protein to treat diseases. It is possible that the synthesis of a single protein in large
amounts may overcome the endogenous protein folding machinery of mammalian cells.
We used the luciferase-GFP fusion protein as a model to address this possibility because
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of its propensity to misfold in E. coli and because it is a large multidomain protein. The
protein would not be expected to fold into its native state without the assistance of some
protein folding machinery.
Visual analysis (Figure 24) and differential centrifugation followed by
immunoblot analysis (Figure 25) indicated the folded state of the luciferase-GFP fusion
protein. Additionally, we utilized GroEL as a probe of luciferase-GFP fusion protein
misfolding by the ability of GroEL to coimmunoprecipitate luciferase-GFP fusion protein
(Figure 26).
Data indicate that the luciferase-GFP fusion protein folds to its native state in
mammalian cells without any exogenous chaperones. Visual analysis revealed diffuse
green fluorescence within cells transfected with the luciferase-gfp fusion gene;
cotransfection of the luciferase-gfp fusion gene and the groEL or groESL genes did not
increase the intensity of the fluorescent signal. Differential centrifugation and
immunoblot analysis of the luciferase-GFP fusion protein indicated that it was soluble
with or without the GroE chaperonins present. GroEL did not coimmunoprecipitate the
luciferase-GFP fusion protein, which indicated that the presumably high levels of protein
synthesis of a single large protein containing several domains did not saturate the
endogenous protein folding machinery of the cell. The levels of protein were presumed
to be high because the strongest promoter available was used, the CMV immediate-early
promoter/enhancer and because cells were transfected transiently. A direct comparison
of the luciferase-GFP fusion protein levels was not done between E. coli and mammalian
cells to correlate the two expression systems. This could have been done with Western
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blot analysis using anti-Luciferase or anti-GFP antibodies conjugated to 125I-protein-A for
a quantitative analysis using a phosphorimager.
The addition of excess GroES and GroEL can increase the productive yield of a
large protein in E. coli, but it appears, in agreement with results from other laboratories,
that each substrate protein must be empirically tested for productive interaction with the
GroE chaperonins in mammalian cells. Concurrently, the syntheses of a single protein
for therapeutic purposes in mammalian cells most likely should not adversely effect the
cells due to saturation of the protein folding components. The overexpression of protein
is likely to result in functional protein, unlike in bacterial cells where some proteins tend
to aggregate and lose function.
The manner in which proteins fold in bacteria and mammalian cells is different.
The folding of the large luciferase-GFP fusion protein is one clear example. Excess
GroE chaperonins are required for the rescue of the luciferase and GFP activities in E.
coli. GroEL physically associates with the luciferase-GFP fusion protein and in
conjunction with GroES, achieves its native conformation. The protein folding
machinery of E. coli most likely folds the luciferase-GFP fusion protein
posttranslationally (Reid and Flynn, 1996; Gaitanaris et al., 1994). The low amount of
protein displayed by differential centrifugation and Western blot analysis of lysates from
cells transformed with only the luciferase-GFP fusion gene probably was due to the
misfolded protein being quickly degraded, leaving only the soluble folded protein (Figure
20). Folding posttranslationally, the luciferase-GFP fusion protein may be very prone to
aggregation because of the multiple domains, LuxA, LuxB and GFP. Excess GroES and
GroEL assists a larger percentage of the luciferase-GFP fusion protein to achieve the
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native state, whereas only excess GroEL increases the amount of luciferase-GFP fusion
protein without productively folding it. GroESL in E. coli may not fold proteins in a
cotranslational manner, but that does not mean that they cannot fold multidomain
proteins. The folding efficiency may be less, but the functional assays for luciferase
(Figure 18) and GFP (Figure 19) indicated that GroESL could mediate the folding of the
large multidomain protein in E. coli.
Mammalian cells most likely fold the luciferase-GFP fusion protein in a
cotranslational manner. The protein folds into its native conformation without the
assistance of overexpressed chaperones. Alternatively, there may be an excess of a
chaperone in COS-7 cells, though it is unlikely. It is not known which chaperones the
luciferase-GFP fusion protein transits during folding or what effect the mammalian
ribosome may have on its synthesis and/or folding. However, the solubility of the
luciferase-GFP fusion protein, visually and biochemically, indicates that the protein
folding machinery in mammalian cells functions in a distinct manner from that of E. coli.
D.

Folding of a large multidomain protein substrate by GroESL
GroES/GroEL mediated protein folding is thought to occur in concert with the

binding of ATP and conformational changes. Non-native polypeptide binds to GroEL
when hydrophobic regions of the polypeptide associate with hydrophobic surfaces
displayed on the channel side of the GroEL apical domain. Binding of ATP and GroES
encloses and releases the polypeptide into the GroEL chamber, now lined with
hydrophilic residues, which promote hydrophobic burial and folding of the polypeptide.
Hydrolysis of ATP starts the ~15 second timer in the cis GroEL ring and promotes
conformational changes in the tram GroEL ring that make it accessible to ATP. Upon
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binding of ATP and possibly polypeptide and GroES to the trans GroEL ring, the cis
GroEL ring complex dissociates, beginning another cycle.
Weissman et al. in their study of methylmalonyl CoA mutase (79-kDa) proposed
that a mechanism different from the paradigm may be in effect for the chaperoninmediated folding of large proteins in E. coli (Weissman et al., 1995). Certainly there are
large proteins found in bacteria, which are presumed to require GroES and GroEL, like
the synthetic example discussed here. They most likely would consist of proteins that
contain individual domains that could be bound within the GroEL cavity, thus upon every
release from GroEL, they may be rebound in the regions or domains that had not been
folded properly during the previous GroEL interaction. The mechanism of chaperoninmediated folding of these proteins is unknown, but the following two models are
possible.
1.

GroES binding to cis GroEL
The large multidomain structure of the luciferase-GFP fusion protein (104 kDa) is

composed of three domains: LuxA, LuxB, and GFP. GroEL may bind any one of those
domains or a combination of domains; however, only a very compact intermediate of <70
kDa can be completely enclosed by GroESL (Xu et al, 1997). GroES cannot completely
enclose the whole luciferase-GFP fusion protein, so at least one of the domains may not
enter the GroEL chamber. A combination of LuxAB (76-kDa) or LuxB/GFP (~62-kDa)
could theoretically fit within GroEL chamber if the GFP or LuxA domain did not enter.
The other possibility is that the single domains, LuxA, LuxB or GFP could be enclosed,
but if LuxB were enclosed, LuxA and GFP would extend out of the chamber, blocking
GroES or surely sterically hindering extensive binding. The most likely scenerio would
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involve interaction of GroEL with either the LuxAB domains or the LuxB/GFP domain
because previous data suggests that LuxB domain is responsible for the temperaure
sensitive nature of the fusion (Escher et al., 1991).
The only manner in which GroES could encapsulate the GroEL bound
polypeptide is if the polypeptide had some unstructured linker-type region that fit through
the space between GroES and GroEL as represented in Figure 31. The nonbound portion
of polypeptide probably would dangle or hang outside until the productive cycle of
folding occurred on the bound portion. This type of folding has not been described in the
literature and is unlikely. The interaction between GroES and GroEL is dynamic. GroES
coordinates the hydrolysis of ATP through defined regions in the apical domain of
GroEL. Steric hindrance by a large domain of either GFP or the luciferase would surely
block or make it much more difficult for GroES to bind and coordinate ATP hydrolysis
on GroEL. Not only would GroES be blocked or hindered from docking, but also once a
moiety is bound, the linker between the luciferase and GFP would be free to “bump”
against GroES. The non-GroEL bound moiety, free outside of GroEL, would be
available for interaction with other macromolecules in the cell. Three previous studies
demonstrated that GroES did not encapsulate methylmalonyl CoA mutase (79-kDa)
(Weissman et al., 1995), a fusion of the mature maltose-binding protein (MBP) linked to
the N-terminus of the alpha subunit of the decarboxylase (El) component of the human
mitochondrial branched-chain alpha-ketoacid dehydrogenase complex (86-kDa) (Huang
and Chuang, 1999) or an 82-kDa polypeptide (Sakikawa et al., 1999). The 82-kDa
polypeptide was the result of three fluorescent proteins, which one would expect to have
some linker regions available for this type of model, however this was not the case and
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Figure 31. Model of luciferase-GFP fusion protein folding in a cis GroEL complex. (A) Unfolded luciferase-GFP
fusion protein exposes regions that can interact with GroEL. (B) GroEL binds the non-native luciferase-GFP fusion
protein in the inner channel. Some of the luciferase-GFP fusion protein hangs outside of the GroEL chamber. (C)
GroES interacts with GroEL and encloses a portion of the luciferase-GFP fusion protein, assisting it to fold. The GFP
moiety is shown here as an example, but the luciferase moiety could also be bound with the GFP hanging outside. (D)
Conformational changes in the cis GroEL complex, possibly by ATP binding to the trans ring, allow release of the bound
luciferase-GFP fusion protein. Three states of the luciferase-GFP fusion protein are shown: folded GFP with unfolded
luciferase. unfolded GFP and folded luciferase, and finally, folded GFP and folded luciferase
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provides the least likely scenario. The second model involves conformational changes of
the cis GroEL ring (GroEL complexed to polypeptide) through GroES binding to the
trans GroEL ring (empty GroEL ring).
2.

GroES binding to trans GroEL
Two studies suggest the possibility of GroES mediated conformational changes of

the cis GroEL complex by interaction with the trans GroEL ring (Weissman et al., 1995;
Huang and Chuang, 1999). In each in vitro investigation, proteinase K digestion was
utilized to determine if the polypeptide was protected by GroES encapsulation. The most
likely mechanism that may occur in vivo is represented by Figure 32.
The nonbound portion of the luciferase-GFP fusion protein sterically prohibits the
binding of GroES to the cis GroEL ring and GroES may bind to the trans GroEL ring.
The actual binding of GroES to the trans GroEL ring may elicit a conformational change
that is transmitted across the equitorial domains to the cis ring complex. This interaction
may or may not occur in the presence of ATP. Once a conformational change has been
transmitted, the cis GroEL complex releases the luciferase-GFP fusion protein into the
cytosol to fold to its native state or rebound to GroEL for another try, utilizing GroES in
the trans configuration again.
The characteristics of the luciferase-GFP fusion protein make it uniquely suited
for examination because the luciferase moiety and the GFP moiety are easily assayed in
situ and in vitro. The in situ evaluation of protein folding offers the advantage of
monitoring protein folding in a biological system during real time without perturbing the
system. GFP activity can be monitored without the addition of any substrate, its only
requirment is molecular oxygen and exictation by UV light. In this study, two forms of
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Figure 32. Model of luciferase-GFP fusion protein folding on the cis GroEL ring with GroES interaction on the
trans GroEL ring. (A) Non-native luciferase-GFP fusion protein exposes regions that can interact with GroEL. (B) The
luciferase-GFP fusion protein binds to the GroEL central chamber, which blocks the access or binding sites for GroES on
the cis ring complex. The GFP moiety is shown being bound here, but it could as well be the luciferase moiety. (C)
GroES binding to the trans GroEL ring causes a conformational change to occur that translates across to the cis GroEL
complex, allowing the bound moiety to fold on GroEL. (D) The luciferase-GFP fusion protein is released as well as the
GroES bound to the trans GroEL ring. Three possible folded polypeptides could result from this model of assisted
folding: folded GFP with unfolded luciferase. unfolded GFP and folded luciferase. and finally, folded GFP and folded
luciferase.
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the luciferase-GFP fusion protein were observed, indicating the soluble or aggregated
state of the luciferase. GroESL interaction with other suspected substrates could be
observed if GFP fusions with GFP were done. The in situ observations serve as
confirming evidence for in vitro biochemical evidence as has been shown in this work.
E.

Protein availability to GroEL and cell survival under heat shock

conditions in mammalian cells
We investigated the availability of GroEL to proteins in heat shocked mammalian
cells. During a pulse-chase experiment of radioactive proteins, GroEL was used to probe
the stability and/or increased misfolding of the protein population within heat shocked
cells as indicated by the number and variety of proteins that associated with GroEL. The
binding of proteins to GroEL or another subtle indirect mechanism may also explain why
cells containing the groEL gene are more resistant to prolonged heat shock.
1.

Availability of proteins to GroEL under heat shock conditions
Heat shock of CHO cells for one hour induced the synthesis of Hsp70 protein

almost 16 fold after 24 hours following the treatment, indicating that cells had reacted to
thermal stress and proteins most likely misfolded under those conditions (Figure 13).
GroEL was used to probe the structural status of proteins during heat shock. GroEL binds
substantially more polypeptides in heat shocked cells than in cells at normal temperature
(Figure 14). Larger polypeptides are bound as well as polypeptides of all size ranges.
The effect of many proteins denaturing due to heat shock throughout the cell most likely
taxes the chaperone reserves: as chaperones bind denatured proteins, more proteins fail to
not only establish their native conformation, but also to keep it. In contrast, the
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overexpression of a single protein, such as the luciferase-GFP fusion protein, is a
relatively singular event, not a global breakdown of protein stability. The synthesis of a
misfolding protein, even at high levels does not appear to saturate or titrate out the
available chaperones within the cell. GroEL, in a stress situation such as heat shock,
bound a greater number of proteins with a more ubiquitous spectrum of polypeptides in
mammalian cells (Figure 14) in much the manner as in nonstressed E. coli (Figure 12).
These results establish the possible usefulness of GroEL as a tool to identify
proteins that do not interact productively with endogenous stress response proteins.
Cellular changes that effect the stress level of the cell, such as heat shock, cold shock,
environmental pollutants or ATP depletion due to ischemia could be investigated. GroEL
could be used to probe and bind the proteins that were misfolding to a greater capacity
than others. The folding state of proteins in cells grown in vitro as a model for a disease
could be probed for protein misfolding. Candidate proteins that associate with GroEL
could be isolated and microsequenced from which degenerate PCR primers could be
developed. The PCR products could be sequenced; hence, the gene and the protein could
be identified.
2.

Cell survival under heat shock conditions
During heat shock many chaperones bind partially denatured proteins in an effort

to protect the cell from death because of irreversible damage to the proteins necessary for
cell survival. Hsp70 and the small HSP’s, for example, bind proteins that expose
hydrophobic regions exposed by the increase of temperature and instability of the bonds
that form the active protein structure. In mammalian cells, GroEL may add another layer
of protection from thermal killing due to protein denaturation (Figure 16).
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GroEL could increase cell survival in two ways. First, GroEL may bind protein,
stabilizing and then releasing it into the bulk cytosol. The release of protein may occur
on a kinetic basis since the absence of GroES does not allow a coordinated cycle to
proceed. The simple ability of GroEL to bind a wide variety of proteins may give it an
advantage over the less promiscuous group II chaperonins.
Second, GroEL may bind but not release proteins. It could act as a misfolded
protein sink. The removal of proteins that could become insoluble may reduce the toxic
effects of aggregation for a space of time, such as from 1 to 2 hours of heat shock when
~70% of the cells were still viable. The capacity of GroEL working in this manner could,
after time, saturate the amount of GroEL available, which may be responsible for the cell
viability decreases after 4 hours of heat shock (Figure 16). There is most likely a
combination of the two possibilities acting in the stressed cells. Proteins that are
intrinsically stable may transit GroEL for modest assistance to maintain stability, while
other proteins may enter GroEL with much less stability. Upon kinetic release, GroEL
rebinds them, thus removing the opportunity to create irreversible aggregates. The
protein misfolding effect becomes irreversible after protein functions necessary for
survival are destroyed, resulting in cell death.
The detailed mechanism of GroEL-induced thermotolerance is currently unknown
in mammalian cells, but GroEL can protect a majority of CHO cells from prolonged heat
stress up to three hours at 45°C. It was expected that GroES and GroEL could offer at
least the same amount of protection to cells under heat stress, but it confired less
protection compared to GroEL alone, though more than cells transfected with vector.
The lower level of protection in the presence GroES and GroEL was most likely due to
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the lower levels of synthesis of GroEL from the genes of the bicistronic groESL vector
(Figure 26). If the levels of GroES and GroEL can be optimized for the highest levels of
synthesis, there may be an even greater amount of protection upon heat stress because the
full chaperonin reaction cycle could take place. The addition of chaperonins could be a
valuable tool in the treatment of diseases with a well-defined protein folding defect that
the endogenous protein folding or stress response machinery cannot correct.
F.

GroESL and Gene Therapy
Previous investigations demonstrated that the overexpression of the groESL genes

with the wild type p53 gene in E. coli resulted in an increased amount of soluble protein
(Yasukawa et al., 1995). Many mutant forms of p53, especially VI43 A, interact with
Hsp70 for an extended period of time compared to wild type p53 (Hainaut and Milner,
1992). Recently, the validity of using misfolding p53 as a model for GroESL activity
was shown. Investigators identified pharmacological compounds that stabilized the DNA
binding domain of wild type and mutant p53 molecules in the active conformation and
restored their wild type properties (Foster et al, 1999). Prototype compounds were able
to slow tumor growth in mice with mutant p53. This suggested that our hypothesis that
misfolding p53 could be stabilized and folded properly was not unfounded in concept.
GroEL simply did not interact with V143A p53 to a detectible degree. We demonstrated
that indeed VI43 A p53 is temperature sensitive and cannot transactivate a reporter gene
linked to a p53 DNA binding element, necessary for reporter gene expression, at the
nonpermissive temperature (Figure 29). The coexpression of VI43 A p53 with the groEL
gene or the groESL bicistronic vector did not restore the ability of the p53 molecule to
transactivate the reporter gene. GroEL and GroES/GroEL could not rescue mutant p53
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based on the transactivation assay (Figure 28 and 29). Direct interaction was examined
through coimmunoprecipitation and western blot analysis of the precipitates. GroEL
could not coimmunoprecipitate either wild type or VI43A p53 (Figure 30). There may
be several reasons for this lack of rescue, recognition or interaction.
First, V143A p53 may not adopt a conformation that GroEL is capable of binding.
GroEL binds proteins that are folding nascently by recognizing the state prior to the
native fold, known as the molten globule state (Martin et aL, 1991) or proteins whose
structure has become unstable under stress such as heat shock. The heat-denatured
species could also revert to the molten globule state which is highly prone to aggregation
due to exposed hydrophobic regions. The VI43 A p53 may not adopt a similar
conformation at 37°C that is recognized by GroEL, though the protein may still be
misfolding into a soluble, stable, dominant negative form of the protein.
Second, GroEL may be capable of interacting with VI43 A p53, but the nature of
p53 activity could be masking the effect. The tetramer of p53 is the active form that acts
to transactivate genes and which our assay was measuring. VI43 A is a dominant
negative version of p53. If one V143A p53 monomer is complexed with three wild type
p53 monomers forming a tetramer, then the tetramer will be inactive, spoiling the activity
of the whole complex. The levels of wild type p53 need to be high, forming all wild type
p53 tetramers, to compensate for the effect of the misfolded V143A p53 mutant. The
transactivation assay may not be sensitive enough to detect a small amount of mutant p53
conversion to the wild type conformation.
GroEL interaction with substrate polypeptides appears to be firmly segregated
when cells are not under stress. Even in the misfolded state, proteins such as p53 do not
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appear to have access to GroEL. Though V143 A p53 is a misfolded conformer, it does
not have access to GroEL. The inability of GroEL to interact with GroEL may signify
why this mutant is disease causing, the endogenous chaperone and degradation
machinery is not capable of controlling it. Quite possibly, it does not adopt a
conformation that signals it as malformed and is hence, not destroyed and continues to
exert its dominant negative effect on the wild type pool of p53 without controlling cell
growth.
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V.

Perspectives

A.

GroESL protein rescue should be protein specific
The development of the luciferase-GFP fusion protein allowed us to determine

that E. coli can somewhat compensate for deficiencies in folding of large proteins that
have more than one domain. Though the effect was less than 100% recovery , more
luciferase-GFP fusion protein was folded properly when the groESL genes were
coexpressed, based on luciferase bioluminescence of bacterial colonies and GFP
fluorescence intensity of individual bacterium.
Eukaryotic cells appear to functionally sequester proteins in a manner that is
different from bacteria (Thulasiraman et al., 1999; Siegers et al., 1999). The substantial
compartmentalization does not allow polypeptides to fold in the bulk cytosol. Large,
multidomain proteins resulting from gene shuffling had to be sequestered from the
moment of synthesis until the final conformationally stable structure was attained (Netzer
and Haiti, 1997). If a protein does misfold and is stable in the cell, then there appears to
be a problem that the endogenous protein folding machinery cannot resolve. The
addition of GroES and GroEL could add some redundancy that may be lacking in the
current state of the cells, which the heat shock survival data demonstrated.
When the cellular protein folding machinery cannot rescue a misfolded protein,
which may contribute to the cause of a disease, GroES and GroEL may still offer the
protein another opportunity to fold correctly. However, the types of diseases that can be
approached in this manner must be carefully considered.
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B.

GroESL as therapeutic agents
The future use of GroES and GroEL as therapeutic agents need to have very

defined targets of interaction with specific properties. First, the target protein should not
be part of a multimeric complex to retain activity. A protein that is active as a monomer
would be ideal. When a protein is rescued by its interaction with GroES and GroEL, it
should be active, regardless of the amount of the other misfolded proteins present.
Activity should not be dependent upon the ratio of properly folded protein to misfolded
protein, but by the overall levels of properly folded protein achieved.
If multisubunit proteins that display dominant negative features are used, they
must be scrutinized to determine the necessary level of phenotypically normal protein
that must be present for the disease to be alleviated. The yield of native protein must also
be addressed because GroEL may not be capable of rescuing all of the misfolding target
proteins necessary in the cell due to the interactions with other proteins that may bind to
GroEL. This aspect is important because a multimeric protein having dominant negative
attributes must have a significant proportion of the mutant protein folded into a wild type
conformation.
For example, in our experiments, we transfected cells with only the VI43A p53
cDNA and groESL genes, then assayed for transactivational ability. Even if 75% of the
VI43A p53 adopted a wild type conformation that had transactivational activity, the 25%
of still misfolded VI43 A p53 would most likely spoil any transactivational ability.
GroEL, like any biological material, does not work at 100% efficiency, so the concept
that even 75% of the mutant proteins could be folded into a wild type conformation is
very unlikely. Additionally, wild type p53 has a half-life on the order of minutes and
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VI43 A has a half-life on the order of hours. If the GroEL-mediated folding of VI43 A
p53 did occur, it is possible that the short half-life property also was conveyed. If that
was the case, then the ratio of native folded V143 A p53 and misfolded V143A is
constantly being shifted in favor of the misfolded VI43 A simply due to the difference in
stability.
In a situation where there is only one allele mutated for p53, the amount of wild
type p53 would increase the necessary amount of functional p53 available. If both alleles
were mutated, then the situation that we have shown with the transfected mutant genes
may apply. Careful consideration of GroEL's capacity to fold the required amount of
protein in vivo should be addressed in each discussion of its usefulness as a therapeutic
tool.
Second, though GroEL is promiscuous in bacterial cells, we have shown that the
capacity to bind proteins is not the only factor that needs to be addressed in this type of
protein folding defect therapy. Access also needs to be determined, physically and to
proteins folding outside of the endogenous protein folding pathway. In order for GroEL
to have an effect on a target protein, it must be able to bind it within the cytoplasm.
Proteins that have a stable, though misfolded conformation, such as VI43 A p53 probably
are not bound by GroEL because they do not display the exposed hydrophobic regions
characteristic of polypeptides that bind GroEL. The protein must be capable of
interacting with GroEL outside of the compartmentation of normal protein folding, or
GroEL may not be able to physically bind the target protein, as is the case with the
luciferase-GFP fusion protein, V143A p53, K304E MCAD (see appendix) and
temperature sensitive bacterial luciferase.
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Third, the physiological amounts of active target protein should be monitored so
that the rescue of the target protein does not result in creating too much active protein. In
some instances, a certain amount of protein instability is necessary under physiological
conditions to maintain the proper balance of active protein. If p53 were stabilized, it
could mimic mutant p53 which has a half-life of hours compared to minutes of wild type
p53. The simple increase of the total amount of p53 would be detrimental and effect the
delicate levels present in normal cells. If the protein half-life is extended, it may result in
too much activity that is detrimental to the cell (Iggo et al., 1990). Care should be used
to maintain a proper balance by monitoring of target protein levels in the body. Though
technically not feasible at the present time, in the future, the pharmacological control of
gene expression of genes introduced for therapy is possible, allowing control of
theraputic agents, possibly even GroESL.
Fourth, patients may need to be immunized with GroEL peptides to induce
immunity because reports have demonstrated a strong reaction of the immune system to
GroEL and its homologs from various bacteria (Beech et al, 1997; Klatser et al., 1997;
Lamb and Young, 1990; Thompson et al., 1990). Antibodies to various forms of GroEL
from virulent bacteria have been discovered and examined (Lemos et al., 1998;
Panchanathan et al., 1998; Zlotta et al, 1997). One possible route around the immune
surveillance that may be explored is to "humanize" GroEL at the amino acid level.
Mammalian cells contain the GroEL-homologue Hsp60 in the matrix of mitochondria.
The immunodominant epitopes of Hsp60 are known. Short substitutions could be made
in GroEL to make it more Hsp60-like, thus reducing its immunogenicity, yet still retain
its protein folding capacity.
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c.

Conclusions
Protein folding between bacteria and mammalian cells occurs generally in

different manners. E. coli required excess chaperonins to fold the luciferase-GFP fusion
protein in vivo, while mammalian cells could fold the protein with the endogenous
protein folding machinery. Proteins are not generally accessible to the bulk cytosol
during folding in mammalian cells, but stressful situations that destabilize protein
structure can allow the GroEL chaperonin to bind misfolding polypeptides. GroEL
cannot be used as a general protein folding component of nascent chains in mammalian
cells due to the preformed sequestering and compartmentation of polypeptides upon
synthesis. GroEL, however, is a potentially valuable tool to probe the folding state of
cells under stress. It could be used as a probe in a variety of situations in which model
cell systems investigate the protein folding effects of stresses such as, heat stress, cold
stress, alcohol incubation, environmental pollutants, heavy metal pollutants or hypoxia.
GroESL are apparently not good candidates for treating the cancers containing
misfolding p53; however, the possibility does exist for the treatment of other protein
folding diseases, but good in vitro models should be well understood before moving into
studies in organisms.
The chaperonins GroES and GroEL are valuable tools and elegant protein folding
machines that have helped us to understand better the processes and attributes of protein
folding in bacterial and mammalian cells. Additional understanding into how
mammalian protein folding occurs will likely employ GroEL, and hopefully in the future
the combination of GroES and GroEL can become a viable option in the treatment of
protein folding diseases.
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VII.

APPENDIX
MCAD
Medium chain acyl-CoA dehydrogenase is a resident protein of mitochondria. A

mutation of this protein, especially at amino acid 304, results in a misfolded protein
without activity. Previous analysis of the K304E MCAD protein demonstrated that it
also misfolds in E. coli and the overexpression of the groESL genes abrogates its
misfolding to a great degree (Bross et al., 1993).
We obtained the cDNA’s for wild type and K304E MCAD from Peter Bross with
the intent to express and use it as a model for GroES/GroEL function in the mammalian
cytosol. Dr. Bross had told us that a collegue had tried expressing the MCAD genes in
the cytosol before, but was unsuccessful. We hoped that we could engineer the plasmids
so that the expression level would be high enough to detect. A Kozak sequence was
placed 5' of the start and the genes were put under transcriptional control of the strong
CMV immediate-early promoter/enhancer. The synthesis from a T7 promoter
demonstrated synthesis from the genes in E. coli, but we were not able to detect either
wild type or mutant activity of the protein from the cytosol of COS-7 cells. The
antibodies used for western blot analysis could not be used for immunoprecipitation
because of many coprecipitiating proteins and lack of sensitivity.
Coimmunoprecipitation of MCAD with GroEL was unsuccessful with either wild type or
K304E. We could not use the MCAD proteins as a model of GroES/GroEL rescue of
misfolding proteins because we could not show protein synthesis by Western blot,
immunoprecipitation or enzymatically, with or without GroES/GroEL. The cytosolic
version of the proteins (the MCAD proteins did not contain the mitochondrial signal
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peptide) may be very susceptible to degradation due to different folding conditions,
which could not be duplicated in the mammalian cytosol as it is in the matrix of
mitochondria.
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